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Gold is for the mistress – silver for the maid – 
Copper for the craftsman cunning at his trade. 
"Good!" said the Baron, sitting in his hall, 
"But Iron – Cold Iron – is master of them all." 
Rudyard Kipling, Cold Iron poem (1910) 
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1 General introduction 
1.1 Catalysis 
 The term "catalysis" was introduced by Berzelius in 1836,1 although mankind used 
catalytic processes for thousands of years without knowing its principles, i.e. for 
fermentation of the alcohol but also to produce sulphuric acid. The word "catalysis" 
originates from Greek and it means "to untie" or "to pick up". By definition catalysis "is 
increasing in the rate of a chemical reaction due to the participation of an additional 
substance - a catalyst". Catalyst itself is not consumed or modified during a chemical 
process and catalytic transformations occur faster and require less activation energy than 
non-catalytic processes. Moreover, using different catalysts, not only one, but a variety 
of different products can be obtained from the same substrate. 
 Catalysis is fundamental for chemistry and has enormous importance, both in 
academia and industry. Hundreds of commercially available catalyst are accessible for 
chemists all around the world. Catalysts allow to lower the cost and to save energy and 
materials, increasing selectivities and yields. They are a key factor for development of 
sustainable organic synthesis and as so, they are one of the pillar of the Green 
Chemistry.2 Without them, synthesis of various complex molecules would not be 
feasible.3 No doubt catalysis has a tremendous economic impact. According to the 
American Chemical Society, over 95% of all chemical products are obtained using at least 
one catalytic transformation.4  
 Catalysis can be divided into two subdisciplines - homogenous and 
heterogeneous. Homogenous catalysis involves one or more reactions where reactants 
and catalyst are in the same phase. There is a huge variety of molecules that can be used 
as homogenous catalysts. Organic molecules, organometallic complexes, acids, bases, 
enzymes and salts can be used as catalysts. Homogenous catalysis relies on well-defined 
active sites (typically one site per molecule of catalyst) which facilitates a rational design 
to obtain specific catalytic performances. Mild experimental conditions are typically 
required and such problems as limited stability, recycling, handling and high cost often 
limit their industrial applications. 
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 Heterogeneous catalysts operate in different phases than other reactants. 
Typically, they are solid and they work in contact with a gas or liquid phase. Owing to this 
feature, they can be readily separated from reactants, and their stability is much higher 
compared to homogenous catalysts. This makes them easy-to-recycle and thus perfect 
for large-scale processes. Indeed, the industrial manufacturing of commodity chemicals 
mostly relies on heterogeneous catalysts. Still, they bring many variables and potential 
problems, such as limited tolerance towards functional groups, dependence of 
reproducibility and selectivity on various parameters, as well as difficulty in investigating 
the reaction mechanism. Still, small to medium scale manufacture processes, especially 
for fine chemicals (like active pharmaceutical ingredients - API), relies mostly on 
homogenous catalysis. In particular, homogeneous catalysis is largely dominant in the 
field of enantioselective catalysis. 
 
1.2 Homogeneous asymmetric hydrogenations 
 Stereospecific synthesis is widely utilized by nature and chiral natural compounds 
surround us everywhere. All natural amino acids are chiral and have the L-form and only 
D-sugars can be metabolized by living organisms. Chirality of enzymes and receptors is a 
consequence of being build from chiral amino acids.5 Also nucleic acids exhibit chirality, 
as sugar building blocks present in their sugar-phosphate skeleton are chiral as well. 
Moreover, many hormones and pheromones possess asymmetric carbon atoms in their 
structures. This is why stereochemistry plays a crucial role in synthesis of new drugs or 
agrochemicals. Enantiopure compounds have to precisely fit to the active sites of 
enzymes. It is also common that two enantiomers of the same molecule can manifest 
completely different properties. In the case of fragrances or flavor additives, they can 
just smell or taste differently. In the case of drugs, one enantiomer can have a 
therapeutic use while second can be highly toxic or even possess strong teratogenic 
properties. Most known and infamous example of such a drug is Thalidomide, which led 
to birth of thousands disabled children in 1950's. This fact led to an increasing need for 
enantiopure chiral molecules, particularly in the field of pharmaceutical intermediates, 
witnessed by the fact that in 1992, the US's Food and Drug Administration (FDA) 
introduced a new policy for the production of new stereoisomeric drugs, were the use of 
single enantiomers was recommended.6 Since then, a rapid growth of new registered 
compounds existing as single enantiomers (rather than mixtures of them) was observed 
and defined the future trend for drugs development. Numerous methodologies were 
developed to meet the need for synthesizing single isomers of API.7 
 Asymmetric hydrogenation (AH) has been one of the first enantioselective 
catalytic transformation developed and is particularly suitable for large-scale applications 
due its operational simplicity and atom economy. It is not a well known fact, that the first 
catalytic homogenous hydrogenation was not based on a noble metal but on copper.8 
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The most commonly accepted date for the birth of homogenous reduction is 1966, when 
Wilkinson found RhCl(PPh3)3 as an effective catalyst for hydrogenation of alkenes.
9 Then 
the idea of replacing the triphenylphosphine from this catalyst with a chiral ligand led to 
the first examples of AH. Research in this direction began in the late 1960’s with the work 
on rhodium complexes of chiral monodentate phosphines, carried out by the groups of 
Knowles10 and Horner.11 Although the early efforts were rewarded with only modest 
enantiomeric excesses, the initial values were gradually increased by careful design of 
the ligands. From the beginning of this research it was clear that the choice of proper 
ligands for a given metal center is essential to obtain a high level of catalytic activity and 
stereoselectivity for the desired transformation. It is worth mentioning, that just 100 
years earlier Pauster, precursor of the asymmetric chemistry, declined the possibility that 
the chiral organic synthesis would be ever possible.12 
 In 1972 Kagan reported DIOP,13 the first example of chiral bidentate phosphorus 
ligand for Rh-catalyzed asymmetric hydrogenation, and few years later Knowles designed 
DIPAMP,14 a chiral diphosphine with C2 symmetry (Figure 1.1). The latter, combined with 
a rhodium source, formed a catalytic system able to hydrogenate α-dehydroamino acids. 
This catalytic system was exploited for the large-scale production of L-dopa, i.e. (S)-3,4-
dihydroxyphenylalanine, used as a drug for Parkinson's disease. After these fundamental 
contributions by Knowles and Kagan, hundreds of chiral bidentate P-ligands for AH were 
developed in the following 30 years. Among them, BINAP15 (Figure 1.1) gained the 
inventor Noyori the Noble Prize in 2001,16 which he shared with Knowles17 and 
Sharpless.18 BINAP is employed in a variety of Ru(II) complexes for the AH of olefins and 
ketones.19 As there was a high need for cheap methods to prepare β-hydroxy esters for 
drugs (i.e. statins for lowering the cholesterol), this was a major occasion for the industry 
to consider asymmetric hydrogenation as an useful methodology. 
 
Figure 1.1 Milestones in homogeneous asymmetric hydrogenation: 
 bidentate P-ligands developed by Kagan, Knowles and Noyori. 
 Given such brilliant achievements, for a long time the structural rigidity typical of 
bidentate systems was considered essential for an effective transmission of the 
stereochemical information in asymmetric catalysis. This situation changed 15 years ago, 
when noble metal complexes with new (and easy to make) chiral monodentate P-ligands 
(phosphonites, phosphites and phosphoramidites) were used to catalyze the 
hydrogenation of pro-chiral olefins, in some cases even outperforming bidentate 
ligands.20 The combinatorial potential of monodentate ligands became evident with the 
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studies on hetero- and homocombinations, autonomously published by Reetz21 and 
Feringa, de Vries et al.22 They proved that a binary combination of two different 
monodentate ligands (La and Lb) can lead to a higher activity and enantioselectivity, 
compared to complex of each single ligand separatly. When employing two monodentate 
ligands La and Lb, it was inevitable to obtain a mixture of the three species [MLaLb] 
(heterocomplex), [MLaLa] and [MLbLb] (homocomplexes), which were decreasing the 
overall activity and results. With the aim to improve the selectivity for the formation of 
heterocomplexes over the homocomplexes, the so-called "supramolecular" ligands were 
developed.23 These ligands, besides the donor atom (usually phosphorous) used to 
coordinate the metal, possess a further functional group capable of non-covalent 
interactions either with another complementarily functionalized ligand or with the 
substrate. This reduces degrees of freedom in the respective metal coordination 
complexes and leads to more pre-organized systems, where a better capacity of 
controlling the metal-catalyzed reaction can be achieved. 
 
1.3 Advantages and limitations of asymmetric hydrogenations 
 Enantioselective catalysis is in principle the most efficient strategy for the 
synthesis of enantiopure molecules (Figure 1.2) and enantioselective hydrogenation of 
pro-stereogenic carbon double bonds (with carbon, oxygen or nitrogen) undoubtedly is 
one of its most well-developed applications. 
 
Figure 1.2 Selected pharmaceuticals accessible by asymmetric hydrogenation of double bonds.
24
 
 There is a long list of factors that make catalytic asymmetric hydrogenation a 
valuable method both on the laboratory and the industrial scale, such as: 
 hydrogenation is a 100% atom-efficient methodology, with a very broad scope as 
well as a good chemoselectivity; 
 high conversions (and enantiomeric excesses) can be obtained without harsh, 
dangerous and energy-consuming conditions; 
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 with thousands developed methods, there is a high level of expertise in the field 
which increases the chance of solving specific problems; 
 scale-up of the process (when economically convenient) is straightforward as the 
process technology is well known.25  
 Enantioselective transfer hydrogenation for the reduction of ketones, imines and 
conjugated C=C double bonds, also gained a prominent position in recent years, even if 
its exploitation in the chemical industry still remains behind the one of asymmetric 
hydrogenation with molecular hydrogen. In this methodology, organic molecules are 
used as an equivalent for H2 - isopropanol and formic acid/triethylamine being by far the 
most used sources of hydrogen.26  
 During last 50 years various catalysts based on transition metals were developed. 
In particular, catalytic systems based on noble metals like palladium, iridium, ruthenium 
and rhodium turned out to be very effective for a broad range of chemical 
transformations. Nevertheless, in spite of the immense academic efforts in the field of 
AH, the amount of implemented processes is rather limited and is bellow 20.27 In spite of 
all advances in the technology, a vast number of chiral pharma intermediates are still 
prepared via traditional resolution of diastereomeric salts. This lack of AH processes can 
be explained by various reasons: 
a) time-to-market pressure doesn't give enough time to optimize or to develop a 
new catalytic methods; 
b) high cost of the catalysts (both the metal and the ligand) coupled to the relatively 
low turnover numbers that can be achieved in most cases makes the technology 
too expensive; 
c) limited availability of noble metals, as long-term supply for the chemical process 
could exceed theirs occurrence in nature; 
d) technology works fine on a limited number of benchmark substrates, however 
the catalyst is often too slow on real pharma intermediates (this is often caused 
by the presence of nitrogen-containing substituents that can bind to the catalyst); 
e) toxicity problems, since even trace amounts of toxic metals are often not allowed 
to occur in the final products. 
These limitations concern also other industry sectors (like agro-chemistry, food industry 
or cosmetic sector) which require the usage of enantiopure compounds. 
 Replacing precious metals with cheap first-row transition metals would be a 
major breakthrough, with an enormous scientific and industrial impact. A comparison of 
prices of noble metals with base metals, shows that the latter are at least 1000 times 
cheaper. To clearly visualize that and compare the cost of noble metals expressed in 
price per gram, base metals costs have to be shown in price per one kilogram (Figure 
1.3).28 For this reason, catalysis with inexpensive transition metals is an area undergoing 
rapid growth.29  
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Figure 1.3 Prices of noble and base metals. 
 
1.4 Iron 
 Global efforts in sustainability, coupled with high prices of noble metals, have 
recently inspired a flurry of activity in iron catalysis.30 Iron is a fundamental element of 
our planet. It is the second most common metal after aluminum and it is accountable for 
one third of the Earth's mass. People have known and used iron since nearly 3200 years 
ago and it always played a crucial role in humans' world. Iron is essential in biology as 
iron-proteins are present within all living organisms, from bacteria's to humans. The red 
color of our blood is caused by an iron-containing protein - hemoglobin - without which 
blood would not be able to transport oxygen in our bodies. Iron is a vital part of human's 
history and culture. It is truly surrounding our lifes without being even noticed by us. 
Nevertheless, most of all, iron means chemistry. It is not a well known fact by most of the 
people, but over 80% of nitrogen in our bodies is originated from the Haber-Bosh 
process of synthesizing ammonia using iron catalyst. 
 Ferrum is a first row transition metal element with an electronic configuration of 
[Ar]4s03d8. We hardly ever find iron as a pure metal, as it readily oxidizes in the presence 
of oxygen and moisture. As so, the most stable compounds have the oxidation state +2 
or +3, but as a group 8 element, iron can exist in a wide range of oxidation states, from -2 
up to +6. In low oxidation states it may act as an iron-centered nucleophile and catalyze 
reactions such as nucleophilic substitutions, additions to carboxylic substrates, 
cycloisomerization and others.31 In its most common oxidation states (+2 and +3), iron 
has a tendency to engage in single electron transfer reactions, and for this reason it has 
found wide application as a catalyst for oxidation processes.24 By contrast, many Fe-
complexes have little propensity to participate in two-electron processes which are 
typical of many precious metal catalyzed reactions starting from hydrogenation. For this 
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reason, until recent years iron has been scarcely exploited for classical reactions 
following the oxidative addition/reductive elimination pathway. 
 From a practical point of view, studies devoted to investigate the use of iron in 
chemical industry processes would meet a urgent need for environmentally friendly and 
economically affordable synthetic methodologies. High-added value compounds such as 
chiral alcohols, amines, esters and amino acids would become accessible by reduction of 
parent olefins, ketones and imines at an economic and environmental cost much lower 
than that involved by noble metal-based processes. Iron can be considered as one of the 
least toxic transition metals and it is widely present in biological systems.32 For this 
reason, its use in catalysis implicates less toxicity problems than the use of other 
transition metals: limits for residual iron traces are hundreds times greater when 
compared to noble metals.33 From a merely scientific perspective, research on iron 
catalysis would disclose new prospects and give exciting insights in the relatively 
underdeveloped field of iron-catalysis, where new catalytic systems and patterns are to 
be devised and studied. Given those facts, many scientists have recently devoted their 
research activity to develop an efficient iron catalyst. When performing SCOPUS® search 
for "iron, catalysis" phrase an increased trend in recent 15 years is clearly seen (Figure 
1.4). So, as proclaimed by Bolm in 2009,34 has a new Iron Age begun? 
 
Figure 1.4 Number of iron catalysis-related publications over the last 35 years. 
 On the other hand, the Fe-based catalytic reductions reported so far suffer from 
serious limitations, such as difficult synthesis/lack of robustness of the catalyst, moderate 
activity/(enantio)selectivity, high cost/poor atom economy of the catalyzed process. 
These limitations need to be overcome, in order for Fe-catalysis to become of practical 
utility for the industrial production of fine chemicals. 
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1.5 Aim of the thesis 
 The aim of the research carried out during my PhD was to develop new iron 
catalysts for hydrogenation of various unsaturated compounds (like olefins or ketones) 
that could possibly satisfy the following requirements:  
a) high efficiency (conversion and enantioselectivity);  
a) simple preparation of the ligands/complexes from commercially available 
materials;  
b) reasonable stability of the catalysts or pre-catalysts to air and moisture; 
c) affordable cost of reagents and good atom economy of the catalytic process. 
 We were trying to base our studies on existing catalytic systems and develop 
them further to meet our expectations. In course of our research, we have investigated 
mostly three classes of iron complexes, namely: 
a) iron N,N,N,N-ligand based complexes for the hydrogenation of olefins and 
ketones (described in Chapter 3); 
b) iron isonitrile complexes for the asymmetric transfer hydrogenation of ketones 
(described in Chapter 4); 
c) (cyclopentadienone)iron complexes for the asymmetric hydrogenation of ketones 
(described in Chapter 5). 
 We tried also to find new possible applications of existing iron catalytic systems, 
which resulted in finding new iron catalysts for ester hydrogenation (described in 
Chapter 6).
  
 
 
 
 
 
2 Iron catalyzed hydrogenations: state of the art 
2.1 General difficulties related to the development of new iron catalysts 
 Iron catalysis, as the first-row transition metal catalysis in general, presents 
unique features which usually are not encountered with traditional precious metal 
compounds. To mimic noble metals, one-electron redox changes must be suppressed 
and two-electron redox interplay (e.g. Fe0/FeII) facilitated. Harnessing radical chemistry, 
contending with multiple oxidation states and coping with paramagnetic compounds are 
all potential obstacles when entering the field of iron chemistry.35 
 Furthermore, most of Fe(II)-complexes are paramagnetic due to the small energy 
gap (Δ0) between the t2g and the eg orbitals (see Figure 2.1), and therefore NMR 
spectroscopy is scarcely useful for their characterization, which mostly relies on mass 
spectrometry and X-ray diffraction. 
 
Figure 2.1 MO diagrams for octahedral crystal field: distribution of six valence electrons 
 in high-spin and low-spin Fe(II)-complexes. 
 
2.2 Multidentate ligands 
 Interactions between ligands and metals are defining the properties of metal 
complexes. Use of tri- and tetradentete ligands is a widely exploited way to stabilize the 
metal centre. They can bear phosphorus and/or nitrogen donors such as porphyrins or 
diimiodiphospines. Besides stabilizing the active metal centre, these structures can be 
easily tuned for specific stability and selectivity needs.36 Nevertheless, in most chemical 
catalyzed transformations, their structure is not affected by the course of the reaction, 
so they just act as "spectators" and the main reactivity is occurring at the metal centre. 
Then, in order to improve the catalytic properties of the complexes, the typical approach 
is to modify the ligand by changing its steric and electronic properties. 
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2.2.1 Cooperative and redox non-innocent ligands 
 One of the main difficulties to use first-row transition metals is their electronic 
structure, different from that of noble metals. As already mentioned in Paragraph 1.4, 
precious metals easily undergo two-electron redox changes (e.g., RhI/RhIII, IrI/IrIII, 
Pd0/PdII) that can be used to promote bond breaking or making. On the contrary, typical 
base metals are more prone to one-electron redox changes. This tendency is a challenge, 
both for reactivity control as well as stabilizing and maintaining the catalytic functions of 
complex.  
 To tackle these undesired electron properties, recent advances brought new type 
of "reactive" ligands that can play much more significant roles in bond-making and bond-
breaking processes.37 The main idea behind those new ligands is their synergistic 
cooperation with the metal, which can facilitate the catalytic transformation. In principle 
they can be divided into two categories, redox non-innocent or cooperative ligands, but 
often they can exhibit properties from both categories. 
 In redox non-innocent (redox active) ligands, it is ambiguous to determine the 
oxidation state, both the metal and the ligand parts of a complex. To do so, usually set of 
spectroscopic studies have to be performed, like: Raman or electron paramagnetic 
resonance (EPR), X-ray absorption (XAS), UV-vis or Mössbauer spectroscopy. The "non-
innocent" term, was introduced by Jørgensen in 1966.38 By delocalizing part of electronic 
density of the complexes, they become a kind of "electronic reservoir" during the 
reaction and catalytic process. As such, they can allow multi-electron transformations for 
metals, for which this kind of transformations are unfavorable. They can also initiate and 
control radical-type transformations. Additionally to the metal, they can become a place 
where a redox process can also occur. As a result, new "redox isomers" can form, which 
should not be confused with resonance structures, and can exhibit a variety of different 
properties and reactivities.  
 Cooperative (or chemically non-innocent) ligands are "participating directly in 
bond-activation reaction and undergo reversible chemical transformations".39 The metal 
part of the complex, although it can (but does not have to) poses an intrinsic reactivity, 
its main role is to act as a binding site and bring reactants together. In that way, the 
metal and the ligand acts cooperatively in a synergistic way and their interactions triggers 
a chemical transformation.  
 Non-innocence should not be identified strictly with a particular group of ligands. 
It is rather a state, which can be attributed to any ligand under the right conditions. 
Observed innocence behavior of ligand in a metal complex, does not guarantee that it 
will act the same with different metal or under different conditions. Only detailed 
spectroscopic investigations can confirm non-innocent structure of the ligand in the 
specific transformation. 
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2.3 Hydrogenation of alkenes and alkynes 
2.3.1 Iron carbonyls 
 The first iron complex - iron pentacarbonyl was discovered in 1891 independently 
by Berthelot40 and Mond.41 Together with its related homoleptic iron clusters (Figure 
2.2), it was used in the initial efforts for iron-catalyzed hydrogenations.42 Carbon 
monoxide ligands served as strong field ligands, capable of stabilizing low spin electronic 
structures of iron(0). 
 
Figure 2.2 Homoleptic ironcarbonyl complexes. 
 Fe(CO)5 was used by Frankle et al. to hydrogenate methyl linoleate and methyl 
linolenate to get monoenoic fatty esters.43 Noyori and co-workers were among next 
researchers who used iron pentacarbonyl to obtain saturated ketones from α,β-
unsaturated ketones with very good yields.44 Wrighton and co-workers found that the 
activity of Fe(CO)5 under ambient conditions is improved upon constant UV irradiation, 
although only low yields were obtained with narrow variety of alkene substrates.45 
The mechanism of the hydrogenation was studied by Grant and co-workers.46 The active 
species in the hydrogenation was found to be Fe(CO)3, with a vacant site for coordination, 
which is formed from Fe(CO)5 upon heating or photoirradiation. This activation pathway 
(with temperatures >150°C or upon constant UV-irradiation) is a drawback which 
prevents the potential practical use of those type Fe0 carbonyl complexes. 
2.3.2 Biomimetic complexes 
 Several biomimetic catalysts were proposed by researchers who took inspiration 
from natural iron-complexes. Kano and co-workers used Fe-porphyrines together with 
NaBH4 as a hydride source to radically hydrogenate styrene, getting TOFs up to 81 h
-1.47 A 
similar approach was later presented by Sakaki et al. with porphyrine 1 to hydrogenate 
α,β-unsaturated esters with a high turnover frequencies (TOFs) up to 4850 h-1 (Scheme 
2.1).48 Studies revealed that besides a hydride from NaBH4, a proton transferred from 
methanol was involved in the hydrogenation. 
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Scheme 2.1 Reduction of α,β-unsaturated ester catalyzed by iron porphyrin 1. 
 Inspired by iron-sulfur clusters present in the active sites of hydrogenase 
enzymes, a deeper biomimetic approach was reported by Inoue et al.49 Using Fe4S4 
cluster 2 activated by PhLi, it was possible to hydrogenate 1-octene and stilbene with 
very good yields, although reported catalyst 2 was more active with (Z)-alkenes (Scheme 
2.2). 
 
Scheme 2.2 Reduction of olefins using bio-inspired iron cluster catalyst 2. 
 
2.3.3 Multidentate P-ligand complexes 
 The first catalyst able to hydrogenate alkyne bond was a multidentate P-complex 
3 developed by Bianchini and co-workers in 1992.50 This catalyst was able to promote the 
reduction of terminal alkynes to corresponding alkenes at room temperature, under 
atmospheric pressure of H2 (Scheme 2.3). The complex 3 is an example of a cooperative 
involvement of the ligand during the transformation, as it can leave a free coordination 
site for the incoming substrate by unfastening one terminal phosphine arm. The bulkier 
alkynes substituents were, the lower conversions were obtained, but the reaction always 
proceeded with a full selectivity of reducing alkynes to alkenes. It was postulated that 
crucial insertion of olefin to iron hydride was not occurring in order to get fully saturated 
products. 
 
Scheme 2.3 Selective reduction of pent-1-yne using multidentate P-complex 3. 
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 A more recent example of polydentate phosphine complex 4 was reported by 
Peters and Daida in 2004 (Scheme 2.4).51 Hydrogenation of alkenes required high catalyst 
loading (10 mol%), while alkynes were undergoing undesired side reactions, such as 
reductive dimerisation or polymerization. Peters proposed that the hydrogenation with 
catalyst 4 occurs with an unusual FeII/FeIV catalytic cycle, together with reversible 
dissociation of the ligand from the iron centre, in a similar way described by Bianchini.53 
 
Scheme 2.4 Hydrogenation of olefins using by polydentate phosphine catalyst 4. 
 The Peters' group continued their efforts to hydrogenate ethene and styrene, but 
new ferraboratrane complex 5 (Scheme 2.5) allowed to achieve only low TOFs  
(up 15 h-1).52 Despite these not encouraging results, a detailed mechanistic studies about 
the transformation were performed which revealed that a boron atom can act as 
a hydride carrier being accompanied by reversible iron-boron bond cleavage. 
 
Scheme 2.5 Hydrogenation of olefins using by ferraboratrane catalyst 5. 
 A selective transformation of alkynes to alkenes by the means of transfer 
hydrogenation was reported by Beller and co-workers in 2012.53 In situ formed catalyst 
from Fe(BF4)2·6H2O and a tetraphos ligand 6, together with formic acid as hydrogen 
source gave nearly quantitative yields for a series of aromatic alkynes (Scheme 2.6).  
 
Scheme 2.6 Selective hydrogenation of alkynes to alkenes using Fe(BF4)2·6H2O/tetraphos ligand 6 complex. 
2.3.4 P,N,P- and N,N,N,N-ligand complexes  
 In 2013 Milstein and co-workers reported acridine-based P,N,P-iron pincer 
complex 7 for hydrogenation of alkynes to alkenes with high yields and excellent E-
selectivity (Scheme 2.7).54 This reaction did not required addition of base. Moreover 
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many functional groups like carbonyl, nitrile or halogen substituents were not affected by 
the course of the hydrogenation. 
 
Scheme 2.7 Selective hydrogenation of alkynes using Milstein acridne-based PNP-iron pincer complex 7. 
 The group of Thomas employed in situ formed complex from a tetradentate 
iminopyridine ligand 8 with FeCl2, which was subsequently reduced with an 
organometallic coupling reagent (iPrMgCl) to form active, low valent catalyst. This 
allowed to avoid to work with a highly air- and moisture sensitive low valent iron species. 
Thomas and co-workers were able to hydrogenate a broad range of mono-substituted, 
1,1- and 1,2-substituted aryl- and alkyl-substituted alkenes (Scheme 2.8).55 
 
Scheme 2.8 Hydrogenation of alkenes with in situ obtained tetradentete N,N,N,N-iron complex. 
2.3.5 (Cyclopentadienyl)iron complex  
 In 2014, a very interesting example of transfer hydrogenation of alkynes with 
isopropanol was reported by Nakazawa and co-workers.56 They used a (hydrido)iron 
complex 9 with Si-H functionalized cyclopentadienyl ligand to achieve conversion of 
alkynes to alkenes and alkanes, although only partial and in a non-selective manner 
(Scheme 2.9). The obtained results were not spectacular, but they were the first 
reported example of iron complex involved in a transfer hydrogenation reaction from 
isopropanol to an alkyne or an alkene. Interesting mechanistic studies were performed, 
according to which, the hydrogen atoms were transferred first by hydrometalation, 
followed by reductive elimination. A more detailed description of (cyclopentadienyl)iron 
complexes will be discussed in the Paragraph 2.4.7. 
 
Scheme 2.9 Alkyne transfer hydrogenation with (hydrido)iron complex 9. 
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2.3.6 Bis(iminopyridine) complexes 
 The most important group of iron catalysts for alkene reduction was introduced 
by group of Chirik in 2004.57 The design of a new iron catalyst 12 stemmed from 
combining previous observations of active carbonyl compounds for alkene 
hydrogenation (Figure 2.2) together with a polymerization catalysts 11 made by Gibson 
and Brookhart.58 As it was confirmed that 10 (Fe(CO)3 with a vacant site) is the active 
species in hydrogenation of olefins promoted by iron carbonyls,46 Chirik postulated that a 
similar reduced bis(iminopyridine) [PDI] bis(dinitrogen) iron complex 12 would be 
isolobal to it (Figure 2.3). Moreover, PDI ligand was straightforward to synthesize and 
easy-to-tune.59 In contrast to the homoleptic iron carbonyl compounds, it provided the 
opportunity to synthesize a library of new catalysts by tuning both steric and electronic 
properties.  
 
Figure 2.3 Concept for a new iron catalyst 12. 
 The first generation catalyst 12 exhibited an excellent activity in the 
hydrogenation of olefins. An unprecedented activity for a base metal was obtained, with 
TOF of 1814 h-1 for reducing 1-hexene at room temperature and under 1 atm H2 (Scheme 
2.10). This result exceeded the efficiency of many classical noble metal catalysts like 
Pd/C, Wilkinon's (Ph3P)3RhCl and Crabtree's [(COD)Ir(PCy3)Py]PF6, under identical 
conditions. Internal alkenes required prolonged reaction times in comparison to terminal 
olefins.  
 
Scheme 2.10 Olefin hydrogenation with catalyst 12. 
 An additional catalyst's feature was the possibility of conducting solvent-free, 
neat reactions. The system was not affected by various functional groups like amines, 
esters, ketones or ethers.60 Albeit the catalyst was undergoing decomposition with α,β-
unsaturated ketones, it was able to achieve TOFs up to 240 h-1 in the hydrogenation of 
α,β-unsaturated esters to corresponding saturated esters. The steric optimization of 
ligand allowed to improve the activity of the catalyst 13 (Figure 2.4), but a more 
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remarkable effect was obtained upon introduction of electron donating substituents like 
NMe2 at the 4-position of the pyridine ring (complex 14). Also dinuclear catalyst 15 
revealed excellent catalytic activity. 
 
Figure 2.4 Ligand optimization effects on hydrogenation of ethyl 3-methylbut-2-enoate. 
 A combination of spectroscopic techniques and density functional theory (DFT) 
calculations revealed that in these formally Fe0 compounds (with neutral ligands), iron 
had actually oxidation state +2 and the metal had transferred two electrons to the 
bis(imino)pyridine ligand (Figure 2.5).61 The latter is supposed to act as a redox-active 
ligand in the course of the catalytic cycle, as it changes its charge state and behave as a 
redox non-innocent ligand (see Paragraph 2.2.1). 
 
Figure 2.5 Incorect Fe(0)
 
and correct Fe(II) structures of complex 12. 
 The Chirik's group evaluated replacement of the imino functionalities present in 
reported iron complexes with phospino groups (Figure 2.6).62 The catalyst 16 had a 
different coordination model, as hydrogen atom replaced one of nitrogen ligands. 
Nevertheless, it did not lead to the increased activity. A lower TOF of 325 h-1 was 
achieved in the hydrogenation of 1-hexene under the same conditions as in Scheme 
2.10. 
 
Figure 2.6 Iron-aminodiphosphine complex 16. 
 Following research on different imino functionalities, new iron α-diimine 
complexes were obtained (Figure 2.7).63 As the dinitrogen-substituted complexes were 
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unstable, ligands like alkynes, alkenes (17) or dialkenes (18) were introduced to stabilize 
the structure. However, using conditions similar to those previously reported for 12 
(Scheme 2.10), only relatively low TOFs (90 h-1) were achieved by both of them in the 
hydrogenation of 1-hexene. 
 
Figure 2.7 α-Diimine iron alkene complexes 17 and 18. 
 Despite the significant achievements made by Chirik's group, their catalysts suffer 
from serious practical limitations which prelude their industrial application. They are 
highly air-sensitive, hence their synthesis and manipulation must take place under 
rigorously dry conditions, inside the glovebox, under argon atmosphere. 
2.3.7 Iron nanoparticles 
 Homogenous reduction of alkenes and alkynes is not limited to iron carbonyls or 
multidantete ligand complexes. Unlike the above mentioned authors, de Vries and co-
workers, reported a non-ligand approach using iron nanoparticles (NPs).64 Fe-NPs were 
prepared by reducing FeCl3 with EtMgCl in THF, basing on methodology described by 
Bedford.65 A quick and quantitative conversion was obtained with cis-1,2 and 1,1-
disubstituted alkenes. A lower reduction rate was observed with 1,2-trans-disubstituted 
and cyclic cis-alkenes. 1-octyne was hydrogenated with TOF 118 h-1. Generally, the 
hydrogenation of tri- and tetrasubstituted alkenes with the Fe-NPs was unsuccessful. 
Also the presence of OH groups in substrates had the retardation effect on the rate of 
reaction. Fe-NPs were found to be rather stable, and were successfully applied in 
continuous hydrogenation of norbornene.  
 Similar iron nanoparticles were also found to be catalytically active, when 
supported on a graphene. They were utilized for hydrogenation reactions with various 
cyclic and terminal olefins.66 The main advantage of thise system was an efficient 
removal of the nanoparticles by simple magnetic decantation and re-using them without 
any significant loss in the activity. 
 To induce a high Z-selectivity in alkene hydrogenation using Fe-NPs, Wangelin, 
and co-workers used them in a biphasic heptane/ionic liquid system.67 The nitrile 
function was essential for achieving high Z-selectivity and it could be introduced either as 
a substituent in the ionic liquid or as an acetonitrile additive. It was also possible to easily 
remove the iron nanoparticles, as the ionic liquid prevented from their aggregation, 
enabling to decant them and being re-used without any loss of activity. 
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 Ultra small Fe-NPs were obtained by Beller and co-workers from the 
decomposition of {Fe[N(SiMe3)2]}2 under hydrogen.
68 These NPs promoted the 
hydrogenation of terminal alkenes and alkynes, as well as cyclic alkenes, but were 
ineffective for non-cyclic internal alkenes and internal alkynes.  
 
2.4 Hydrogenation of ketones and imines 
2.4.1 Iron carbonyl in situ systems 
 Noble metals remained the only option for the catalytic hydrogenation of 
carbonyl compounds until 1980s, when Markó and co-workers reported the use of 
Fe(CO)5 together with triethylamine to hydrogenate various ketones and aldehydes to 
the corresponding alcohol products.69 
 More recently, in 2004 Gao and co-workers used Markó's catalytic system 
together with a chiral ligand 19 for an asymmetric transfer hydrogenation (ATH) with 
isopropanol as a hydrogen source (Scheme 2.11).70 This system revealed good to very 
high conversions with moderate to good enantiomeric excesses. The highest ee values 
(up to 98% ee) were obtained for sterically crowded ketones. 
 
Scheme 2.11 Asymmetric transfer hydrogenation of ketones using catalytic system with ligand 19. 
2.4.2 P,N,N,P-complexes 
 The Gao's system (Scheme 2.11) was an inspiration for Morris and co-workers. In 
2008, they synthesized a well-defined iron diiminophospine complexes 20a-b.71 The 
mentioned catalysts were prepared by the condensation of commercially available 
diamines and phosphinealdehyde (Scheme 2.12). It was expected that due to 
hydrogenation reaction course, the imine donors in synthesized complexes would be 
reduced to amines. 
 
Scheme 2.12 First generation diiminophospine complexes 20. 
 Complex 20a was employed for the ATH of a range of ketones and imines using 
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isopropanol and allowed to obtain high conversions, but only modest enantioselectivities 
(Scheme 2.13). TOFs up to 907 h-1 were reported, which were comparable with those of 
the ruthenium catalyst developed up to that moment. 
 
Scheme 2.13 ATH of ketones and imines using complex 20a. 
  Further research led to an unexpected results. Morris discovered that the active 
species in the reaction were actually iron nanoparticles formed from complexes 20.72 
This was the first reported example of use of Fe-NPs to promote enantioselective 
transformations. According to the authors, the flexible six-membered chelate rings were 
responsible for the occurring formation of Fe-NPs. Under reducing conditions, they 
allowed ligand dissociation to form active Fe-NPs. To prevent this phenomenon, Morris 
and co-workers developed the second generation "FeATHer" complexes 21a-d, featuring 
five-membered rings, obtained from the condensation of an enantiopure diamine and 
dialkyl- or diarylphosphinoacetaldehydes (Figure 2.8).73 
 
Figure 2.8 Examples of 2
nd
 generation of "FeATHer" precatalysts 21. 
The maximum TOF obtained by the second generation catalysts in the ATH of ketones 
(under similar conditions presented on Scheme 2.13) reached 30 000 h-1, together with 
high enantiomeric excesses (up to 90%). Along many investigated structural changes in 
his second generation catalysts, crucial for activity appeared to be the substituent on 
phosphorus. It had to be moderate size and have moderate donor ability, otherwise 
complexes were catalytically inactive.74 
 Complex 21d proved to be also an active catalyst for ATH of variety of prochiral 
ketimines bearing diphenylphosphinoyl group at the nitrogen (Scheme 2.14). High 
conversions (up to 91%) with excellent ee (95-99%) were reported. 
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Scheme 2.14 ATH of diphenylphosphinoyl ketoimine using 2
nd
 generation "FeATHer" complex 21d. 
 Further mechanistic studies on this complex revealed that before the actual 
catalysis starts, the ligand gets modified twice (Scheme 2.15).75 The first step of 
activation is deprotonation of 21d using a strong base in order to form bis-anionic bis-
eneamide complex 21d.1. In the second activation step occurs a slow addition of a 
proton and a hydride from isopropanol to one of the eneamide groups, forming 21d.2. 
This "one-side" hydrogenated monoanionic amido-enamido complex is the active iron 
complex in the ATH. Remarkably, further studies of Morris' group confirmed that a "both-
sides" hydrogenated complex is a totally non-active catalyst.76 In the course of the 
catalytic cycle the P,N,N,P-ligand 21d2 picks up a proton and a hydride from isopropanol 
(21d.3 -> 4) to deliver them to the substrate (21d.5). The hydride transfer from iron to 
the carbonyl group of acetophenone proceeds according to an outer-sphere pathway, 
with no substrate coordinated to the metal, and proton transfer from the amino group of 
the ligand to the carbonyl oxygen. As the diiminodiphosphino ligand actively participates 
in the mechanism of C=O reduction by mediating the proton transfer, this is the perfect 
example of redox non-innocent ligand. The described outer-sphere mechanism, closely 
resembles the one described by Noyori for Ru(II).77  
 
Scheme 2.15 Proposed mechanism of activation of the 2
nd
 genaraton of "FeATHer" complex 21d. 
 Following the lead of importance of unsymmetrical ligands, the third generation 
catalysts 22 (obtained by condensation of enantiopure P−NH−NH2 diamine and dialkyl- or 
diaryl-phosphinoacetaldehydes) meant to involve all of the iron complex rapidly into the 
Iron catalyzed hydrogenations: state of the art 
 
hydrogenation (Figure 2.9).78  
 
Figure 2.9 Examples of 3
rd
 generation of "FeATHer" precatalysts 22. 
 As expected, treatment of new complexes with excess of base, allowed to directly 
convert them to catalytically active unsymmetrical amide-enamide catalyst. The obtained 
catalysts were very active for the ATH of a huge range of ketones and ketoimines, 
achieving TOF up 150 s-1 and 99% ee (Scheme 2.16). Moreover, an easy synthesis of the 
pre-catalyst allowed to optimize its structure for certain substrates. 
 
Scheme 2.16 ATH of ketones using 3
rd
 generation "FeATHer" complex 22a. 
 The Morris' group continued their research towards a new catalyst for the 
asymmetric hydrogenation using molecular hydrogen, instead of transfer hydrogenation 
with isopropanol.79 The new complex 23 prepared by the condensation of enantiopure 
P−NH2 amine and dicyclohexylphosphinoacetaldehyde (Scheme 2.17) was activated with 
LiAlH4 and alcohol to obtain active P,NH,P catalyst for reducing ketones and imines. TOFs 
up to 1980 h-1 with ee up to 85% were obtained, but the structure of the active catalyst is 
still not clear. 
 
Scheme 2.17 4
th 
generation precatalyst 23 for AH of ketones and imines. 
2.4.3 Macrocyclic complexes 
 Gao and co-workers performed further studies on diamino- and 
diiminodiphospine ligands to turn them into macrocyclic structures.80 They described a 
condensation of bis(o-formylphenyl)-phenylphosphane 24 and (R,R)-cyclohexane-1,2-
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diamine 25 which led to a 22-membered diiminodiphospine macrocycle 26 (Scheme 
2.18). It was followed by a reduction of 26 with NaBH4, which yielded corresponding 
diaminodiphospine ligand 27. 
 
Scheme 2.18 Synthesis of chiral macrocyclic ligands 26 and 27. 
 New macrocycles, together with Fe3(CO)12, were compared in ATH of 
propiophenone (Scheme 2.19). The diiminodiphospine ligand 27 appeared to be much 
more active than diiminodiphospine macrocycle 26. By contrast, use of different iron 
sources (like iron(0) Fe2(CO)9, iron(II) FeCl2 or iron(III) FeCl3) gave almost no activity in the 
reaction with both ligands.  
 
Scheme 2.19 ATH of propiophenone catalyzed by iron complexes with chiral macrocycles 26 and 27. 
 Gao and co-workers found that the use of ammonium salts is promoting the 
reaction, although its role remained unknown. The substrate screening revealed high 
activity of the catalytic system for a broad range of aromatic and heteroaromatic ketones 
(Scheme 2.20).  
 
Scheme 2.20 ATH of ketones catalyzed by iron complexe with chiral macrocycle 27. 
 To gain more knowledge about possible interactions between iron and the 
macrocycle, Gao and co-workers synthesized iron catalyst 28, but it possessed lower 
catalytic activity than catalytic system formed in situ (Scheme 2.21). In fact, this could 
suggest that 28 is not the active species in the ATH of ketones.  
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Scheme 2.21 ATH of acetophenone catalyzed by chiral P2N4−Fe(0) complex 28. 
 Subsequent work of Gao's group showed also the high activity of chiral 
macrocycle 27 in the AH of aromatic and heteroaromatic ketones (Scheme 2.22).81 
Preliminary studies on the hydrogenation's mechanism suggest formation of chiral 
macrocycle-modified iron nanoparticles which could be the active species.  
 
Scheme 2.22 AH of ketones using macrocyclic ligand 27. 
 Recently Mezzetti and co-workers developed new chiral C2-symetric P2N2-
macrocyclic ligands and their iron(II) isolated complexes.82,83 Chiral P2N2 -iron(II) complex 
29 revealed very good activity in ATH, both in terms of conversion and enantioselectevity 
(Scheme 2.23).84  
 
Scheme 2.23 ATH with chiral P2N2 -iron(II) complex 29. 
 Replacing diimino macrocycle, with diamino analogue, led to even higher activity 
in ATH of ketones (Scheme 2.24).85 Excellent results in terms of yields (up to 98%) and 
enantioselectivities (up to 91% ee) were obtained with ketones, enones and imines, 
albeit using only 0.1 mol% of catalyst. In both of presented classes of complexes, iron's 
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isonitrile ligands, turned out to affect both the enantioselectivity and the activity of the 
catalyst. 
 
Scheme 2.24 ATH with chiral P2(NH)2 -iron(II) complex 30. 
2.4.4 P,N,P-pincer complexes 
 In 2011 Milstein and co-workers reported the use of (hydrido)iron(II) pincer 
P,N,P-complex 31 in ATH of ketones, achieving high turnover numbers (TONs) – up to 
1880.86 Despite using only 0.05 mol% catalyst loading, the reaction proceeded under 
room temperature (Scheme 2.25). 
 
Scheme 2.25 ATH with iron(II) pincer complex 31. 
 A possible reaction mechanism for ketone hydrogenation (Scheme 2.26), features 
hydride transfer from activated catalyst 31.1 to the coordinated substrate (31.2 -> 31.3), 
according to an inner-sphere pathway. Remarkably, in this mechanism the pyridine ring 
of the tridentate ligand plays a key role flipping between the aromatic (31.4) and the 
dearomatised form (31.1), thus acting as a redox non-innocent ligand. 
 
Scheme 2.26 Possible reaction mechanism for ketone hydrogenation using complex 31. 
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 Using the second-generation iron pincer catalyst 32 featuring a borohydride 
ligand, the same research group was able to achieve comparable TONs as the first 
generation, without any addition of base required (Scheme 2.27).87 
 
Scheme 2.27 Base-free ATH with iron(II) pincer complex 32. 
2.4.5 Multidentate N- and P-ligand complexes 
 Beller and co-workes worked also on ATH of ketones.88 The employed catalytic 
system combined Fe3(CO)12 or FeCl2, the ligand 33 and PPh3, in isopropanol as hydrogen 
donor (Scheme 2.28). The reaction outcome was strongly dependent on the choice of 
base, but when iPrONa or tBuONa were used, corresponding alcohols were obtained 
with high yields, regardless applied iron source employed. 
 
Scheme 2.28 ATH with a terpy ligand 33. 
 Beller's group also pursued a biomimetic approach, using in situ generated iron 
poprphyrines instead of iron triphenylphospine systems (Scheme 2.29).89 This system was 
less base-dependent and allowed to obtain excellent conversion in the transfer 
hydrogenation of ketones with isopropanol, again independent on the applied iron 
source. 
 
Scheme 2.29 ATH with a in situ generated iron poprphyrine from 34. 
 A well-defined iron(II) tetradentate phospine complex 35 was employed by Beller 
and co-workers for the selective hydrogenation of α,β-unsaturated aldehydes.90 Excellent 
yields of allylic alcohols were obtained from corresponding allylic aldehydes, as well as 
alcohols from aromatic, heteroaromatic or alkyl aldehydes (Scheme 2.30). This complex 
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could leave a free coordination site for the incoming substrate by unfastening one 
terminal phosphine arm, as proposed by Bianchini et al. for the related iron-catalyzed 
hydrogenation of alkynes.50 
 
Scheme 2.30. ATH with a iron(II) tetradentate phospine complex 35. 
2.4.6 Isonitrile complex 
 In 2010 Reiser and co-workers reported a chiral bis(isonitrile)iron(II) complexes 36 
for the ATH of aromatic and heteroaromatic ketones.91 The transformation proceeded 
under mild conditions but although obtaining very good conversions, only modest 
enantioselectivities could be achieved (up to 67% ee). 
 
 
Scheme 2.31 ATH with a chiral bis(isonitrile)iron(II) complex 36 
 For this transfer hydrogenation, a Meerwein-Ponndorf-Verley-type mechanism 
was proposed (Scheme 2.32). After activation of 36 with tBuOK, isopropanol is being 
coordinated to iron (36.1) and the catalytic cycle follows with reduction of coordinated 
isonitrile ligand to an imine (36.2). Formed acetone is being removed and the reaction 
follows an inner-sphere pathway, with substrate coordination at the FeII centre (36.3). 
Remarkably, the formation of an iron hydride does not take place. Rather, the imine with 
a hydride absorbed from isopropanol, transfers it to the substrate (36.4). Therefore, in 
this case the ligand shows a clearly non-innocent behavior owing to the peculiar 
properties of the isonitrile group. Catalytic cycle is closed by displacing the newly 
reduced carbonyl with a fresh isopropanol from the reaction solution. 
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Scheme 2.32 Meerwein-Ponndorf-Verley mechanism for ATH with bis(isonitrile)iron(II) complex 36. 
2.4.7 (Cyclopentadionene)iron complexes 
2.4.7.1 Reduction of aldehydes, ketones and imines 
 (Cyclopentadionene)iron complexes were firstly reported by Reppe and Vetter in 
1953.92 They are easy to synthesize and to purify (they are stable to flash 
chromatography over silica). Moreover their structure can be easily tuned. For a long 
time, despite their unique structural features they were not highly investigated - they 
were regarded as "scientific curiosities". It took over 40 years until they were studied 
with more attention by Knölker93 and Pearson.94 In 1999, Knölker and co-workers 
synthesized and isolated the first (hydrocyclopentadienyl)iron complex 38 (now known as 
the Knölker catalyst) from the bench-stable (cyclopentadienone)iron complex 37 using a 
Hieber-base reaction (Scheme 2.33).95 
 
Scheme 2.33 Obtaining iron hydrocyclopentadienyl complex 38 by a Hieber-base reaction from 37. 
 Still, as the main focus of the research was to obtain the metal-free 
cyclopentadienone ligand, the potential use of hydride 38 in catalysis remained unseen 
until 2007. In this year Casey and Guan96 reported that complex 38 possesses similar 
properties to structurally related Shvo catalyst, which was known since 1985 (Scheme 
2.34).97 
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Scheme 2.34 Shvo dimeric pre-catalyst 39 and its active structures 39.1 and 39.2. 
 Casey and Guan demonstrated that the hydride 38 is a highly efficient catalyst for 
the chemoselective hydrogenation of aldehydes, ketones and imines under mild 
conditions (Scheme 2.35). A large number of groups, such as isolated carbon-carbon 
double or triple bonds, halides, nitro groups or epoxides, were perfectly tolerated under 
the described conditions. Further computational studies performed by Sun and co-
workers confirmed that catalyst 38 is not able to hydrogenate olefins and alkynes under 
relatively low temperatures.98 Hydride 38 was also proved to work under transfer-
hydrogenation conditions.  
 
Scheme 2.35 Hydrogenation and transfer hydrogenation using (hydrocyclopentadienyl)iron complex 38. 
 The main drawback of the active hydride 38, was its sensitivity to air and light, 
which makes the glove-box necessary to handle it. Later contributions by other 
researchers demonstrated that it is possible to use bench-stable (cyclopentadienone)iron 
pre-catalysts such as 37 and to activate them in situ (Scheme 2.36, top part - Activation). 
The first method is based on the selective mono-decoordination of one of the CO ligands 
with oxidative cleavage using Me3NO.
99 The same effect can be also obtained by UV 
radiation.100 Obtained complex act-A can be considered as a frustrated Lewis pair and as 
such, under hydrogen, is able to split H2 and form the active hydride B. The hydride itself, 
can be also generated by in situ Hieber reaction of (cyclopentadienone)iron A with 
aqueous bases.101 
 The mechanism of the transformation with this non-innocent ligand has been 
carefully studied.102 As in the Shvo's ruthenium catalyst, the ligand is able to shuttle 
between the cyclopentadienone act-A and hydroxycyclopentadienyl B form, enabling an 
uncharacteristic catalytic cycle involving Fe(0) and iron Fe(II) (Scheme 2.36, Cycle I). The 
active species act-A splits hydrogen and then catalyzes the reduction of carbonyl 
compounds according to a concerted outer-sphere mechanism, in which the OH group of 
the ligand allows transient substrate's activation by hydrogen-bonding. Moreover, 
hydride B is acting under the same mechanism (Scheme 2.36, Cycle II) is also able to 
catalyze dehydrogenation of alcohols to carbonyl compounds in an Oppenauer-type 
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oxidation and "hydrogen-borrowing" reactions (like amination of alcohols). 
 
Scheme 2.36 Catalytic pathways of i) hydrogenation of C=O and C=N double bonds (Cycle I), and ii) Oppenauer-type 
alcohol oxidation (Cycle II) catalyzed by cyclopentadienone complexes act-A. 
 After optimizing the conditions for ketone hydrogenation, Beller and co-workers 
obtained TON up to 3800 using pre-catalyst 37 (Scheme 2.37).103 
 
Scheme 2.37 Hydrogenation of ketones using bench-stable 37. 
2.4.7.2 Asymmetric reductions 
 Attempts to perform enantioselective reductions using Knölker-type catalysts 
were made by the groups of Berkessel104 and Wills.105 Berkessel and co-workers replaced 
one of CO ligands from 39 with a chiral phosphoramidite ligand under UV irradiation or 
using Me3NO (Scheme 2.38).  
 
Scheme 2.38 Introducing a chiral ligand to the (cyclopentadienone)iron complex 38. 
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 Using this chiral pre-catalyst 40, acetohpenone was hydrogenated with only 31% 
ee. Moreover, hydrogenation required constant UV radiation to cleave the second CO 
ligand and to form active hydride species. To investigate the reason of a low 
enantioselectivity, NMR studies were performed. They revealed that upon 
hydrogenation, two iron hydride diastereoisomers 41a and 41b are formed at the newly 
generated iron-stereocenter in ratio 1:0.7 (Scheme 2.39). This occurred because of the 
non-selective dissociation of CO from the pre-catalytic complex 40 and explains the low 
enantioselectivity of the reaction. Moreover, upon hydrogenation, a partial removal of 
the chiral ligand occurred and gave 2% of the achiral, but most likely highly active hydride 
complex 42. 
 
Scheme 2.39 Formation of diastereoizomers upon hydrogenation of 40. 
 Wills and co-workers presented a different approach to solve the chirality 
problem.105 Instead of replacing a CO with a chiral ligand, they decided to use a chiral 
cyclopentadienyl ligand by insertion of a remote chiral centre in addition to the planar 
symmetry of a (cyclopentadienone)iron complex, thus obtaining pre-catalyst 43 (Scheme 
2.40). Performing the ATH of acetophenone in the presence of 43 with formic 
acid/triethylamine as a hydrogen source, only up to 25% ee was achieved. This poor 
enantiocontrol was independent on the metal employed, as the corresponding 
ruthenium chiral catalyst was able to achieve only 21% ee. 
 
Scheme 2.40 ATH of acetophenone using chiral (cyclopentadienone)iron complex. 
 Beller and co-workers developed a methodology for the asymmetric 
hydrogenation of N-aryl ketoimines based on the use of the achiral pre-catalyst 37 in 
combination with a chiral phosphoric acid - (S)-TRIP.106 For this reaction, the authors 
proposed a mechanism in which the Brønsted acid acts as a “chiral template” forming 
hydrogen bonds simultaneously with the substrate and with the catalyst (Scheme 2.41). 
A large number of different N-aryl ketoimines were hydrogenated with high yields and 
excellent ee. In a subsequent paper, Beller and co-workers used also this system to 
hydrogenate variety of quinoxalines to tetrahydroquinoxalines and 2H-1,4-benzoxazines 
to dihydro-2H-benzoxazines, again with high yields and excellent ee.107 In other 
Iron catalyzed hydrogenations: state of the art 
 
publication, Beller and co-workers used this methodology also for asymmetric reductive 
amination of ketones with anilines, once more with high yields and excellent ee.108 
Scheme 2.41 Hydrogenation of imines using iron pre-catalyst 37 and (S)-TRIP. 
 The above-mentioned methodology was employed in a combinatorial multi step, 
one-pot hydroamination of alkynes followed by enantioselective hydrogenation (Scheme 
2.42).109 The first step was catalyzed by gold(I) complex 44, followed by hydrogenation 
carried out using 37 with a chiral Brønsed acid. Once more, high yields and 
enantioselectivities were obtained. 
 
Scheme 2.42 One-pot enantioselective reductive hydroamination using 44, 37 and (S)-TRIP. 
2.4.7.3 Amination of aldehydes, ketones and alcohols  
 The cyclopentadienone complex 37 was also applied for reductive amination by 
the group of Renaud.110 This transformation was efficient for variety of primary or 
secondary amines and worked with both ketones and aldehydes. In a subsequent article, 
Renaud and co-workers reported that more electron-rich (cyclopentadienone)iron 
complex 45 was more effective for the reductive amination of aromatic aldehydes 
(Scheme 2.43).111 
 
Scheme 2.43 Reductive amination using complexes 37 and 45. 
 Feringa and Barta exploited further possibilities of amine functionalization using 
(cyclopentadienone)iron complex 37. They performed simple and direct N-alkylation of 
amines with alcohols using a hydrogen-borrowing process.112 A variety of primary 
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alcohols and amines were coupled with good yields. 
 
Scheme 2.44 N-alkylation of amines with alcohols using complex 37. 
 In comparison to reductive amination by Renaud (Scheme 2.43 and Scheme 
2.45A), alcohol substrates were acting as a hydrogen source in this process (Scheme 
2.45B), making it much easier to perform. Drawback of this hydrogen borrowing process, 
was its ineffectiveness with other than primary alcohols. 
Scheme 2.45 Comparison of: A) reductive amination and B) hydrogen borrowing methodologies to obtain alkylated 
amines. 
 Very recently, the hydrogen borrowing strategy was greatly improved by Zhao 
and co-workers.113 Using iron hydride 38, the active form of the pre-catalyst 37, together 
with a Lewis acid (finding AgF as the most efficient), they managed to perform amination 
of not only of primary alcohols, but secondary as well (Scheme 2.46). Mechanism of this 
transformation proceeded via hydrogen borrowing from alcohol (as so, use of an 
enantiopure alcohol leads to racemate product). The exact nature of the Lewis acid was 
not determined. Most likely AgF assisted in the imine formation step and activated it 
towards reduction by iron hydride 38. 
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Scheme 2.46 Lewis acid supported amination of secondary alcohol using catalyst 38. 
2.4.7.4 Other applications of iron cyclopetadienone complexes 
 In Paragraph 2.3.5, an alkyne transferhydrogenation with (hydrido)iron complex 
10 is described. Also in the following Paragraph 2.5.1, use of (cyclopentadienone)iron 
complexes 37 and 45 in the hydrogenation of sodium bicarbonate is presented. 
 
2.5 Hydrogenation of other carbonyl compounds 
2.5.1 Hydrogenation of sodium carbonate and carbon dioxide 
 The first hydrogenation of carbon dioxide and sodium bicarbonate using an iron 
catalyst, was described by Beller and co-workers in 2010 (Scheme 2.47).114 They used 
catalyst formed in situ from Fe(BF4)·6H2O and the tetraphos ligand 6 (similar catalytic 
system was used in later studies in the selective transfer hydrogenation of alkynes to 
alkenes, Paragraph 2.3.3). Obtained results were very promising for the use of iron 
catalyst in this new field. 
 
Scheme 2.47 Hydrogenation of sodium bicarbonate and carbon dioxide using tetraphos ligand 6. 
 In the follow-up research, they exploited analogous in situ formed catalytic 
system with ligand 46, used also later (as well-defined 35) in aldehyde hydrogenation 
(already described in Paragraph 2.4.5). A huge improvement in the catalyst activity was 
observed (Scheme 2.48).115 Sodium bicarbonate was hydrogenated with excellent TONs 
exceeding 7500. Carbon dioxide was reduced to methyl formate in the presence of 
methanol and triethylamine (as a base) with TONs reaching almost 1700. When 
hydrogenation was carried out in the presence of a secondary amine, DMF was obtained 
with TONs up to 5100. 
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Scheme 2.48 Hydrogenation of sodium bicarbonate and carbon dioxide using tetraphos ligand 44. 
 A new iron pincer complex 47 was used by Milstein and co-workers for the 
hydrogenation of bicarbonate and CO2.
116 Hydrogenation of CO2 was effective with TONs 
up to 788, but the hydrogenation of sodium bicarbonate led only to moderate yields 
(Scheme 2.49).  
 
Scheme 2.49 Hydrogenation of sodium bicarbonate and carbon dioxide using pincer complex 47. 
 Gonsalvi and co-workers used a tetraphos iron(II) catalyst 48 to hydrogenate 
sodium bicarbonate with very good TONs up to 1229 (Scheme 2.50).117 
 
Scheme 2.50 Hydrogenation of sodium bicarbonate using catalyst 48. 
 Recently Zhou and-coworkers proved that the (cyclopentadienone)iron complex 
37 can be also applied for hydrogenation of sodium bicarbonate with a good TONs up to 
450 (Scheme 2.51).118 Attempts to hydrogenate carbon dioxide were unsuccessful.  
 
Scheme 2.51 Hydrogenation of sodium bicarbonate using iron complex 37. 
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 In a recent work of Renaud and co-workers used previously described for 
reductive amination (see Paragraph 2.4.7.3), a diamino-related iron complex 45 which 
led to hydrogenations of sodium bicarbonate with TONs up to 1246 (Scheme 2.52).111 
 
Scheme 2.52 Hydrogenation of sodium bicarbonate using (cyclopentadienone)iron complex 45. 
2.5.2 Ester hydrogenation 
 In 2014 Milstein observed that the P,N,P-ligand complex 47, previously reported 
for the hydrogenation of carbon dioxide, was active in the hydrogenation of esters 
(Scheme 2.53).119 This was the first example of iron catalyst able to catalyze this 
transformation, although it was able to hydrogenate only activated trifluoroacetic esters 
to trifluoroethanol and as so, it presented no practical applications.  
 
Scheme 2.53 Hydrogenation of activated esters using catalyst 47. 
 Iron catalyzed hydrogenation of non-activated esters was described subsequently 
by groups of Beller120 and Guan/Fairweather.121 Inspired by osmium-catalysts for 
hydrogenation of esters,122 they found independently that a P,N,P-pincer (hydrido-
borohydride)iron complex 49 was able to hydrogenate esters under base-free conditions 
and with excellent yields (Scheme 2.54). Fully saturated alcohols were obtained from 
corresponding α,β-unsaturated esters. This catalyst was also active with fatty esters 
under neat conditions.  
 
Scheme 2.54 Hydrogenation of esters using catalyst 49. 
 The presented catalysts 47 and 49 clearly opened a new chapter in the ester 
hydrogenation, proving that it can be accomplished using complexes with a cheap and 
abundant metal such as iron. Yet, in order for these catalysts to become really suitable 
for the industrial use, their catalytic activity still has to be improved, and the pincer 
ligands ideally should be replaced with less expensive and easy-to-handle ones.  
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2.6 Summary of iron catalyzed reductions 
 In recent years, the iron catalyzed reductions were progressing really fast. In this 
chapter nearly 40 well-defined catalysts were described, from which the majority was 
reported just in recent 10 years. Selection of most important contributions and most 
important iron based catalytic systems is presented on Figure 2.10.  
 Undoubtedly the biggest contribution to the olefin reduction was brought by 
Chirik and co-workers (14) and up to now there are no examples of more active catalysts 
for carbon-carbon double bond reduction. Also no asymmetric hydrogenation was 
reported with any olefin. In alkyne reduction the best results were reported by Beller and 
co-workers (6) and Milstein and co-workers (8). Their systems provided good activity and 
selectivity, but a good catalyst for reduction of alkynes to fully unsaturated alkanes is still 
missing. 
 The biggest variety of catalyst is offered for the reductions of C=O bond. Many 
structurally different catalysts were proved to be effective in this field: P,N,N,P-ligands 
(22a), macrocylic P2N4- (27) or P2N2-ligands (30), pincer P,N,P-ligands (33), P,P,P,P-ligands 
(35), isonitrile (36) or cyclopentadienyl (38). Nearly all of the reported ligands are acting 
as chemically or redox non-innocent, proving that this is the best option to stabilize low 
valent iron species. In recent year, field of iron catalyzed reductions was expanded to 
hydrogenation of esters thanks to the P,N,P-catalysts 45 and 49, first developed by 
Milstein and co-workers and second reported independently by Beller and co-workers 
and Guan/Fairweather and co-workers.  
 Still, almost all of the catalysts reported so far, suffer of at least one serious 
limitation among the following: difficult synthesis, lack of robustness and moderate 
activity/enantioselectivity. In particular, it should be pointed out that Fe-based reduction 
catalysts are often difficult to handle due to air- and moisture-sensitivity. As a 
consequence, the usage of a glovebox is commonplace for synthesis and manipulation of 
many iron catalysts, and in some cases even for the setup of hydrogenation tests.107 
These drawbacks need to be overcome in order for iron catalysis to become of practical 
utility for the industrial manufacturing of fine chemicals. 
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Figure 2.10 Selection of the most important and effective iron based systems 
 for reductions of olefins, alkynes, ketones and esters. 
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3 Iron complexes with N,N,N,N-ligands 
3.1 Tetradentate N-ligands to stabilise Fe(II) metal center 
 Our initial studies, particularly focused attention on Fe(II) complexes, as the 
oxidation state +2: 
a) is the most stable oxidation state of iron under moderately reducing conditions; 
b) is compatible with the presence of the coordinated hydride required for some 
kinds of hydrogenation mechanisms; 
c) in principle, can allow two-electron redox processes with Fe0/FeII or FeII/FeIV 
interplay as well as mechanisms with participation of “non-innocent” ligands. 
 On the other hand, Fe(II) is very prone to oxidation to Fe(III), and therefore it 
usually needs to be handled under extra-dry and oxygen-free conditions. The best way to 
stabilize the reactive Fe(II) metal centre is the use of polydentate ligands, which provide 
the desired stabilization by means of kinetic (steric) and thermodynamic (entropic) 
effects. In particular tetradentate nitrogen-ligands were appealing, since: 
a) N-donors are expected to efficiently stabilize the relatively hard Fe(II); 
b) compared to P-ligands, which are also extensively used in iron catalysis, they are 
easier to prepare and more stable.  
 In fact, P-ligands are themselves often prone to oxidation, especially in the case of 
electron-rich phosphines. Indeed, tetradentate N-ligands considerably stabilize the Fe2+ 
cation, forming robust Fe(II) complexes having two coordination sites available for 
catalysis (Figure 3.1).123 According to the geometry of the chelating ligand, the two 
ancillary ligands X and Y may occupy cis- or trans- coordination sites. 
 
Figure 3.1 Octahedral Fe(II)-complexes featuring N,N,N,N-ligands. 
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3.2 Iron complexes for C-H oxidation 
 In recent decades, mononuclear tetradentate Fe(II) complexes for C-H oxidation 
were studied very carefully.124 Besides many metalloporphyrin catalysts, which are 
mimicking the reactivity of cytochrome P450, a variety of other tetradentate ligands 
were developed (Figure 3.2).  
 
Figure 3.2 Examples of relevant tetradentate N,N,N,N-ligands used to prepare mononuclear iron(II) complexes for 
alkane oxidations.
125
 
 Compared to porphyrins, tetradentate N,N,N,N-ligands usually require multi-step 
synthesis and offer lower stability to harsh oxidation conditions, but still, they are more 
appealing for the industry as cheaper and easier to prepare on a large scale. To be stable 
and useful in oxidation chemistry, these strong field tetradentate ligands have to be rigid 
and low reactive. As these principle requirements were in line with our assumption to 
use tetradentate N-ligands to stabilize Fe(II) for hydrogenation purposes, we decided to 
take inspiration directly from them. 
3.3 Chiral tetradentate N-ligand complexes 
 As a starting point for the development of new iron catalysts, the chiral 
octahedral Fe(II) complex Fe2 (Scheme 3.1) developed by White and Chen126 was chosen 
by virtue of its stability to air and moisture, easy preparation and modular structure, 
facilitating possible modifications. X-ray crystallographic analysis revealed that the chiral 
bipyrrolidine scaffold functionalized with two pyridine rings, constitutes a tetradentate 
N-ligand which leaves two cis coordination sites for the iron centre.127 
 
Scheme 3.1 Aliphatic C-H oxidation by catalyst Fe2. 
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 Whereas White and co-workers applied Fe2 for the oxidation of aliphatic C-H 
bonds, our aim was to test it in the enantioselective hydrogenation of activated olefins 
(i.e. possessing a donor atom close to the C=C bond). In this mechanistic speculation, iron 
would promote the reduction, while retaining its +2 oxidation state (Scheme 3.2). The 
critical step would be the formation of the Fe(II) hydride complex Fe2.1 by heterolytic 
splitting of H2 (step I). The substrate would be then expected to coordinate via the lonely 
electron pair on its donor atom (Fe2.2), rather than via the π-orbital of the C=C bond, 
since Fe(II) prefers relatively hard ligands. At this point, hydride transfer to the terminal 
olefinic carbon atom and protonation of the internal one were supposed to take place 
(Fe2.3). Eventually, H2 splitting with concomitant release of the reduced product would 
close the catalytic cycle.  
 
Scheme 3.2 Proposed catalytic cycle for olefin reduction promoted by complex Fe2. 
 The tetradentate ligand 50 was synthesized via SN2 reaction between (S,S)-2,2’-
bipyrrolidine and 2-picolyl chloride in a biphasic solvent system (Scheme 3.3). 
Subsequent reaction of 50 with iron(II) chloride tetrahydrate in acetonitrile gave the 
bench-stable neutral complex Fe1. The latter was then treated with silver 
hexafluoroantimonate to remove the chloride ligands by precipitation of AgCl, obtaining 
the dicationic complex Fe2. 
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Scheme 3.3 Synthesis of complexes Fe1 and Fe2. 
 On the basis of the mechanistic hypothesis shown at (Scheme 3.2), it was decided 
to endow the ligand with a functional group capable of mediating the proton transfer 
(Figure 3.3). Our plan was to introduce methoxy groups in the ortho position of the 
pyridine rings of Fe2. 
 
Figure 3.3 Modified complex Fe4 bearing two methoxy groups in the ortho position of the pyridine rings. 
 The straightforward synthetic pathway to complex Fe2 was easily modified to 
prepare complex Fe4 (Scheme 3.4). 6-metoxy-2-picolylbromide 52 was obtained by Appel 
reaction from 6-methoxypicolinalcohol 51, synthesized by reducing 6-
methoxypicolinaldehyde. Following previously described steps, complexes Fe3 and Fe4 
was obtained with a good yield. 
 
Scheme 3.4 Synthesis of complexes Fe3 and Fe4. 
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 All four iron complexes (Fe1-4) were tested in the hydrogenation of the 
benchmark substrate methyl 2-acetamidoacrylate (S1) under the conditions reported in 
Scheme 3.5.  
 
Scheme 3.5 Attempts to hydrogenate S1 using complexes Fe1-4. 
 Reactions were performed in toluene, acetonitrile, dichloromethane, methanol 
and tetrahydrofuran. No sign of conversion was observed in any of them. Neither 
prolonged reaction times nor higher temperatures (50 °C) led to any conversion. 
Complexes were tested also in the transfer (Scheme 3.6) and pressure (Scheme 3.7) 
hydrogenations of acetophenone (S2), but they resulted inactive as well. 
 
Scheme 3.6 Attempts to transfer hydrogenate S2 using complexes Fe1-4. 
 
Scheme 3.7 Attempts to hydrogenate S2 using complexes Fe1-4. 
 In order to rule out the possibility that the observed lack of reactivity was derived 
from the scarce solubility of the complexes Fe1-4 in some of the solvents used for the 
preliminary tests, new complexes with more lipophilic counter ions were prepared 
(Scheme 3.8).  Instead of hexafluoroantimonate, the newly synthesized complexes Fe5 
and Fe6 beared, respectively, tetrafluoroborate and tetrakis[3,5-
bis(trifluoromethyl)phenyl]-borate (shortly indicated as BArF).
128 Such highly lipophilic 
counterion greatly improves the solubility of organometallic complexes in several organic 
solvents, including nonpolar ones such as toluene. 
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Scheme 3.8 Synthesis of more soluble complexes Fe5 and Fe6. 
 Complex Fe5 was prepared by combining ligand 54 with the iron(II) 
tetrafluoroborate hexahydrate, whereas synthesis of complex Fe6 was attempted 
according to two different methods. Method A involved treatment of Fe5 with NaBArF in 
DCM which caused the precipitation of sodium tetrafluoroborate, while the desired 
complex remained in solution. In method B, addition of freshly prepared AgBArF to a 
solution of the dichloride complex Fe3 in ACN caused AgCl precipitation while complex 
Fe6 remained in solution. In this method a stoichiometric amount of NaBArF did not 
succeed in removing both chloride ligands because of the better solubility of NaCl in ACN 
compared to AgCl. Thus, for the method B to be effective in ACN, the use of pure AgBArF 
salt instead of NaBArF was crucial. 
 Once synthesized, complexes Fe5 and Fe6 were tested in the hydrogenation of 
methyl 2-acetamidoacrylate (Scheme 3.9) using solvents in which catalyst Fe4 was 
insoluble (toluene, THF, DCM), but still no conversion was observed. 
 
Scheme 3.9 Attempts to hydrogenate S1 using complexes Fe5-6. 
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 The negative results obtained with this family of complexes clearly indicated that 
the hypothetic catalytic cycle (Scheme 3.2) did not took place. It is likely that, in the first 
activation step, the heterolytic splitting of the hydrogen molecule does not occur and no 
Fe-H species forms under the hydrogenation conditions.  
 However, following another approach,129 it was possible to install a hydride ligand 
on N,N,N,N-ligand complex Fe1 (Scheme 3.10). Unfortunately, the obtained deep purple 
complex Fe7 turned out to be very air-sensitive and unstable, and shortly become brown 
after minimal contact with air and as so, it was not possible to use it in catalytic tests. 
 
Scheme 3.10 Synthesis of iron hydride complex Fe7. 
 
3.4 Achiral tetradentate N-ligand complexes 
 Another family of N,N,N,N-ligand complexes, inspired by P,N,N,P-ligands 
developed by Morris and co-workers71 were designed specifically to be employed in 
ketone reduction (Figure 3.4). The simple achiral complexes Fe8-9 (Scheme 3.11) were 
expected to work in a similar fashion, according to an outer-sphere mechanism (with no 
substrate coordination to the metal centre) already described by Noyori for Ru(II).77 This 
mechanism involves the reduction of C=O double bond via transfer of a hydride from the 
metal centre and of a proton from a -NH group on the ligand. As such, it requires the 
presence of at least one primary or secondary amino group coordinated to the metal. 
This functional group can also be generated in situ by reduction of an imine, as in the 
case of Morris’ complexes (see Paragraph 2.4.2 and Scheme 2.15 for a detailed 
discussion of the catalytic cycle).  
 
 
Figure 3.4 New achiral N,N,N,N-ligand complexes inspired by complex 21d. 
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Scheme 3.11 Achiral N,N,N,N-ligand complexes and proposed Noyori-like catalytic cycle for C=O hydrogenation and 
transfer hydrogenation 
 The synthesis of complexes Fe8 and Fe9, did not pose any particular problem 
(Scheme 3.12). The diimine ligand 54 was prepared by condensation between 
ethylenediamine and 2-pyridinecarboxaldehyde and then reduced with NaBH4 to give the 
saturated analogue 55. Both 54 and 55 were treated with iron tetrafluoroborate 
hexahydrate in acetonitrile, yielding complexes Fe8 and Fe9 respectively.  
 
 
Scheme 3.12 Synthesis of achiral N,N,N,N-ligand complexes Fe8-9. 
 Complexes Fe8 and Fe9 were tested as catalysts both in the pressure (Scheme 
3.13) and transfer hydrogenation (Scheme 3.14) of acetophenone. 
 
 
Scheme 3.13 Attempts to hydrogenate S2 using complexes Fe8-9. 
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Scheme 3.14 Attempts to transfer hydrogenate S2 using complexes Fe8-9. 
  These N-based Morris-like complexes, unlike the original P,N,N,P-ones, showed 
no catalytic activity for the pressure hydrogenation of acetophenone. Under transfer 
hydrogenation conditions only diimine complex Fe8 achieved 42% conversion of S2. 
Complexes Fe8-9 were also inactive in olefin hydrogenation of S1 (Scheme 3.15). 
 
 
Scheme 3.15 Attempts to hydrogenate S1 using complexes Fe8-9. 
 
3.5 Introduction of CO ligands on tetradentate N-ligand complexes  
 In the attempt to improve the catalytic activity of these two families of 
tetradentate N-ligand complexes (Fe1-9), it was decided to endow them with a CO ligand. 
The latter is present as an ancillary ligand in several of the catalysts for hydrogenation of 
ketones, aldehydes and imines. 
 Carbon monoxide acts as σ-donor through its HOMO, which is mainly localized on 
the carbon atom and can thus be roughly identified with the lone pair present on C. The 
CO ligand is also a strong π-acceptor: in the so-called back-donation process, electron 
density is released from filled d-orbitals of electron-rich, low oxidation state metals (such 
as Fe0 and FeII) into the empty π* molecular orbital of CO (LUMO). Owing to this 
stabilizing capability, the presence of a CO ligand may be beneficial to catalytic cycles 
where Fe(0)- and/or Fe(II)-species are involved.  
 As shown in Scheme 3.16, complexes Fe2, Fe8 and Fe9 were treated with gaseous 
carbon monoxide, in order to exchange the coordinated acetonitrile with CO. Despite 
inconclusive ESI-MS for Fe10, a disappearance of CN stretching bands (2300-2250 cm-1) 
was observed and could mean successful CO insertion. No reaction was observed with 
Fe8 (even with 20 bar of CO). Complex Fe11, as confirmed by ESI-MS and IR, was 
successfully obtained. 
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Scheme 3.16 Introduction of CO ligands to N,N,N,N-ligand complexes. 
 With the newly synthesized complexes Fe10 and Fe11, the reduction of C=C and 
C=O double bonds on the benchmark substrates S1 and S2 was investigated. Both of 
them appeared to be inactive in hydrogenation (using conditions from Scheme 3.13 and 
Scheme 3.15), whereas Fe10 gave 29% conversion in transfer hydrogenation of S2 (with 
no ee - Scheme 3.17). Although this result was not groundbreaking, it proved importance 
of strong π-acceptor ligands for iron catalysts, as parent complex Fe2 was not active at all 
in any of the investigated transformations.  
 
 
Scheme 3.17 Attempts to transfer hydrogenate S2 using complexes Fe10-11. 
 
3.6 Concluding remarks 
 The negative results obtained with synthesized N,N,N,N-ligand complexes in the 
hydrogenation of C=C and C=O double bonds indicate that N-based tetradentate ligands 
(Figure 3.5), despite being an effective option for stabilizing the Fe(II) metal centre, are 
not particularly good candidates for promoting Fe-catalyzed reductions. In addition to 
the N-based tetradentate ligand, they require strong π-acceptors like CO, to stabilize the 
low valent iron species produced in the course of the reaction. 
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Figure 3.5 Tetradentate N-ligands complexes synthesized in this work of thesis in comparison with Morris’ P,N,N,P-
complex 21d and Thomas' catalytic system based on ligand 8. 
 The structural analogy of the achiral N,N,N,N-complexes Fe8 and Fe9 with Morris’ 
P,N,N,P-complex 21 on one side and the striking difference in terms of catalytic activity 
on the other, suggest that the stereoelectronic nature of N- and P-ligands is a decisive 
factor. The two more relevant stereolectronic differences between N-ligands and 
phosphines (which are extensively used in Fe-catalysed reductions) concern the hardness 
and the capability of accepting π-backdonation from metals in low oxidation states. 
Compared to phosphines, amines are harder, as the small, electronegative nitrogen atom 
is less easily polarizable than phosphorus. Moreover, N-ligands are weaker π-acceptors. A 
possible solution to this problem was later (i.e., after we gave up our tests with this 
family of catalysts) proposed by Thomas and co-workers, as they used Grignard 
compounds to activate in situ formed iron(II) complex from ligand 8.55 As reported in 
Paragraph 2.3.4, they managed to hydrogenate variety of olefins with a catalytic system 
generated in situ. Our efforts to form a well-defined hydride catalyst from complex Fe7 
(Scheme 3.10) were unsuccessful, as we did not have access to a glovebox, necessary to 
handle such sensitive compounds.  
 In conclusion, it appears that the presence of strong π-acceptor ligands is crucial 
for the relatively electron-rich Fe(0)- and/or Fe(II)-species to be catalytically active in 
reduction mechanisms. This inference is supported by the fact that almost all of the iron 
complexes that catalyze the hydrogenation of multiple C-X bonds (X = C, O) possess at 
least two P-ligands. The exceptions are represented by catalysts 14, 36 and 38 (Figure 
2.10), which work according to mechanisms where the chelating ligand acts as a “non-
innocent” ligand, rather than as a simple bystander. Furthermore, it is noteworthy that 
complexes 38 and 36, despite having no P-ligands, bear other strong π-acceptor ligands, 
namely CO and isonitrile.  
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3.7 Experimental section 
General remarks 
 All reactions were carried out in flame-dried glassware with magnetic stirring under 
nitrogen atmosphere, unless otherwise stated. Synthesis of complexes was performed under 
argon using standard Schlenk-techniques.  
 The solvents for reactions were distilled over the following drying agents and transferred 
under nitrogen: CH2Cl2 (CaH2), MeOH (CaH2), CH3CN (CaH2), THF (Na), dioxane (Na), toluene (Na), 
hexane (Na), Et3N (CaH2). Acetophenone and i-PrOH were distilled on CaH2 (a small amount of 
PPh3 was added when distilling isopropanol) and stored over molecular sieves. Et2O and DMF 
were purchased in bottles with crown cap, over molecular sieves, and stored under nitrogen. The 
commercially available starting products [3,5-bis(trifluoromethyl)bromobenzene, (S,S)-2,2’-
bipyrrolidine D-tartrate trihydrate, 6-methoxy-2-pyridinecarboxaldehyde, 2-pyridine 
carboxaldehyde, 2,2’-bis(bromomethyl)-1,1’-biphenyl, 2-fluoronitrobenzene, (R)-binaphthol] 
were used as received. 
 The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualisation was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution, a 
nynhidrine solution or a ceric ammonium molybdate solution. Flash column chromatography was 
performed using silica gel (60 Å, particle size 40-64 μm) as stationary phase, following the 
procedure by Still and co-workers.130 Gas chromatography was performed by a GC instrument 
equipped with a flame ionization detector, using the chiral capillary column MEGADEX DACTBSβ, 
diacetyl-t-butylsilyl-β-cyclodextrin. 
 Proton NMR spectra were recorded on a spectrometer operating at 400.13 MHz. Proton 
chemical shifts are reported in ppm (δ) relative to tetramethylsilane (TMS) with the solvent 
resonance employed as the internal standard (CDCl3, δ = 7.26 ppm; CD2Cl2, δ = 5.32 ppm; 
(CD3)2SO, δ = 2.50 ppm; CD3OD, δ = 3.33 ppm; CD3CN, δ = 1.94 ppm). The following abbreviations 
are used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad signal. The coupling constant values are given in Hz. 13C-NMR spectra were 
recorded on a 400 MHz spectrometer operating at 100.56 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective 
solvent resonance as the internal standard (CDCl3, δ = 77.23 ppm; CD2Cl2, δ = 54.00 ppm; 
(CD3)2SO, δ = 39.51 ppm; CD3OD, δ = 49.05; CD3CN, δ = 118.26 ppm).  
 High resolution mass spectra (HRMS) were performed on a Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker Daltonics) – 
4.7 T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro Interdipartimentale 
Grandi Apparecchiature) c/o Università degli Studi di Milano. Low resolution mass spectra (MS) 
were acquired either on a Thermo-Finnigan LCQ Advantage mass spectrometer (ESI ion source) 
or on a VG Autospec M246 spectrometer (FAB ion source).  
 Elemental analyses were performed on a Perkin Elmer Series II CHNS/O Analyzer 2000. 
 Infrared spectra were recorded on a standard FT/IR spectrometer.  
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(2S,2'S)-1,1'-Bis(pyridin-2-ylmethyl)-2,2'-bipyrrolidine
126
 (S,S-PDP) 50 
NaOH (0.74 g, 18.4 mmol, 6.4 eq) and 2-(chloromethyl)pyridine hydrochloride 
(1.04 g, 6.3 mmol, 2.2 eq) were added in sequence to a stirred suspension of (S,S)-
2,2’-bipyrrolidine D-tartrate trihydrate (1.00 g, 2.87 mmol, 1 eq) in 12 mL 
H2O/CH2Cl2 1:1. The obtained mixture was stirred overnight at RT, then diluted 
with 1M NaOH and extracted with CH2Cl2 (3x). The combined organic phases were 
dried with Na2SO4 and concentrated in vacuo to give a sticky oil. The crude was purified by FCC 
(CH2Cl2/MeOH/aqueous NH3 33% 95:5:2). The collected fractions were combined, diluted with 
CH2Cl2, washed with 1M NaOH (2x) and dried with Na2SO4. Evaporation of solvents afforded the 
product as a colorless oil in 97% yield. 1H NMR (400 MHz, CDCl3): δ 8.52 (d, J = 4.2 Hz, 2H), δ 7.61 
(td, J = 7.6, 1.7 Hz, 2H), δ 7.42 (d, J = 7.8 Hz, 2H), δ 7.12 (dd, J = 7.0, 5.2 Hz, 2H), δ 4.21 (d, J = 14.0 
Hz, 2H), δ 3.53 (d, J = 14.4 Hz, 2H), δ 3.02 (m, 2H), δ 2.83 (m, 2H), δ 2.26 (q, J = 8.6 Hz, 2H), δ 
1.91-1.68 (m, 8H).  
[FeCl2(S,S-PDP)]
126 Fe1 
Under Ar, FeCl2·4H2O (554 mg, 2.79 mmol, 1 eq) was added to a stirred solution 
of ligand 50 (899 mg, 2.79 mmol, 1 eq) in 16 mL CH3CN. Upon addition, 
immediate precipitation of a dark orange solid was observed. The reaction 
mixture was stirred overnight at RT, then Et2O was added to aid precipitation. 
The solvent was decanted off via syringe. The precipitate was washed two more 
times with Et2O, until the decanted solvent was colorless. The orange solid was 
dried in a tarred Schlenk tube under N2 stream for 2 hours, then under high vacuum. Yield: 84%. 
ESI-MS in CH3CN: [M-Cl]
+ m/z 413.3. Elemental analysis: calculated C 53,48%, H 5,83%, N 12,47%; 
found C 53,14%, H 5,95%, N 12,45%. 
[Fe(CH3CN)2(S,S-PDP)](SbF6)2
126
 Fe2 
Under Ar, silver hexafluoroantimonate (98%, 937 mg, 2.67 mmol, 2 
eq) was added to a stirred suspension of Fe1 (600 mg, 1.34 mmol, 1 
eq) in 17 mL CH3CN. The mixture became purple and an off-white 
solid precipitated. The flask was covered with aluminum foils to 
protect the silver salts from light and the mixture was stirred 
overnight at RT. Silver chloride was filtered off under Ar and the 
filtrate was evaporated under high vacuum. The purple residue was re-dissolved in CH3CN, 
filtered through a 0.2 μm Acrodisc® LC PVDV syringe filter and concentrated. The 
filtration/evaporation procedure was repeated two more times to ensure no silver salts remains. 
The last time the filtrate was evaporated under N2 stream and then under high vacuum, 
obtaining Fe2 as a dark purple solid in 82% yield. The complex could be crystallized as follows. 
Under Ar, 356 mg Fe2 were dissolved in 4 mL CH3CN, then 12.5 mL Et2O were added. After 4 days 
at -30 °C, some purple rod-shaped crystals were present. Solvents were decanted off and the 
solid was washed with Et2O (3x). The purple crystals were dried under high vacuum for 2 hours 
(252 mg). Crystallization yield: 69%. 1H NMR (400 MHz, CD3CN): δ 43.8 (br s, 2 H), 17.8 (br s, 1H), 
δ 17.4-16.5 (br s, 4H), δ 16.1 (br s, 2H), δ 10.8 (br s, 2H), δ 9.7 (br s, 2H), δ 9.0-8.3 (br s, 4H), δ 4.5 
(br s, 2H), δ 3.5 (br s, 2H), δ 2.4-1.9 (br s, 8 H), δ 0.1 (br s, 2H). ESI-MS in CH3CN: [M-CH3CN]
2+ m/z 
209.5, [M-2CH3CN+F]
+ m/z 397.4, [M-2CH3CN+SbF6]
+ m/z 613.0; [SbF6]
- m/z 235.2. IR (Nujol): 
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2308.37 cm-1, 2273.66 cm-1 (weak, CH3C≡N stretching). 
2-(Hydroxymethyl)-6-methoxypyridine 51 
NaBH4 (96%, 0.85 g, 21.6 mmol, 2.9 eq) was added portion wise to a stirred 
solution of 6-methoxy-2-pyridinecarboxaldehyde (97%, 1.04 g, 7.37 mmol, 1 
eq) in 20 mL MeOH kept at 0 °C. The reaction mixture was stirred at RT for 3 
hours, then distilled H2O was added and MeOH was evaporated. The aqueous layer was 
extracted with CH2Cl2 (3x), the collected organic phases were washed with brine, dried with 
Na2SO4 and filtered. Evaporation of solvents afforded a pale yellow liquid which was used in the 
following step without further purification. Yield: 98%. 1H NMR (400 MHz, CDCl3): δ 7.51 (t, J = 7.7 
Hz, 1H), δ 6.80 (d, J = 7.2 Hz, 1H), δ 6.59 (d, J = 8.2 Hz, 1H), δ 4.64 (s, 2H), δ 3.89 (s, 3H), δ 3.65 (br 
s, 1H). 
2-(Bromomethyl)-6-methoxypyridine 52 
CBr4 (99%, 3.61 g, 10.8 mmol, 1.5 eq) and PPh3 (2.83 g, 10.8 mmol, 1.5 eq) 
were added in sequence to a stirred solution of 51 (1.00 g, 7.18 mmol, 1 eq) in 
18 mL CH2Cl2 kept at 0 °C. Upon addition of the triphenylphosphine the 
solution became purple/brown. The reaction mixture was allowed to warm up at RT and was 
stirred for 2 hours, after which period a whitish precipitate was present. Solvents were 
evaporated to give a brown oil, which was purified by FCC (hexane/AcOEt 98:2). 52 was obtained 
as a colourless oil in 80% yield. 1H NMR (400 MHz, CDCl3): δ 7.56 (t, J = 7.8 Hz, 1H), δ 7.00 (d, J = 
7.2 Hz, 1H), δ 6.67 (d, J = 8.4 Hz, 1H), δ 4.48 (s, 2H), δ 3.96 (s, 3H). 
(2S,2'S)-1,1'-Bis((6-methoxypyridin-2-yl)methyl)-2,2'-bipyrrolidine (S,S-PDP-OMe) 53  
NaOH (512 mg, 12.8 mmol, 5.0 eq) and 2-(bromomethyl)-6-methoxypyridine 
52 (1137 mg, 5.6 mmol, 2.2 eq, dissolved in 9 mL CH2Cl2) were added in 
sequence to a stirred suspension of (S,S)-2,2’-bipyrrolidine D-tartrate 
trihydrate (890 mg, 2.6 mmol, 1.0 eq) in 9 mL H2O. The obtained biphasic 
mixture was stirred overnight at RT, then diluted with 1M NaOH and 
extracted with CH2Cl2 (3x). The combined organic phases were dried with 
Na2SO4, filtered and concentrated in vacuo to obtain a sticky yellow oil. The crude was purified by 
FCC (CH2Cl2/MeOH/aqueous NH3 33% 97:3:2). The collected fractions were combined, diluted 
with CH2Cl2, washed with 1M NaOH (2x) and dried with Na2SO4. Evaporation of solvents afforded 
the product as a pale yellow oil in 97% yield. 1H NMR (400 MHz, CDCl3): δ 7.51 (t, J = 7.6 Hz, 2H), 
δ 6.98 (d, J = 7.2 Hz, 2H), δ 6.57 (d, J = 8.0 Hz, 2H), δ 4.14 (d, J = 14.4 Hz, 2H), δ 3.91 (s, 6H), δ 
3.45 (d, J = 14.4 Hz, 2H), δ 3.10 (m, 2H), δ 2.87 (br s, 2H), δ 2.29 (m, 2H), δ 1.90-1.68 (m, 8H). 13C 
NMR (100 MHz, CDCl3): δ 163.49, 158.25, 138.83, 115.27, 108.14, 65.23, 60.54, 55.34, 53.35, 
26.16, 23.74.  
[FeCl2(S,S-PDP-OMe)] Fe3 
Under Ar, FeCl2·4H2O (273 mg, 1.37 mmol, 1 eq) was added to a stirred 
solution of ligand 53 (525 mg, 1.37 mmol, 1 eq) in 8 mL CH3CN. The yellowish, 
slightly turbid solution was stirred overnight at RT. 10 mL Et2O were added 
and a sticky brown solid precipitated. Solvents were decanted off and the 
residue was dried under high vacuum, then dissolved in CH2Cl2. Addition of 
pentane caused precipitation of a brown solid again. The solvents were 
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decanted off and the solid was dried under high vacuum, giving Fe3 in 91% yield. ESI-MS in 
CH3CN: [M-Cl]
+ m/z 473.2, [ligand+H]+ m/z 383.4. 
[Fe(CH3CN)2(S,S-PDP-OMe)](SbF6)2 Fe4 
Under Ar, silver hexafluoroantimonate (98%, 207 mg, 0.59 mmol, 
2eq) was added to a stirred thick brown solution of Fe3 (150 mg, 0.29 
mmol, 1 eq) in 5 mL CH3CN. The reaction mixture became beige and 
a white precipitate formed. The flask was covered with aluminum 
foils and the mixture was stirred overnight at RT. On the next day 
silver chloride was filtered off under Ar and the clear brown filtrate 
was evaporated to dryness. The residue was re-dissolved in CH3CN, filtered through a 0.2 μm 
Acrodisc® LC PVDV syringe filter and concentrated. The filtration/evaporation procedure was 
repeated two more times to ensure no silver salts remains. The last time the filtrate was 
evaporated under N2 stream and then under high vacuum, obtaining a brilliant brown solid in 
90% yield. 1H NMR (400 MHz, CD3CN): δ 8.02 (t, J = 7.4 Hz, 2H), δ 7.11 (d, J = 8.0 Hz, 2H), δ 6.99 
(d, J = 9.6 Hz, 2H), δ 4.81 (d, J = 17.2 Hz, 2H), δ 4.67 (d, J = 17.2 Hz, 2H), δ 4.12 (br s, 2H), δ 3.88 
(s, 6H), δ 3.63 (m, 2H), δ 3.55 (m, 2H), δ 2.45 (br s, 2H), δ 2.30-2.10 (m, 4H), δ 2.08-1.95 (br s, 
8H), δ 1.93-1. 82 (m, 2H). ESI-MS in CH3CN: [M-2CH3CN]
2+ m/z 219.5, [M-CH3CN]
2+ m/z 239.6, [M-
2CH3CN+SbF6]
+ m/z 673.1, [ligand+H]+ m/z 383.4; [SbF6]
- m/z 235.3. 
[Fe(CH3CN)2(S,S-PDP-OMe)](BF4)2 Fe5 
Under Ar, a solution of ligand 53 (300 mg, 0.78 mmol, 1 eq) in 10 mL 
CH3CN was transferred via cannula into a stirred solution of iron(II) 
tetrafluoroborate hexahydrate (97%, 273 mg, 0.78 mmol, 1 eq) in 10 
mL CH3CN. The resulting pale yellow solution was stirred overnight at 
RT, then the solvent was evaporated and the yellow residue was 
washed with Et2O (2x), decanting off the solvent via syringe. Drying 
under high vacuum afforded a yellow-greenish solid in 47% yield. 1H NMR (400 MHz, CD2Cl2): δ 
8.1 (br, 2H), δ 7.4 (br, 2H), δ 6.7 (br, 2H), δ 5.2 (br, 2H), δ 4.9-4.6 (br, 4H), δ 4.03 (br, 8H), δ 3.0 
(br, 2H), δ 3.2-2.5 (br, 10H), δ 2.39 (br, 2H), δ 1.3 (br, 2H). ESI-MS in CH3CN: [M-2CH3CN]
2+ m/z 
219.3, [M-CH3CN]
2+ m/z 239.4, [M-2CH3CN+F]
+ m/z 457.3, [ligand+H]+ m/z 383.3; [BF4]
- m/z 87.1. 
[Fe(CH3CN)2(S,S-PDP-OMe)](BArF)2 Fe6 
Method A. Under Ar, NaBArF (230 mg, 0.26 mmol, 2 eq) was added to 
a stirred solution of Fe5 (90 mg, 0.13 mmol, 1 eq) in 10 mL CH2Cl2. 
The reaction mixture became turbid and, after stirring for 1 hour, was 
filtered under Ar through celite. Evaporation of the filtrate gave Fe6 
as a whitish solid in 99% yield. Method B. Under Ar, AgBArF (381 mg, 
0.40 mmol, 2 eq) was added to a stirred thick brown solution of Fe3 
(100 mg, 0.20 mmol, 1 eq) in 8 mL CH3CN. Upon addition the reaction mixture became turbid and 
a white solid precipitated. The reaction mixture was stirred overnight with minimal light exposure 
and the precipitate was then filtered off under Ar. The filtrate was evaporated to dryness, the 
brown residue was taken up with 10 mL CH3CN and filtered through a 0.2 μm Acrodisc
® LC PVDV 
syringe filter. The evaporation/filtration procedure was repeated to ensure no silver salts 
remains. Evaporation of solvents afforded Fe16 as a dark brown solid in 78% yield. IR (Nujol): 
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2306.45 cm-1, 2277.52 cm-1 (CH3C≡N stretching). 
[Fe(Cl)(H)(S,S-PDP)]34a Fe7 
Attempted synthesis. Under Argon, a 1 M solution of NaHBEt3 in toluene (110 
μL, 0.11 mmol, 1 eq) was added dropwise to a stirred fine suspension of Fe1 
(50 mg, 0.11 mmol, 1 eq) in 3 mL THF. Upon addition the yellow reaction 
mixture darkened. Evaporation of solvents yielded to the isolation of a deep 
purple solid, which turned brown after short contact with air.  
 
(E,E)-N1,N2-Bis(pyridin-2-ylmethylene)ethane-1,2-diamine (PED) 54 
2-pyridinecarboxaldehyde (642 mg, 570 μL, 5.93 mmol, 2 eq) was added 
to a stirred solution of ethylenediamine (180 mg, 200 μL, 2.96 mmol, 1 
eq) in 4 mL Et2O and the resulting orange solution was stirred overnight at 
7O °C. Solvents were removed and the residue was taken up with 
Et2O/hexane 3:1, dissolving only the desired product. Solvents were thus decanted off and 
evaporated, obtaining 54 as an orange powder in 80% yield. 1H NMR (400 MHz, CD2Cl2): δ 8.62 
(ddd, J = 4.8, 1.7, 1.0 Hz, 2H), δ 8.42 (s, 2H), δ 8.02 (dt, J = 7.9, 1.0 Hz, 2H), δ 7.76 (td, J = 7.7, 1.7 
Hz, 2H), δ 7.34 (ddd, J = 7.5, 4.8, 1.2 Hz, 2H), δ 4.05 (s, 4H). 
[Fe(CH3CN)2(PED)](BF4)2 Fe8 
Under Ar, a yellow solution of ligand 54 (487 mg, 2.04 mmol, 1 
eq) in 20 mL CH3CN was added to a stirred solution of iron(II) 
tetrafluoroborate hexahydrate (97%, 711 mg, 2.04 mmol, 1 eq) in 
10 mL CH3CN. Upon addition the reaction mixture turned red and 
then darkened. After stirring overnight at RT, solvents were 
evaporated and the residue was washed with Et2O (3x). The 
obtained dark red/purple solid was then dried under high vacuum. Yield: 91%. ESI-MS in CH3CN: 
m/z 167.6 [M-CH3CN]
+; m/z 87.2 [BF4]
-. IR (Nujol): 2282.34 cm-1 (CH3C≡N stretching). 
N1,N2-Bis(pyridin-2-ylmethyl)ethane-1,2-diamine (PED-red) 55 
NaBH4 (96%, 200 mg, 5.03 mmol, 3 eq) was added portion wise to a 
stirred solution of 54 (400 mg, 1.68 mmol, 1 eq) in 20 mL MeOH. The 
resulting mixture was stirred overnight at RT, then 15 mL 1M NaOH were 
added and MeOH was evaporated. The aqueous layer was extracted with 
CH2Cl2 (4x) and the collected organic phases were washed with 1M NaOH, dried with Na2SO4 and 
filtered. Evaporation of solvent afforded 55 as a yellow oil in 97% yield. The product was used 
without further purification. 1H NMR (400 MHz, CD2Cl2): δ 8.55 (d, J = 4.8 Hz, 2H), δ 7.67 (td, J = 
7.7, 1.8 Hz, 2H), δ 7.37 (d, J = 7.8 Hz, 2H), δ 7.19 (dd, J = 7.5, 4.9Hz, 2H), δ 3.91 (s, 4H), δ 2.80 (s, 
4H), δ 2.03 (s, 2H). 
[Fe(CH3CN)2(PED-red)](BF4)2 Fe9 
Under Ar, a solution of ligand 55 (240 mg, 1.0 mmol, 1 eq) in 10 
mL CH3CN was added via cannula into a stirred solution of iron(II) 
tetrafluoroborate hexahydrate in 10 mL CH3CN. The solution 
turned red and then purple. After stirring for 1 hour, the solution 
was concentrated to 1 mL volume and 10 mL Et2O were added. A 
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purple solid precipitated and the solvent was decanted off. The solid was washed once more with 
Et2O. Evaporation of solvents gave Fe9 as a purple powder in 88% yield. ESI-MS in CH3CN: [M-
2CH3CN]
+ m/z 149.4, [M-CH3CN]
+ m/z 169.5; [BF4]
- m/z 87.1. IR (KBr): 3415.31cm-1 (medium, 
broad N-H stretching), 2253.41 cm-1 (medium, C≡N stretching). 1H NMR (400 MHz, CD3CN): δ 
26.0-23.5 (br, 2H), δ 20.0-17.5 (br, 2H), δ 14.0-13.0 (br, 4H), δ 12.5-12.0 (br, 2H), δ 9.3-8.7 (br, 
4H), δ 6.2 (br, 2H), δ 3.4-1.9 (br, 8H). 
[Fe(CO)2(PDP)2](SbF6)2 Fe10 
Complex Fe2 (48 mg, 0.051 mmol) was dissolved in 4 mL acetone 
obtaining a purple solution. The latter was then purged three times with 1 
bar CO and stirred under CO atmosphere for 2 hours. Evaporation of the 
resulting mixture afforded Fe10 as a pale brown solid in 89% yield.ESI-MS 
in CH3CN: [M-CH3CN]
2+ m/z 209.5, [M-2CH3CN+SbF6]
+ m/z 613.0; [SbF6]
- 
m/z 235.2. IR (KBr): disappearance of C≡N stretching bands. 
[Fe(CO)2(PED-red)2](BF4)2 Fe11 
Complex Fe9 [Fe(CH3CN)2(PED-red)](BF4)2 (300 mg, 0.079 mmol) 
dissolved in 4 mL acetone was then purged three times with 1 bar 
CO and stirred under CO atmosphere for 2 hours. Evaporation of 
solvents gave Fe11 as a dark green/black powder in 94% yield. 
ESI-MS in MeOH: [M-2CO-2H]2+ m/z 296.2; [2BF4+Na]
- m/z 197.3. 
IR (Nujol): 2091.42, 2043.21, 2010.43 cm-1 (weak, C≡O stretching). 
Synthesis of AgBArF.
128 
 
Sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate128 NaBArF 
A brown suspension of activated Mg turnings (1.00 g, 41.2 mmol, 6.9 
eq) and I2 (catalytic, some crystals) in 10 mL Et2O was prepared. To this 
suspension a solution of 3,5-bis(trifluoromethyl)bromobenzene (10.0 
g, 33.8 mmol, 5.6 eq) in 50 mL Et2O was added dropwise. The reaction 
mixture darkened and was heated to reflux for 45 minutes. After 
cooling down to RT, sodium tetrafluoroborate (0.67 g, 6.0 mmol, 1 eq) 
was added and the resulting mixture was stirred for 64 hours, at the end of which it was 
quenched by adding a saturated Na2CO3 aqueous solution (50 mL) and stirring for 20 minutes. 
The mixture was then filtered through celite, phases were separated and the aqueous layer was 
extracted with Et2O (4x). The combined organic phases were dried with Na2SO4, filtered and 
evaporated to yield a brown gummy solid, which was crystallized from CH2Cl2/hexane 1:1. NaBArF 
was obtained as an off-white powder in 94% yield. 1H NMR (400 MHz, (CD3)2SO): δ 7.72 (s, 4H), δ 
7.63 (s, 8H). 
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Potassium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate
128
 KBArF 
A solution of 3,5-bis(trifluoromethyl)bromobenzene (10.0 g, 33.8 
mmol, 5.6 eq) in 50 mL Et2O was added dropwise to a stirred 
suspension of Mg turnings (862 mg, 35.5 mmol, 5.9 eq) and catalytic 
iodine in 15 mL Et2O. The reaction mixture initially discolored and 
started boiling, then became dark brown. It was heated to reflux for 50 
minutes and then stirred at RT for 2 hours. A 20-mL Et2O solution of 
BF3·Et2O (1.13 mL, 6.03 mmol, 1 eq) was dropped into the reaction flask over 20 minutes. After 
heating to reflux for 6 hours and stirring for further 18 hours, the reaction mixture was slowly 
poured into an Erlenmeyer flask containing a stirred solution of K2CO3 (67 g, 485 mmol, 80 eq in 
276 mL H2O). The precipitated MgCO3 was filtered through celite washing with Et2O (4x), and 
phases were separated. The aqueous layer was saturated with KBr and extracted with Et2O (4x). 
The collected organic phases were evaporated to yield a pale orange solid. The solid was 
dissolved in 52 mL CH2Cl2/THF 1:1 and layered with 52 mL hexane. After 3 days filtration on 
Buchner afforded KBArF as an off-white solid, which was then dried under high vacuum. Yield: 
86%. 
Silver tetrakis[3,5-bis(trifluoromethyl)phenyl]borate128 AgBArF 
In an Erlenmeyer flask covered with an aluminum foil, a colorless 
solution of silver nitrate (380 mg, 2.22 mmol, 1 eq) in 14 mL CH3CN 
was added to an orange solution of KBArF (2.00 g, 2.22 mmol, 1 eq) in 
20 mL CH3CN. Upon addition the solution became turbid. After stirring 
for 15 minutes, 25 mL of Et2O were added and a white solid 
precipitated. The mixture was filtered through celite and the filtrate 
was concentrated to dryness. The residue was dissolved in THF and filtered again. Evaporation of 
solvent afforded a pale brown solid, which was crystallized as follows. The solid was dissolved in 
50 mL THF and the solution was layered with 80 mL hexane, then kept at -30 °C for 8 days with 
minimal light exposure. Filtration on Buchner gave AgBArF as a white solid in 83% yield (after 
drying under high vacuum). 
Hydrogenation's procedures 
General procedure for the hydrogenation of methyl 2-acetamidoacrylate (S1). A Parr multi-reactor 
was employed, allowing six reactions in parallel under hydrogen. The selected complex (4 mg, 
0.05 eq) and methyl 2-acetamidoacrylate (15-20 mg, 1 eq) were weighted in 4-mL GC-vials with 
screw cap containing a magnetic stirring bar. The vessels were purged with nitrogen and solvent 
(2 mL) was added via syringe. A 25 gauge needle was inserted in the septum of the capped vials, 
which then were placed in the respective autoclaves and purged three times with 50 bar of 
hydrogen. The reactions were magnetically stirred under hydrogen pressure at the desired 
temperature for a given time and then analyzed for conversion and ee determination. 
General procedure for the hydrogenation of acetophenone (S2). A Parr multi-reactor was 
employed, allowing six reactions in parallel under hydrogen pressure. The selected complex (5 
mg, 0.05 eq) and the desired base (0.50 or 0.75 eq) were weighted in special glass vessels, which 
were then purged with nitrogen. Isopropanol (7 mL) and acetophenone (15-30 μL, 1 eq) were 
added via syringe. The vessels were placed in the respective autoclaves and purged three times 
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with 50 bar of hydrogen. The reactions were stirred under hydrogen pressure at the desired 
temperature for a given time and then analysed for conversion and ee determination. 
General procedure for the transfer hydrogenation of acetophenone (S2). A carousel multi-reactor 
was employed, allowing eight reactions in parallel under nitrogen atmosphere. Under N2 flow, 
the selected complex (4 mg, 0.05 eq) and the desired base (0.50 or 0.75 eq) were introduced in 
special glass vessels, which were then closed with screw caps and purged with nitrogen. Distilled 
isopropanol (2 mL) and acetophenone (10-20 μL, 1 eq) were added via syringe and the reactions 
were stirred under nitrogen at the desired temperature for a given time, then analyzed for 
conversion and ee determination. 
Conditions for conversion and ee determination 
Methyl 2-acetamidopropanoate P1. Conversion and ee were determined by GC (capillary column: 
MEGADEX DACTBSβ, diacetyl-tert-butylsilyl-β-cyclodextrin, 0.25 μm; diameter 
= 0.25 mm; length = 25 m; carrier: hydrogen; flow: 1 mL/min; oven 
temperature: 140 °C for 6 min, then a 8 °C/min gradient is applied): tsubstrate = 
3.9 min; tR = 5.2 min; tS = 6.0 min. 
1-Phenylethanol P2. Conversion and ee were determined by GC (capillary column: MEGADEX 
DACTBSβ, diacetyl-tert-butylsilyl-β-cyclodextrin, 0.25 μm; diameter = 0.25 mm; 
length = 25 m; carrier: hydrogen; hydrogen pressure: 1 bar; oven temperature: 75 
°C for 5 min, 20 °C/min gradient until 95 °C, 95 °C for 15 min, then a 20 °C/min 
gradient is applied): tsubstrate = 9.3 min; tproduct-en1 = 17.5 min; tproduct-en2 = 19.8 min. 
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4 Iron complexes with isonitrile ligands 
4.1 Isonitrile complexes 
 Isonitriles (also known as isocyanides) are organic molecules with peculiar 
reactivity, possessing a nucleophilic carbon which displays nucleophilic and electrophilic 
properties at the same time.131 Isonitriles are also valuable ligands in coordination 
compounds. When an isocyanide coordinates to a metal, the lone electron pair on the 
formally divalent carbon atom (roughly corresponding to the HOMO) forms a σ-type 
bond to the metal. If the metal has filled d-orbitals which are capable of overlapping with 
empty anti-bonding orbital (LUMO) on the ligand, a second bond of π-type may form. 
Through the mechanism of back-donation, isonitriles efficiently stabilize metals in low 
oxidation states. They share this ability with some other ligands, such as CO and 
phosphines. 
 Low interest in this type of ligands may be attributed to their linear structure, 
which is rather prohibiting the arrangement of mononuclerar chelates and can lead 
instead to multinuclear or polymeric metal complexes. The building of large-sized ligand 
backbones is required in order to encompass two isonitrile groups pointing toward the 
same metal centre.132 
 
4.2 Novel complexes featuring bis(isonitrile) ligand 
 According to the considerations reported in the previous paragraph, the synthesis 
of novel complexes featuring isonitrile ligands was undertaken. Building on the chiral 
(S,S)-2,2’-bipyrrolidine scaffold, already exploited for the design of N,N,N,N-ligands (see 
Paragraph 3.3),126 the novel tetradentate complex Fe12 was prepared (Figure 4.1). 
Iron(II) complex Fe12 was inspired by Reiser’s catalyst 36 (see Paragraph 2.4.6) and was 
expected to be active in the asymmetric transfer hydrogenation of aromatic ketones. Its 
ligand possesses two isonitrile groups, which can act as π-acceptors on one side and as 
non-innocent ligands on the other.  
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Figure 4.1 Novel bis(isonitrile) complex Fe12, inspired to the catalyst 36. 
 The proposed catalytic cycle for the asymmetric transfer-hydrogenation of 
ketones, could proceed according to the Meerwein-Ponndorf-Verley-type mechanism 
(see Scheme 4.1). We postulated activation of catalyst Fe12 by tBuOK (or another base) 
and isopropanol coordination to form Fe12.1. After subsequent reduction of coordinated 
isonitrile to imine using a proton from isopropanol (Fe12.2), resultant acetone would be 
replaced by substrate to form Fe12.3. The final step would proceed by an inner-sphere 
mechanism where hydride transfer to the coordinated substrate is mediated by the 
imine part of the ligand (Fe12.4), rather than from iron, which role is limited just to 
coordinate the oxygen atom. Thus, as in the case of catalyst 36, we postulated that 
desired catalyst would be a cooperative non-innocent one. 
 
Scheme 4.1 Expected Meerwein-Pondorff-Verley-like ATH mechanism for the new complex Fe12. 
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 Synthesis of bis-formamide 58 starts relies on a different functionalization of the 
two benzyl bromide groups in commercially available 2,2’-bis(bromomethyl)-1,1’-
biphenyl. First benzyl bromide was converted to mono-formamide 57 by reaction with 
NaN(CHO)2 followed by treatment with tBuOK in ethanol (Scheme 4.2). Compound 57 
was then reacted with 2,2’-bipyrrolidine to yield the bis-formamide 58. 
 
Scheme 4.2 Synthesis of 58. 
 The bis-isonitrile 60 was obtained by dehydration of 58 using two different 
methods. Additionally also a third method was applied and contained dehydration of 57, 
followed by nucleophilic substitution with the 2,2'-bispyrrolidine core. Irrespective of the 
synthetic approach employed (Scheme 4.3), ligand 60 was always isolated as a product 
showing two very close spots in TLC, which could not be separated by flash column 
chromatography or by RP-HPLC. 
 
Scheme 4.3 Three different preparations of ligand 60. 
  The NMR spectrum of 60 showed a 
peculiar signal splitting of benzylic CH2 group (Figure 
4.2). The integral ratio between the split doublets 
was the same in all batches. Hindered rotation of the 
pyrrolidine-pyrrolidine bond or unusual 
configurational stability of the N-stereocenters 
might caused of the observed outcome. 
 
 
Figure 4.2 Downfield part of CH2 AB spin system of 60 (4H). 
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 ESI-MS spectra in CH3CN show two peaks at m/z 551 (protonated ligand [M+H]
+) 
and m/z 1163 (CuI complex [2M+Cu]+, whose formation occurs within the ESI source), 
thus indicated that ligand 60 is present as a single species. 
 Ligand 60 was used to prepare complexes Fe12-14 (Scheme 4.4). Use of iron(II) 
chloride tetrahydrate as iron source and methanol as solvent gave the neutral, highly 
insoluble complex Fe12. Treatment of the latter with AgBArF in acetonitrile was found to 
be effective for obtaining the more soluble complex Fe13. Complexation reaction in 
acetonitrile between 60 and iron(II) tetrafluoroborate hexahydrate afforded the 
dicationic complex Fe14. 
 
Scheme 4.4 Synthesis of bis(isonitrile) complexes Fe12-Fe14.
 
 These new bis(isonitrile) complexes Fe12-14 were then tested in the asymmetric 
transfer hydrogenation of acetophenone (Table 4.1). 
Table 4.1 Catalytic screening of bis(isonitrile) complexes in the transfer hydrogenation of S2. 
 
Entry Complex T (°C) Time (h) Base Conv. (%) ee (%) 
1 Fe12 50 18 t-BuOK 51 13 
2 Fe12 50 18 NaOH 52 5 
3 Fe12 50 90 t-BuOK 87 11 
4 Fe13 25 18 t-BuOK 11 14 
5 Fe13 25 18 NaOH 48 16 
6 Fe13 50 18 t-BuOK 12 5 
7 Fe13 50 18 NaOH 73 12 
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8 Fe14 25 66 t-BuOK 34 0 
9 Fe14 50 66 t-BuOK 36 9 
 
 All complexes turned out to be able to catalyze the transfer hydrogenation of 
acetophenone, although with a low level of stereocontrol (Fe13, ee up to 16%, entry 5).  
 The neutral complex Fe12 promoted the reaction with up to 87% conversion 
(entry 13), but with a low enantiomeric excess (5-13% ee). Remarkably, a very long 
reaction time (90 hours) was necessary to achieve such level of conversion, while in the 
standard reaction time (18 hours) the maximum conversion was slightly above 50% 
(entry 1). This observation suggested that probably the catalyst Fe12 did undergo 
degradation, but rather kept on promoting the reaction with a very slow rate. Regarding 
bases, NaOH afforded conversion comparable to tBuOK (entry 5), but with decreased ee - 
only 5%.  
 The most soluble complex Fe13 gave the best result over 18 hours at 50 °C, 
achieving 73% conversion and 12% ee (entry 7). Remarkably, the catalytic activity of Fe13 
greatly depended upon the nature of the base used in the reaction. In each attempt, 
conversions with NaOH were higher than in the corresponding reactions with t-BuOK 
(entries 4 vs. 5, 6 vs. 7). A further base screening was conducted and it revealed that no 
reactions occurs in the presence of KOH, TEA, Na2CO3 or K2CO3. 
 The dicationic complex Fe14 was able to catalyze the reaction as well, but with 
lower conversions than the ones obtained with neutral complex Fe12. Complex Fe14 
afforded low enantiomeric excess and it required temperature elevated to 50 °C to 
obtain it (9% ee, entry 9).  
 The bis(isonitrile) complexes employed in this first catalytic screening showed 
ability to promote the transfer hydrogenation of acetophenone with moderate - yet not 
outstanding - activity. The positive results obtained prompted us to investigate more 
deeply the application of isonitrile Fe(II)-complexes for ketone reductions.  
 
4.3 Tetra(isonitrile) complexes 
 We decided to synthesize new tetra(isonitrile) complexes Fe15 and Fe16, which 
were more directly inspired to Reiser’s catalyst 36 (Scheme 4.5). They were expected to 
display higher catalytic activity compared to the previously tested bis(isonitrile) 
complexes, because they possessed four isonitrile groups coordinated to the metal 
centre. The chiral scaffold was a binaphthyl moiety, connected to the linear isonitrile 
function by a rigid linker (benzene ring). 
 The synthetic route, started with a nucleophilic aromatic substitution between 
(R)-BINOL and o-fluoronitrobenzene, yielding 61. The latter was reduced to diamine 62, 
which was then subjected to bis-formylation in formic acid using zinc oxide as a promoter 
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to obtain bis-formamide 63. Dehydration of 63 using phosphoryl chloride gave ligand 64 
with 44% overall yield. Complexation of 64 with standard Fe(II) sources (iron chloride 
tetrahydrate and iron tetrafluoroborate hexahydrate) afforded complexes Fe15 and 
Fe16. 
 
Scheme 4.5 Synthesis of (tetra)isonitrile complexes Fe15 and Fe16. 
 New complexes Fe15 and Fe16 were tested in the transfer hydrogenation of 
acetophenone Table 4.2. 
Table 4.2 Catalytic screening of tetra(isonitrile) complexes in the transfer hydrogenation of S2. 
 
Entry Complex T (°C) Solvent Base Conv. (%) ee (%) 
1 Fe15 50 i-PrOH t-BuOK 6 - 
2 Fe15 50 i-PrOH KOH 6 - 
3 Fe15 50 H2O HCOONa 0 - 
4 Fe15 50 HCOOH:TEA 5:2 TEA 0 - 
5 Fe16 50 i-PrOH t-BuOK 2 - 
6 Fe16 50 i-PrOH NaOH 5 - 
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 To our surprise, complexes Fe15 and Fe16 were not catalytically active in the 
transfer hydrogenation of ketones. Conversions at 50 °C over 18 hours were always very 
low, regardless of the base used. In particular, complex Fe15 was tested employing 
different hydrogen donor reagents. Besides the standard isopropanol/potassium tert-
butoxide and isopropanol/potassium hydroxide systems (entries 1 and 2), also the 
combinations water/sodium formate and formic acid/triethylamine were used, but 
without success (entries 3 and 4). 
 The observed lack of activity might be due to the fact that employed isonitriles 
are aromatic and not aliphatic as in complexes 36, Fe15 or Fe16. Under this hypothesis, 
the critical step of the catalytic cycle have to be the hydride transfer from the reduced 
isonitrile (imido) function to the coordinated substrate, as depicted in Scheme 4.6 (see 
Scheme 4.1 for the complete catalytic cycle). The hydride transfer may be disfavored 
when R is not aliphatic, as the isonitrile is less electron-rich. 
 
Scheme 4.6 An aromatic isonitrile (R = Ar) can be less prone to transfer the hydride to the substrate,  
compared to an aliphatic one. 
 
4.4 Second generation of tetra(isonitrile) complexes 
 Considering possible reasons of failure of the previously synthesized 
tetra(isonitrile) complexes, our efforts continued to synthesize new aliphatic isonitrile 
iron(II) complexes, which were expected to be active catalysts for ketone transfer 
hydrogenation (Scheme 4.7).  
Scheme 4.7. Synthesis of 2
rd
 generation of isonitrile complexes Fe17 and Fe18. 
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 Synthesis of new complexes Fe17 and Fe18 started from commercially available 
(R)-2,2'-bis(bromomethyl)-1,1'-binaphthalene, which was converted into the bis-nitrile 
65. Various methods for reducing nitrile 65 to amine 66 were tested, but the one with 
LiAlH4 /AlCl3 proved to be the most efficient.
133 Bis-formylation of 66 and subsequent 
dehydration of 67 using phosphoryl chloride afforded ligand 68. The workup of isonitrile 
68 was problematic, as the use of a saturated aqueous solution of NaHCO3 (generally 
used to quench isonitrile-forming reactions) caused product re-hydration to substrate 67. 
We supposed that probably aq. NaHCO3 did not quenched the acidity generated from 
POCl3 hydrolysis fast enough, which led to the acid-catalysed re-hydration to the 
isonitrile. As expected, use of a stronger base (10% aq. Na2CO3) prevented the re-
hydration of 68. Complexation with standard Fe(II) sources afforded complexes Fe17 and 
Fe18, which were tested in transfer hydrogenation of acetophenone (Table 4.3). 
 
Table 4.3 Catalytic screening of the second generation tetra(isonitrile) complexes in the transfer hydrogenation of S2. 
 
Entry Complex T (°C) Time Conv. (%) ee (%) 
1 Fe17 25 18 40 29 
2 Fe17 25 48 42 26 
3 Fe17 50 18 64 25 
4 Fe18 25 18 12 15 
5 Fe18 25 48 12 15 
6 Fe18 50 18 13 8 
 
The hypothesis of the necessity of aliphatic "arms" of isonitrile complexes to 
provide the efficient hydride transfer was confirmed. Catalyst Fe17 was able to induce 
29% ee with a 40% conversion (entry 1). Prolonged reaction time did not changed this 
result, suggesting that catalyst Fe17 got deactivated in the course of ATH (entry 2). 
Elevated temperature led to significantly higher conversion (64%), but along with an 
erosion of enantiomeric excess (25% ee, entry 3). Dicationic complex Fe18 revealed much 
lower catalytic activity (entry 4) and much lower stability in time or at higher 
temperature (entries 5-6). 
Upon comparison with the bis(isonitrile) complexes, obtained enantiomeric 
excess was nearly twice higher (29% ee for Fe17 vs. 16% ee for Fe13), but it could be 
described only as very moderate when compared to the original catalyst 36 developed by 
Reiser and co-workers (up to 67% ee).91 
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4.4.1 Possible improvements to the second generation isonitrile complexes 
Positive results in ATH of acetophenone with the second generation 
tetra(isonitrile) complexes, encouraged us to think, how to increase the stereocontrol in 
the course of the reaction. Three possible structural modifications to tetra(isonitrile) 
complexes were evaluated as the most promising strategies (Figure 4.3): 
 
 
Figure 4.3 Possible structural improvements to the Fe-isonitrile catalysts. 
Proceeding with the first proposal, we attempted to install substituents on the α 
position of the alkyl chain. Unfortunately, this pathway was quickly abandoned. We were 
not able to synthesize a cyclopropane derivative according to a route published for 
phenylacetonitrile (Scheme 4.8).134 Instead of the desired product 69, only extensive 
degradation of the starting material 68 was observed. 
 
Scheme 4.8 Unsuccessful attempt to introduce steric bulk in in β-position of "isonitrile arm". 
Our efforts to proceed with Strategy B and introduce steric bulk in β-positions of 
the isonitrile groups were successful. In addition to the previously reported synthesis of 
Fe17 (Scheme 4.7), bis-nitrile 65 was methylated to 70 before being reduced to bis-
amine 71 (Scheme 4.9). Following formylation and dehydrataion, new ligand 73 was 
obtained. Together with iron(II) chloride tetrahydrate, a new complex Fe19 was 
successfully obtained and tested in ATH of acetophenone (Table 4.4). 
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Scheme 4.9. Introduction of steric bulk in β-positions of the isonitrile groups. 
 
Table 4.4 Catalytic screening of the improved second generation tetra(isonitrile) complex Fe19 in the transfer 
hydrogenation of S2. 
 
Entry T (°C) Conv. (%) ee (%) 
1 25 40 6 
2 50 55 <2 
To our great disappointment, installation of additional methyl groups on the alkyl 
chains led only to low or neglectable enantioselectivity along with lower conversions 
than in the case of previous Fe-isonitrile catalysts. 
The last of proposed synthetic strategies, based on introducing steric bulk in 
binaphthyl 3,3'-positions (C from Figure 4.3) is still under investigation in our lab.  
 
4.5 Summary of the isonitirile complexes 
 In summary, being inspired by catalyst developed by Reiser and co-workers, we 
synthesized two new families of isonitrile complexes, eight of them in total. The first 
family of them, bis(isonitrile) iron catalysts Fe12-14, showed a moderate activity in terms 
of conversion and a low enantiomeric excess. The second family - tetra(isonitrile) 
complexes - proved to be better family of catalysts for the asymmetric transfer 
hydrogenation of ketones. Although initial attempts in the ATH with complexes Fe15 and 
Fe16 were unsuccessful, they were a confirmation of the postulated mechanism of this 
catalytic transformation, as required hydride transfer was disfavored when the isonitrile 
arm was aromatic and thus, less electron-rich. In second generation of tetra(isonitrile) 
complexes (Fe17-Fe18) this drawback was removed, but still obtained enantiomeric 
excess was rather low (up to 29% ee). In order to improve the transfer of the 
stereochemical information from the (R)-BINOL derived backbone, introductions of steric 
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bulk in different positions of the molecule were investigated, results obtained so far 
failed or led to lack of enantiocontrol in the ATH of ketones (Fe19). Synthesis of (R)-
BINOL derived isonitriles with bulky 3,3'-substituents is currently underway in Gennari 
group. 
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4.6 Experimental section 
General remarks 
 All reactions were carried out in flame-dried glassware with magnetic stirring under 
nitrogen atmosphere, unless otherwise stated. Synthesis of complexes was performed under 
argon using standard Schlenk-techniques.  
 The solvents for reactions were distilled over the following drying agents and transferred 
under nitrogen: CH2Cl2 (CaH2), MeOH (CaH2), CH3CN (CaH2), THF (Na), dioxane (Na), toluene (Na), 
hexane (Na), Et3N (CaH2). Acetophenone and i-PrOH were distilled on CaH2 (a small amount of 
PPh3 was added when distilling isopropanol) and stored over molecular sieves. Et2O and DMF 
were purchased in bottles with crown cap, over molecular sieves, and stored under nitrogen. The 
commercially available starting products [3,5-bis(trifluoromethyl)bromobenzene, (S,S)-2,2’-
bipyrrolidine D-tartrate trihydrate, 6-methoxy-2-pyridinecarboxaldehyde, 2-pyridine 
carboxaldehyde, 2,2’-bis(bromomethyl)-1,1’-biphenyl, 2-fluoronitrobenzene, (R)-binaphthol] 
were used as received. 
 The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualisation was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution, a 
nynhidrine solution or a ceric ammonium molybdate solution. Flash column chromatography was 
performed using silica gel (60 Å, particle size 40-64 μm) as stationary phase, following the 
procedure by Still and co-workers.135 Gas chromatography was performed by a GC instrument 
equipped with a flame ionization detector, using the chiral capillary column MEGADEX DACTBSβ, 
diacetyl-t-butylsilyl-β-cyclodextrin. 
 Proton NMR spectra were recorded on a spectrometer operating at 400.13 MHz. Proton 
chemical shifts are reported in ppm (δ) relative to tetramethylsilane (TMS) with the solvent 
resonance employed as the internal standard (CDCl3, δ = 7.26 ppm; CD2Cl2, δ = 5.32 ppm; 
(CD3)2SO, δ = 2.50 ppm; CD3OD, δ = 3.33 ppm; CD3CN, δ = 1.94 ppm). The following abbreviations 
are used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad signal. The coupling constant values are given in Hz. 13C-NMR spectra were 
recorded on a 400 MHz spectrometer operating at 100.56 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective 
solvent resonance as the internal standard (CDCl3, δ = 77.23 ppm; CD2Cl2, δ = 54.00 ppm; 
(CD3)2SO, δ = 39.51 ppm; CD3OD, δ = 49.05; CD3CN, δ = 118.26 ppm).  
 High resolution mass spectra (HRMS) were performed on a Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker Daltonics) – 
4.7 T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro Interdipartimentale 
Grandi Apparecchiature) c/o Università degli Studi di Milano. Low resolution mass spectra (MS) 
were acquired either on a Thermo-Finnigan LCQ Advantage mass spectrometer (ESI ion source) 
or on a VG Autospec M246 spectrometer (FAB ion source).  
 Elemental analyses were performed on a Perkin Elmer Series II CHNS/O Analyzer 2000. 
 Infrared spectra were recorded on a standard FT/IR spectrometer.  
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N-((2'-(Bromomethyl)biphenyl-2-yl)methyl)-N-formylformamide 56 
Sodium diformylamide (0.34 g, 3.5 mmol, 1.2 eq) was added to a stirred 
solution of 2,2’-bis(bromomethyl)-1,1’-biphenyl (1.00 g, 3.0 mmol, 1 eq) in 10 
mL DMF. The reaction mixture was then stirred for 18 hours at 100 °C, then the 
solvent was evaporated. The residue was taken up with water and extracted 
with CH2Cl2 (3x). The collected organic phases were dried with Na2SO4, filtered and evaporated. 
The crude was purified by FCC (hexane/AcOEt 8:2), giving 56 as a pale yellow oil in 72% yield. 1H 
NMR (400 MHz, CDCl3): δ 8.90 (s, 2H), δ 7.60 (dd, J = 7.6, 1.4 Hz, 1H), δ 7.48-7.35 (m, 4 H), δ 7.34-
7.30 (m, 1 H), δ 7.29-7.25 (m, 1H), δ 7.18 (br s, 1 H), δ 4.63 (d, J = 14.2 Hz, 1H), δ 4.56 (d, J = 14.2 
Hz, 1H), δ 4.43 (d, J = 10.0 Hz, 1H), δ 4.24 (d, J = 10.0 Hz, 1H). ESI-MS in CH3CN: [M-CO+Na]
+ m/z 
326.2, [M+Na]+ m/z 354.2.  
N-((2'-(Bromomethyl)biphenyl-2-yl)methyl)formamide 57 
Sodium tert-butoxide (20 mg, 0.18 mmol, 0.05 eq) was added to a stirred milky 
suspension of 56 (1.2 g, 3.6 mmol, 1 eq) in 20 mL EtOH. Upon addition the 
mixture became immediately clear. After 5 minutes, solid ammonium chloride 
was added and the reaction mixture was filtered through celite washing with 
CH2Cl2. Evaporation of the filtrate afforded 57 as a yellow oil which was purified with FCC 
(CH2Cl2/AcOEt 98:2). The product was obtained as a colourless oil in 91% yield. 
1H NMR (400 
MHz, CDCl3): δ 8.12 (s, 1H), δ 7.56 (d, J = 10.7, 1H), δ 7.48-7.32 (m, 5H), δ 7.28-7.10 (m, 2H), δ 
6.38 (br s, 1H), δ 4.32 (m, 2H), δ 4.27 (m, 2H). ESI-MS in CH3CN: [M+Na]
+ m/z 326.1.  
N,N'-(2',2''-(2S,2'S)-2,2'-Bipyrrolidine-1,1'-diylbis(methylene)bis(biphenyl-2',2-diyl))bismethylene)-
diformamide 58 
NaOH (80 mg, 2.0 mmol, 6.7 eq) and 57 (204 mg, 0.66 
mmol, 2.2 eq) were added in sequence to a stirred 
suspension of (S,S)-2,2’-bipyrrolidine D-tartrate 
trihydrate (104 mg, 0.30 mmol, 1 eq) in 24 mL 
H2O/CH2Cl2 1:1. The obtained mixture was stirred 
overnight at RT, then diluted with 1M NaOH and extracted with CH2Cl2 (3x). The combined 
organic phases were dried with Na2SO4 and concentrated in vacuo. The crude was purified by FCC 
(CH2Cl2/MeOH/aqueous NH3 33% 95:5:2). The collected fractions were combined, diluted with 
CH2Cl2, washed with water (2x) and dried with Na2SO4. Evaporation of solvents afforded 58 in 
92% yield. 1H NMR (400 MHz, CDCl3): δ 8.16 (s, 2H), δ 7.68 (s, 2H), δ 7.46-7.36 (m, 6H), δ 7.35-
7.20 (m, 6H), δ 7.16 (m, 2H), δ 4.27 (m, 4H), δ 3.83 (d, J = 11.8 Hz, 2H), δ 2.72 (s, 2H), δ 2.56 (d, J 
= 11.8 Hz, 2H), δ 1.91 (br s, 2H), δ 1.56 (br s, 2H), δ 1.90-1.31 (m, 8H). ESI-MS in CH3CN: [M+H]
+ 
m/z 587.6; [M+Na]+ m/z 609.5. 
(2S,2'S)-1,1'-Bis((2'-(isocyanomethyl)biphenyl-2-yl)methyl)-2,2'-bipyrrolidine (ISO) 60 
Method 1. To a mixture of 58 (1.34 g, 2.3 mmol, 1 eq) and 
triethylamine (0.86 mL, 9.6 mmol, 4.2 eq) in 13 mL CH2Cl2 at 
0 °C trichloromethyl chloroformate (diphosgene, 0.28 mL, 
2.3 mmol, 1 eq) dissolved in 3 mL CH2Cl2 was added with 
stirring over 1 h. After stirring for 25 minutes, the 
temperature was allowed to rise to 20 °C and the solution was washed with a saturated NaHCO3 
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aqueous solution. The organic phase was evaporated and the crude was purified by FCC 
(CH2Cl2/MeOH 99.5:0.5). Ligand 60 was obtained as a foamy solid in 89% yield. Method 2. A 
mixture of 58 (81 mg, 0.14 mmol, 1 eq) and TEA (0.13 mL, 1.38 mmol, 10 eq) in 1 mL THF was 
cooled to 0 °C. POCl3 (28 μL, 0.30 mmol, 2.2 eq) was then added dropwise. After stirring 
overnight at RT, the yellow mixture was transferred into cold distilled water and extracted with 
CH2Cl2 (3x). The collected organic phases were dried with Na2SO4, filtered and evaporated. 
Purification of the crude by FCC (CH2Cl2/MeOH 99.5:0.5) gave 60 as a yellow viscous oil in 54% 
yield. Method 3. NaOH (70 mg, 1.7 mmol, 6.3 eq) and 59 (170 mg, 0.60 mmol, 2.2 eq) were 
added in sequence to a stirred suspension of (S,S)-2,2’-bipyrrolidine D-tartrate trihydrate (94.0 
mg, 0.27 mmol, 1 eq) in 20 mL H2O/CH2Cl2 1:1. The obtained mixture was stirred overnight at RT, 
then diluted with 1M NaOH and extracted with CH2Cl2 (3x). The combined organic phases were 
dried with Na2SO4 and concentrated in vacuo. The crude was purified by FCC (CH2Cl2/MeOH 
99:1). Evaporation of solvents afforded 60 in 57% yield. 1H NMR (400 MHz, CD2Cl2): δ 7.63 (d, J = 
8.1 Hz, 2H), δ 7.57-7.31 (m, 10H), δ 7.19-7.05 (m, 4H), δ 4.50-4.24 (m, 4H), δ 3.75 (d, J = 12.4 Hz, 
2H, rotamer I), δ 3.66 (d, J = 14.2 Hz, 2H, rotamer II), δ 3.64 (d, J = 12.1 Hz, 2H, rotamer III), δ 3.55 
(d, J = 14.0 Hz, 2H, rotamer IV), δ 2.90-2.58 (m, 4H), δ 2.31 (m, 1H, rotamer I), δ 2.12 (m, 1H, 
rotamer II), δ 1.93-1.79 (m, 3H), δ 1.65-1.31 (m, 8H), δ 1.12 (m, 1H). 13C NMR (100 MHz, CD2Cl2): 
δ 158.00, 139.95, 139.48, 137.62, 131.78, 129.51, 129.39, 128.05, 127.92, 127.74, 127.06, 
126.48, 64.98, 57.23, 53.96, 43.82, 29.7, 25.04, 24.02. ESI-MS in CH3CN: [M+H]
+ m/z 551.6; 
[2M+CuI]+ m/z 1163.5. HRMS: [M+H]+ calculated m/z 551.31692, found 551.31741. 
[FeCl2(ISO)] Fe12 
Under Ar, FeCl2·4H2O (56 mg, 0.27 mmol, 1 eq) was added to a 
stirred solution of ligand 60 (148 mg, 0.27 mmol, 1 eq) in 5 mL 
MeOH. Upon addition, the yellow solution became turbid 
brown. The reaction mixture was stirred overnight at RT, then 
Et2O was added to aid precipitation. The solvent was decanted 
off via syringe. The precipitate was washed again with Et2O (3x) 
and CH2Cl2 (1x). The beige solid was then dried under under high vacuum. Yield: 69%. FAB-MS in 
MeOH: [M-Cl]+ m/z 641. 
2-(Bromomethyl)-2'-(isocyanomethyl)biphenyl 59 
POCl3 (37 μL, 0.40 mmol, 1.2 eq) was added dropwise to a stirred suspension of 
formamide 57 (102 mg, 0.34 mmol, 1 eq) and DIPEA (0.29 mL, 1.68 mmol, 5 eq) in 5 
mL CH2Cl2 kept at 0 °C. The reaction mixture was then stirred overnight at RT. On the 
next day a saturated NaHCO3 aqueous solution and CH2Cl2 were added, phases were 
separated and the aqueous layer was extracted with CH2Cl2 (3x). The collected organic phases 
were anhydrified with Na2SO4, filtered and evaporated. The crude was purified by FCC 
(hexane/AcOEt 9:1), obtaining 60 as a pale yellow foamy solid in 54% yield. 1H NMR (400 MHz, 
CD2Cl2): δ 7.69 (dd, J = 7.6, 0.8 Hz, 1H), δ 7.62 (dd, J = 7.7, 1.6 Hz, 1H), δ 7.56 (td, J = 7.6, 1.6 Hz, 
1H), δ 7.53-7.44 (m, 3H), δ 7.32 (dd, J = 7.6, 1.6 Hz, 1H), δ 7.24 (dd, J = 7.6, 1.6 Hz, 1H), δ 4.45 (d, 
J = 11.4 Hz, 1H), δ 4.42 (s, 2H), δ 4.34 (d, J = 11.4 Hz, 1 H). 
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 [Fe(CH3CN)2(ISO)](BArF)2 Fe13 
Under Ar, AgBArF (245 mg, 0.25 mmol, 2 eq) was added 
to a stirred suspension of [FeCl2(ISO)] Fe12 (85 mg, 0.13 
mmol, 1 eq) in 4 mL CH3CN. Upon addition a whitish 
precipitate formed. After stirring for 4 hours with 
minimal light exposure, the reaction mixture was filtered 
under Ar through celite. Evaporation of the filtrate gave 
Fe13 as a brown solid in 93% yield. 
[Fe(CH3CN)2(ISO)](BF4)2 Fe14 
Under Ar, iron(II) tetrafluoroborate hexahydrate (97%, 356 
mg, 1.02 mmol, 1 eq) was added to as stirred suspension of 
ligand 60 (561 mg, 1.02 mmol, 1 eq) in 10 mL CH3CN. After 
stirring overnight at RT, solvents were evaporated and the 
residue was washed with Et2O (3x). The obtained yellow 
solid was then dried under high vacuum. Yield: 86%. ESI-MS 
in CH3CN: [M-2CH3CN+F]
+ m/z 625.4. 
2,2'-Bis(2-nitrophenoxy)-1,1'-binaphthalene136 61 
2-fluoronitrobenzene (4.92 g, 34.9 mmol, 2 eq) was added to a stirred 
suspension of (R)-binaphthol (5.00 g, 17.4 mmol, 1 eq) and potassium 
carbonate (5.07 g, 36.7 mmol, 2.1 eq) in 60 mL DMF. The resulting yellow 
reaction mixture was heated overnight at 80 °C, then poured into cold 
water, with immediate precipitation of a yellow solid. The precipitate was filtered on Buchner 
washing with hot water (4x). After drying under high vacuum, 61 was obtained as a pale yellow 
solid in 98% yield. 1H NMR (400 MHz, DMSO): δ 8.11 (d, J = 8.8 Hz, 2H), δ 8.02 (d, J = 8.0 Hz, 2H), 
δ 7.84 (dd, J = 8.0, 1.2 Hz, 2H), δ 7.48 (t, J = 7.6 Hz, 4H), δ 7.39-7.32 (m, 4H), δ 7.25-7.16 (m, 4H), 
δ 7.01 (d, J = 8.0 Hz, 2H). 
2,2'-([1,1'-Binaphthalene]-2,2'-diylbis(oxy))dianiline136 62 
One drop of H2SO4 was added to a stirred suspension of Pd/C (10%, 200 mg, 
0.19 mmol, 0.01 eq) and 61 (9.09 g, 17.2 mmol, 1 eq) in 100 mL THF, then 
hydrogenated overnight under 1 bar H2. On the next day, the hydrogen 
burette was re-loaded and the reaction mixture was stirred for another 
night under 1 bar H2. The mixture was then filtered through celite washing 
with THF. Evaporation of the filtrate gave 62 as a whitish solid, which was used without 
purification in the following step. Yield: 99%. 1H NMR (400 MHz, DMSO): δ 8.03 (d, J = 9.2 Hz, 2H), 
δ 7.99 (d, J = 8.0 Hz, 2H), δ 7.46 (td, J = 6.8, 1.2 Hz, 2H), δ 7.39 (td, J = 6.8, 1.2 Hz, 2H), δ 7.24 (d, J 
= 8.0 Hz, 2H), δ 7.10 (d, J = 9.2 Hz, 2H), δ 6.88 (td, J = 6.8, 1.2 Hz, 2H), δ 6.78-6.72 (m, 4H), δ 6.50 
(td, J = 7.6, 1.2 Hz, 2H), δ 4.60 (s, 4H). 
N,N'-(([1,1'-Binaphthalene]-2,2'-diylbis(oxy))bis(2,1-phenylene))diformamide 63 
Dianiline 62 (1.00 g, 2.13 mmol, 1 eq) was added to a stirred suspension 
of ZnO (174 mg, 2.13 mmol, 1 eq) and formic acid (3.5 mL, excess). The 
reaction mixture was heated overnight at 70 °C, then was filtered through 
celite washing with CH2Cl2 (3x). The filtrate was washed with water (x2) 
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and saturated NaHCO3 solution (1x). The organic layer was anhydrified with Na2SO4, filtered and 
evaporated to give a brown solid. Purification by FCC (CH2Cl2/AcOEt 93:7) afforded 63 as a pale 
pink solid in 78% yield. 1H NMR (400 MHz, CDCl3): δ 8.55-8.38 (m, 1H), δ 8.23 (m, 1H), δ 8.00-7.88 
(m, 4H), δ 7.82 (d, J = 1.2 Hz, 1H), δ 7.55-7.34 (m, 6H), δ 7.29-7.22 (m, 2H), δ 7.09-6.83 (m, 5H), δ 
6.75-6.66 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 158.54, 151.47, 145.18, 133.81, 130.98, 130.54, 
128.81, 128.35, 127.25, 125.39, 125.31, 124.25, 123.83, 122.00, 121.10, 118.76, 117.46. ESI-MS 
in CH3CN: [M+Na]
+ m/z 547.6, [2M+Na]+ m/z 1071.2. 
2,2'-Bis(2-isocyanophenoxy)-1,1'-binaphthalene (ISAR) 64 
POCl3 (287 μL, 3.07 mmol, 2.1 eq) was dropped into a stirred solution of 63 
(767 mg, 1.46 mmol, 1 eq) and TEA (1.2 mL, 8.77 mmol, 6 eq) in 6 mL CH3CN. 
During the addition the reaction mixture darkened and became turbid. After 
stirring overnight at RT, the reaction mixture was poured into chilled NaHCO3 
aqueous solution and CH2Cl2 was added. Phases were separated and the 
aqueous layer was extracted with CH2Cl2 (3x). The combined organic phases were dried with 
Na2SO4, filtered and evaporated. Purification of the crude by FCC (hexane/AcOEt 95:5) afforded 
ligand 64 as an off-white foam in 58% yield. 1H NMR (400 MHz, CD2Cl2): δ 7.99 (d, 11.9 Hz, 2H), δ 
7.93 (d, 11.0 Hz, 2H), δ 7.46 (t, 10.3 Hz, 2H), δ 7.35 (m, 2H), δ 7.23 (t, 10.0Hz, 2H), δ 7.15 (td, J = 
10.1, 2.3 Hz, 2H), δ 6.91 (m, 2H). 
[FeCl2(ISAR)2] Fe15 
Under Ar, a solution of ligand 64 (181 mg, 0.38 mmol, 2 
eq) in 5 mL CH2Cl2 was added via cannula into a stirred 
solution of FeCl2·4H2O (38 mg, 0.19 mmol, 1 eq) in 7 mL 
MeOH. From the two yellow solution a reddish 
suspension formed. The reaction mixture was stirred overnight at RT, then solvents were 
removed under high vacuum and the residue was washed with hexane (2x), decanting the 
solvent off. Fe15 was obtained as an orange solid in 80% yield. ESI-MS in CH3CN: [M-Cl]
+ m/z 
1067.5. 
[Fe(CH3CN)2(ISAR)2](BF4)2 Fe16 
Under Ar, iron(II) tetrafluoroborate hexahydrate 
(107 mg, 0.31 mmol, 1 eq) was added to a stirred 
solution of ligand 64 (300 mg, 0.61 mmol, 2 eq) 
in 7 mL CH3CN. Upon addition the solution 
turned reddish/brown. The reaction mixture was 
stirred overnight at RT, then the solvent was 
concentrated to a volume of 1 mL. Addition of 15 mL Et2O caused precipitation of a dark yellow 
solid. Solvents were evaporated again and the residue was washed with Et2O, removing the 
solvent via syringe (3x). Fe16 was obtained as a dark yellow powder in 78% yield. ESI-MS in 
CH3CN: [M-2CH3CN]
2+ m/z 516.7, [M-CH3CN]
2+ m/z 536.6; [2BF4+Na]
- m/z 197.5.  
(R)-2,2'-([1,1'-binaphthalene]-2,2'-diyl)diacetonitrile 65 
To a suspension of (R)-2,2'-bis(bromomethyl)-1,1'-binaphthalene (1.3 g, 2.95 
mmol, 1 eq) in 6 mL DMF, solid KCN (0.44 g, 6.8 mmol, 2.3 eq) was added. After 
stirring overnight at 70 °C, DMF was evaporated and the reaction mixture was 
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dissolved in CH2Cl2 and water was added. Phases were separated and the aqueous layer was 
extracted with CH2Cl2 (3x). The combined organic phases were dried with Na2SO4, filtered and 
evaporated. Purification of the crude by FCC (hexane/AcOEt 8:2) allowed to obtain 65 with 49% 
yield. 1H NMR (400 MHz, CDCl3): δ 8.1 (d, J = 8.8 Hz, 2H), δ 8.0 (d, J = 8.4 Hz, 2H), δ 7.8 (d, J = 8.4 
Hz, 2H), δ 7.6 (dt, J = 7.2, 1.2 Hz, 2H), δ 7.4 (dt, J = 7.2, 1.2 Hz, 2H), δ 7.1 (d, J = 8.8 Hz, 2H), δ 3.4 
(d, J = 9.5 Hz, 2H), δ 3.3 (d, J = 9.5 Hz, 2H). 
(R)-2,2'-([1,1'-binaphthalene]-2,2'-diyl)diethanamine 66 
To a solution of AlCl3 (0.81 g, 6.1 mmol, 4.2 eq) and LiAlH4 (0.23 g, 6.1 mmol, 
4.2 eq) in 15 mL of THF, a solution of 65 (0.48 g, 1.44 mmol, 1 eq) was added 
dropwise. Mixture was stirring overnight under low N2 flow. Reaction was 
diluted with 5 mL of water and 8 mL of 3 M H2SO4 was added dropwise under 
N2 flow. Reaction mixture was diluted with CH2Cl2. Phases were separated and the aqueous layer 
was extracted with CH2Cl2 (3x). The combined organic phases were dried with Na2SO4, filtered 
and evaporated. Crude 66 was used without purification in the following step. 1H NMR (400 MHz, 
CDCl3): δ 7.9 (m, 2H), δ 7.7 (m, 2H), δ 7.6 (m, 2H), δ 7.5 (m, 2H), δ 7.4 (m, 2H), δ 7.1 (m, 2H), δ 2.8 
(m, 2H), δ 2.6 (m, 2H), δ 1.6 (br, 2H)  
(R)-N,N'-([1,1'-binaphthalene]-2,2'-diylbis(ethane-2,1-diyl))diformamide 67 
Crude 66 was dissolved in 5 mL of ethyl formate and refluxed for 48 h. 
Purification of the crude by FCC (DCM/MeOH 97:3) allowed to obtain 67 
in 60% yield. 1H NMR (400 MHz, CDCl3): δ 8.0 (d, J = 8.8 Hz, 2H), δ 7.9 (d, J 
= 8.4 Hz, 2H), δ 7.7 (d, J = 8.4 Hz, 2H), δ 7.5 (dt, J = 7.2, 1.2 Hz, 2H), δ 7.3 
(dt, J = 7.2, 1.2 Hz, 2H), δ 7.0 (d, J = 8.8 Hz, 2H), δ 3.5 (m, 2H), δ 3.3 (m, 2H), δ 2.6 (m, 2H). ESI-MS 
in CH3CN: [M-Na]
+ m/z 419.6. 
(R)-2,2'-bis(2-isocyanoethyl)-1,1'-binaphthalene (ISAL)68 
POCl3 (90 μL, 0.9 mmol, 2.2 eq) was dropped into a stirred solution of 67 (165 
mg, 4.2 mmol, 1 eq) and TEA (0.3 mL, 3.35 mmol, 8 eq) in 6 mL DCM. During 
the addition the reaction mixture darkened and became turbid. After stirring 
3 h at RT, the reaction mixture was poured into chilled NaCO3 aqueous 
solution and CH2Cl2 was added. Phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3x). The combined organic phases were dried with Na2SO4, filtered and evaporated. 
Purification of the crude by FCC (DCM) afforded ligand 64 as an off-white foam in 84% yield. 1H 
NMR (400 MHz, CDCl3): δ 8.1 (d, J = 8.8 Hz, 2H), δ 8.0 (d, J = 8.4 Hz, 2H), δ 7.6 (d, J = 8.4 Hz, 2H), δ 
7.5 (m, Hz, 2H), δ 7.3 (m, 2H), δ 7.0 (d, J = 8.4 Hz, 2H), δ 3.3 (m, 4H), δ 2.8 (m, 4H). 
[FeCl2(ISAL)2] Fe17 
Under Ar, a solution of ligand 68 (111 mg, 0.39 mmol, 
2 eq) in 5 mL CH2Cl2 was added via cannula into a 
stirred solution of FeCl2·4H2O (39 mg, 0.20 mmol, 1 
eq) in 7 mL MeOH. From the two yellow solution a 
reddish suspension formed. The reaction mixture was 
stirred overnight at RT, then solvents were removed under high vacuum and the residue was 
washed with hexane (2x), decanting the solvent off. Fe17 was obtained as an orange solid in 76% 
yield. ESI-MS in CH3CN: [M-Cl+ACN]
+ m/z 851.9. 
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[Fe(CH3CN)2(ISAL)2](BF4)2 Fe18 
Under Ar, iron(II) tetrafluoroborate 
hexahydrate (70 mg, 0.20 mmol, 1 eq) was 
added to a stirred solution of ligand 68 (145 
mg, 0.4 mmol, 2 eq) in 5 mL CH3CN. Upon 
addition the solution turned brown. The 
reaction mixture was stirred overnight at RT, then the solvent was concentrated to a volume of 1 
mL. Addition of 15 mL Et2O caused precipitation of a dark yellow solid. Solvents were evaporated 
again and the residue was washed with Et2O, removing the solvent via syringe (3x). Fe18 was 
obtained as a dark yellow powder in 78% yield. ESI-MS in CH3CN: [M-2CH3CN]
2+ m/z 516.7, [M-
CH3CN]
2+ m/z 858.3; [2BF4+Na]
- m/z 1055.5.  
(R)-2,2'-([1,1'-binaphthalene]-2,2'-diyl)bis(2-methylpropanenitrile) 70 
Under N2, in a Shlenk flask, to a solution of tBuOK (0.93 g, 8.25 mmol, 5.5 eq) in 
THF (3 mL) at -300C, a solution of nitrile 65 (0.50 g, 1.5 mmol, 1 eq) and methyl 
iodide (0.84 mL, 13.5 mmol, 9 eq) in THF (4 mL) is added slowly over 20 
minutes. The reaction was allowed to reach R.T. and was stirred for 1 hour. The 
reaction was quenched with water (8 mL) and diluted with EtOAc (15 mL). Phases were separated 
and the aqueous layer was washed with EtOAc (2 x 10 mL). The combined organic layers were 
washed with water (20 mL), brine (20 mL) and dried over Na2SO4, filtered and evaporated 
affording 70 in 82% yield (0.48 g, 1.23 mmol). 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 8.9 Hz, 2H), 7.91 
(d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.9 Hz, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.23 (d, J = 7.8 Hz, 2H), 6.98 (d, J = 8.6 Hz, 
2H), 1.89 (s, 6H), 1.56 (s, 6H). ESI-MS in MeOH: [M+Na]+ m/z 411.4 (calcd. for C28H24N2 388.5). 
(R)-2,2'-([1,1'-binaphthalene]-2,2'-diyl)bis(2-methylpropan-1-amine) 71 
To a solution of AlCl3 (260 mg, 1.96 mmol, 3 eq) and LiAlH4 (75 mg, 1.96 
mmol, 3 eq) in 5 mL of Et2O, a solution of 70 (250 mg, 0.65 mmol, 1 eq) in 
THF (5 mL) was added dropwise. Mixture was stirring overnight under low N2 
flow. Reaction was diluted with 5 mL of water and 8 mL of 3 M H2SO4 was added dropwise under 
N2 flow. Reaction mixture was diluted with CH2Cl2. Phases were separated and the aqueous layer 
was extracted with CH2Cl2 (3x). The combined organic phases were dried with Na2SO4, filtered 
and evaporated. Crude 71 was used without purification in the following step. 1H NMR (400 MHz, 
CDCl3): δ 8.0 (m, 2H), δ 7.8 (m, 2H), δ 7.7 (m, 2H), δ 7.5 (m, 2H), δ 7.4 (m, 2H), δ 7.1 (m, 2H), δ 2.8 
(m, 2H), δ 2.6 (m, 2H), δ 1.16 (s, 6H), δ 0.70 (s, 6H). 
(R)-N,N'-([1,1'-binaphthalene]-2,2'-diylbis(2-methylpropane-2,1-diyl))diformamide 72 
Crude 71 was dissolved in 5 mL of ethyl formate and refluxed for 48 h. 
Purification of the crude by FCC (DCM/MeOH 97:3) allowed to obtain 67 in 
64% yield. 1H NMR (400 MHz, DMSO) δ 8.00 (d, J = 9.0 Hz, 2H), 7.90 (d, J = 
7.7 Hz, 2H), 7.83 (d, J = 9.0 Hz, 2H), 7.77 (s, J = 17.6 Hz, 2H), 7.40 (t, J = 7.3 
Hz, 2H), 7.18 (t, J = 7.3 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 3.24 (dd, J = 13.2, 5.9 Hz, 2H), 3.17 (d, J = 
4.8 Hz, 2H), 1.03 (s, J = 6.5 Hz, 6H), 0.70 (s, 6H). 
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(R)-2,2'-bis(1-isocyano-2-methylpropan-2-yl)-1,1'-binaphthalene 73 
POCl3 (50 μL, 0.59 mmol, 2.2 eq) was dropped into a stirred solution of 72 
(120 mg, 0.265 mmol, 1 eq) and TEA (0.3 mL, 2.12 mmol, 8 eq) in 3 mL THF. 
During the addition the reaction mixture darkened and became turbid. After 
stirring overnight at RT, the reaction mixture was poured into chilled NaCO3 
aqueous solution and CH2Cl2 was added. Phases were separated and the aqueous layer was 
extracted with CH2Cl2 (3x). The combined organic phases were dried with Na2SO4, filtered and 
evaporated. Purification of the crude by FCC (DCM/MeOH 95:5) afforded ligand 73 as an off-
white foam in 66% yield. 1H NMR (400 MHz, CD2Cl2) δ 8.05 (d, J = 9.0 Hz, 2H), 7.93 (d, J = 8.1 Hz, 
2H), 7.76 (d, J = 9.0 Hz, 2H), 7.48 (s, 2H), 7.24 (s, 2H), 6.95 (d, J = 8.6 Hz, 2H), 3.44 (s, 4H), 1.34 (s, 
6H), 1.02 (s, 6H). 
Fe19 
Under Ar, a solution of ligand 72 (65 mg, 0.144 mmol, 
2 eq) in 2.5 mL CH2Cl2 was added via cannula into a 
stirred solution of FeCl2·4H2O (14 mg, 0.072 mmol, 1 
eq) in 2.5 mL MeOH. From the two yellow solution a 
orange suspension formed. The reaction mixture was stirred overnight at RT, then solvents were 
removed under high vacuum and the residue was washed with hexane (2x), decanting the 
solvent off. Fe19 was obtained as an orange solid in quantitative yield. ESI-MS in CH3CN: [M-
Cl+ACN]+ m/z 964.1 (calcd. for C60H56Cl2FeN4 958.3). 
General procedure for the transfer hydrogenation of acetophenone (S2). A carousel multi-reactor 
was employed, allowing eight reactions in parallel under nitrogen atmosphere. Under N2 flow, 
the selected complex (4 mg, 0.05 eq) and the desired base (0.50 or 0.75 eq) were introduced in 
special glass vessels, which were then closed with screw caps and purged with nitrogen. Distilled 
isopropanol (2 mL) and acetophenone (10-20 μL, 1 eq) were added via syringe and the reactions 
were stirred under nitrogen at the desired temperature for a given time, then analyzed for 
conversion and ee determination. 
Conditions for conversion and ee determination 
1-Phenylethanol P2. Conversion and ee were determined by GC (capillary column: MEGADEX 
DACTBSβ, diacetyl-tert-butylsilyl-β-cyclodextrin, 0.25 μm; diameter = 0.25 mm; 
length = 25 m; carrier: hydrogen; hydrogen pressure: 1 bar; oven temperature: 75 
°C for 5 min, 20 °C/min gradient until 95 °C, 95 °C for 15 min, then a 20 °C/min 
gradient is applied): tsubstrate = 9.3 min; tproduct-en1 = 17.5 min; tproduct-en2 = 19.8 min. 
Chapter 4 
 
  
  
 
 
 
 
 
 
5 Chiral (cyclopentadienone)iron complexes 
5.1 (R)-BINOL derived complexes137 
 Cyclopentadienone(iron) complexes are very robust pre-catalysts which can be 
used in a range of hydrogenations and transfer hydrogenations, as it was described in the 
Paragraph 2.4.7. When compared to other iron complexes described in Chapter 2, they 
present the advantage of not being sensitive to air or moisture, besides being easy to 
synthesize and purify using simple silica gel chromatography. The most well known 
cyclopentadienone(iron) is complex 37, which can be activated in situ and transformed 
into active (cyclopentadienyl)iron hydride 38 – best known as “Knölker-Casey catalyst”. 
The transformation 37 → 38 can be accomplished by the Hieber base reaction101 or by 
oxidative/photolytic cleavage of CO ligand with subsequent H2 splitting (Scheme 5.1).
99,100  
 
Scheme 5.1 Activation of cyclopentadienone(iron) pre-catalyst 37 to form the Knölker-Casey catalyst 38. 
 Despite their inherent advantages of cyclopentadienone(iron) complexes, the 
development of chiral complexes to be used as enantioselective pre-catalysts still remains 
a major challenge (see Paragraph 2.4.7.2). Replacement of one of the CO ligands with a 
chiral phosphoramidite by Berkessel and co-workers led to formation of two 
diasteroisomers, which in effect led to only 31% ee in the AH of ketones (Figure 5.1a).104 
Insertion of a stereocenter in the ring fused with cyclopentadienone made by Wills and 
co-workers, led to only 25% ee, most likely as an effect of the excessive distance between 
the stereocentre and the reaction centre (Figure 5.1b).105 The best result so far was 
obtained by Beller and co-workers, who used a chiral phosphoric acid additive as a sort of 
"chiral template" between catalyst 38 and the substrate: ketimines could be 
hydrogenated with excellent conversions and enantiomeric excesses (up to 98% ee), but 
this methodology was not be applied for ketones (Figure 5.1c).106-109 
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Figure 5.1 Reported attempts for enantioselective transformations using cyclopentadienone(iron) complexes. 
 Seeking room for improvement of chiral transformations with 
cyclopentadienone(iron) complexes, we decided to investigate this field, particularly 
focusing on the asymmetric hydrogenation of ketones. In principle, our approach was 
related to that used by Wills and co-workers,105 as we wanted to introduce the 
stereocentre directly to the cyclopentadienone ligand. We thus decided to develop new 
chiral complex basing on (R)-BINOL [(R)-1,1'-bi-2-naphthol] backbone (Figure 5.2), 
analogously to what done by Cramer et al.138 for their chiral rhodium(I) Cp complex 74. 
The selected (R)-BINOL backbone possesses numerous advantages, as it is a stable, rigid, 
readily available and relatively cheap chiral starting material (it costs ~1 €/g).139  
 
Figure 5.2 Idea for synthesizing a new chiral iron pre-catalyst Fe20. 
 As we foresaw that the binaphthyl stereoaxis would be relatively far from the 
reaction centre, we speculated that certain structural modifications could improve the 
transfer of the stereochemical information or just act as a directing groups for substrates 
(Scheme 5.2). This is observations were in line with previously used BINOL-derived 
complexes.138,140 
 
Scheme 5.2 General structure of new chiral iron pre-catalysts and expected importance of binaphthyl  
3,3’-substituents and cyclopentadienone 2,5-substituents in AH. 
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 We first decided to synthesize the 3,3'-unsubstituted pre-catalyst Fe20, featuring 
TMS groups in the 2,5-positions of cyclopentadienone ring (Scheme 5.3). The early steps 
of our synthesis (up to 77) involved quite simple chemical transformations, already 
described by Maruoka and co-workers.141 The sequence started from (R)-BINOL which 
was triflated to 75. Following bis-methyl derivative 76 was obtained by Kumada cross-
coupling with a Grignard reagent without a loss of enantiopurity.142 Radical bromination 
of compound 76 using NBS yielded the bis-bromide 77. Following a procedure reported 
for related benzyl bromide substrates,143 the bis-bromide 77 was treated with (TMS-
ethynyl)magnesium bromide in the presence of CuI, but no conversion was observed. 
However, the synthesis of the bis-alkyne 79 could be achieved under similar conditions 
using the bis-iodide 78, readily obtained from 77 by halogen exchange, as a substrate. 
Cyclization of 79 in the presence of Fe2(CO)9 under the conditions reported by Renaud 
and co-workers99a afforded a new pre-catalyst Fe20. Complex Fe20 met our expectations 
and proved to be stable in air and upon purification using silica column chromatography. 
 
Scheme 5.3 Synthesis of new chiral iron complex Fe20. 
 The new chiral cyclopentadienone(iron) pre-catalyst Fe20 was tested in the 
asymmetric hydrogenation of acetophenone under conditions similar to the one reported 
by Beller and co-workers for the achiral pre-catalyst 37 (Scheme 5.4).101 
 
Scheme 5.4 AH of acetophenone S1 using chiral complex Fe20. 
 The first catalytic attempt led to 62% conversion and low enantiomeric excess - 
just 8% ee. Moderate conversion was not discouraging, as we expected to that the newly 
synthesized pre-catalyst Fe20 may require optimization of the hydrogenation's 
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conditions. As for the low enantiomeric excess, the result confirmed our suspects that the 
pre-catalyst without 3,3'-substituents could have problems of inefficient transfer of 
stereochemical information from the stereocentre to the reaction centre (Scheme 5.2).  
 With the expectation that an enhanced steric bulk next to the cyclopentadienone 
ring could enhance the transmission of stereochemical information, we tried to prepare 
the pre-catalyst Fe21, featuring four methyl groups next to the cyclopentadienone ring. 
Thus, we tried to methylate compound 77, but unfortunately this reaction was 
unsuccessful and only led to decomposition of the starting material (Scheme 5.5).  
 
Scheme 5.5 Attempt to increase the steric bulk by introducing methyl groups.  
 This additional attempt led us back to conclusion that it would be the best to 
install bulky substituents in the 3,3'-positions of the binaphthyl moiety. Molecular 
modeling suggested that the best substituent would be the flat and rigid β-naphthyl. We 
selected commercially available (R)-3,3'-dibromo-[1,1'-binaphthalene]-2,2'-diol as the 
starting point of the new synthetic pathway (Scheme 5.6). This chiral substrate was 
triflated to yield 81 and then compound 82 was obtained, using Suzuki-Miyaura cross 
coupling with β-naphthyl boronic acid. The latter reaction proceeded very slowly, most 
likely because of the bulkiness of β-naphthyl substituents. Subsequent Kumada coupling 
with MeMgI afforded 83, which was brominated under radical conditions to yield the bis-
bromide 84. As it was expected that that the bis-bromide 84 would not be reactive with 
(TMS-ethynyl)magnesium bromide, conversion into the corresponding diiodide was 
attempted by Filkenstein reaction with NaI. To our disappointment, this reaction did not 
proceed as easily as in the case of the bis-bromide 77 (devoid of 3,3'-substituents). Three 
compounds (co-spotting in TLC) were present in the reaction crude, and it was not 
possible to separate them. Moreover, crude compound 85 turned out to be very unstable 
(it immediately decomposed after contact with CDCl3 and shortly after contact with 
DCM). Nevertheless, crude compound 85 was used in following reaction with (TMS-
ethynyl)magnesium bromide without any purification. 1H NMR of the obtained crude was 
inconclusive, but it was decided to use the putative compound 86 as such in the reaction 
with Fe2(CO)9. Unfortunately, the bis-β-naphthyl complex Fe22 did not form.  
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Scheme 5.6 Attempts to synthesize β-naphthyl complex Fe22. 
 
5.2 Towards a new family of chiral cyclopentadienone(iron) complexes144 
The lesson learned from the first, unsuccessful attempt to obtain Fe22 was that 
the bulky 3,3’-substituents had to be introduced at a late stage of the synthetic pathway, 
as their presence hampered the functionalization of the 2,2’-positions of the binaphthyl 
system. Moreover, we started to analyze the possibility to prepare differently 3,3’-
substituted complexes from a common precursor synthesized on gram scale. Ideally, this 
versatile "scaffold complex" could be easily modified in one or two synthetic steps, 
allowing to obtain a library of different new 3,3’-substituted complexes (Scheme 5.7), and 
to evaluate the importance of their 3,3'-substituents.  
 
Scheme 5.7 New approach to synthesize new family of chiral iron complexes.  
 Before starting such plan, it was necessary to verify if the chiral 
cyclopentadienone(iron) complexes are stable to conditions we wanted to apply for their 
subsequent modifications. In a series of preliminary tests we evaluated if the 
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demethylating agent BBr3 (and its side product - HBr) would interfere with our complex or  
whether in the typical experimental conditions of the Suzuki-Miyaura coupling can cause 
in situ Hieber reaction, which would form the sensitive iron hydride complex and 
eventually lead to decomposition of the complex. We prepared a series of test reactions, 
using two pre-catalysts available in our lab - Fe20 and 37 (Scheme 5.8). In every case, a 
quantitative recovery of iron complexes was accomplished. This proved that our concept 
and gave a "green light" for the new synthetic strategy. 
 
Scheme 5.8 Verification of stability of cyclopentadienone(iron) complexes. 
 We individuated a synthetic plan to access the 3,3'-dimethoxy-substituted 
complex Fe23. Based on the observations made by Maruoka and co-workers145 for related 
BINOL-derivatives, we expected that the relatively small methoxy group should give less 
steric problems than the bulky β-naphthyl group used in the previous synthetic attempt 
(Scheme 5.6). The first synthetic steps (up to 93) were carried out as described by 
Maruoka and co-workers (Scheme 5.9).145 The synthetic pathway started from (R)-BINOL, 
which was protected using methyl chloromethyl ether (MOMCl). Protected 87 was 
subjected to ortho-lithiation, followed by formation of the bis-borate 88 and subsequent 
oxidation to 89. The hydroxy groups of 89 were methylated using MeI in the presence of 
K2CO3 to yield 90. The MOM protection was removed by acidic hydrolysis and afforded 
3,3'-dimethoxy-2,2'-BINOL derivative 91. The latter compound was converted into the bis-
triflate 92, which was methylated by Kumada coupling in the presence of MeMgI and 
[Ni(dppp)Cl2] to yield the known compound 93. The radical bromination to yield the bis-
bromide 94 was carried out under the conditions described by Cramer and co-workers.138 
Compound 94 was converted into the bis-iodide 95. Unexpectedly, the reaction of 95 with 
(TMS-ethynyl)magnesium bromide in the presence of CuI, which was effective for the of 
3,3'-unsubstituted analog 78, did not work with compound 95. We then screened without 
success a number of different possible conditions to synthesize compound 96: i) 
additional to CuI use of Pd(PPh3)4; ii) reaction of 95 with the Gilman's cuprate (TMS-
ethynyl)2CuLi; iii) Kumada cross coupling using 92 and (TMS-ethynyl)magnesium bromide. 
To our delight, substitution of 95 with (TMS-ethynyl)lithium allowed to obtain the diyne 
96 with a high yield. 
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Scheme 5.9 Synthesis of direct precursor of complex Fe23 - the diyne 96. 
 We assumed that the alkynylation of 95 in the presence of (TMS-ethynyl)lithium 
was assisted by the methoxy groups in the adjacent 3,3’-position of the binaphthyl moiety 
(see Scheme 5.10 A). The latter hypothesis was confirmed by the fact that the 3,3’-
unsubstituted bis-iodide 78 did not react with (TMS-ethynyl)lithium (Scheme 5.10 B). 
 
Scheme 5.10 Directing effect of the 3,3'-dimethoxy groups on the nucleophilic substitution in 95. 
 Cyclization of diyne 96 in the presence of Fe2(CO)9 yielded a new chiral complex 
Fe23 with 67% yield (Scheme 5.11). 
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Scheme 5.11 Synthesis of complex Fe23 
 To simplify our work and proceed with multi-gram step synthesis (starting from up 
to 20 g of (R)-BINOL) of complex Fe23, a number of purifications were skipped in order to 
optimize our synthetic protocol. In this eleven-step synthetic pathway, no purification 
was used until compound 90 which was purified using column chromatography with 55% 
yield calculated from starting (R)-BINOL. Only three more chromatographic purification 
were used - for 92, 93 and the final complex Fe23. The bis-bromide 94 could be efficiently 
crystallized with comparable yield to initially used column chromatography (84% vs. 89%) 
and the latter bis-iodide 95 was purified by simple filtration. Purification of the diyne 96 
was also skipped, resulting later in exactly the same yield (54% for two steps) of final 
complex Fe23. Calculating from starting material (R)-BINOL, overall yield of this chiral 
(cyclopentadienone)iron complex Fe23 was 15.8%. Theoretically speaking, this accounts 
for 0.38 g of Fe23 from every 1 g of (R)-BINOL used in the synthetic pathway. 
 
5.3 Conditions screening 
 The new cyclopentadienone(iron) complex Fe23 was tested in the AH of 
acetophenone. It allowed to obtain similar conversion to the Fe20, but the enantiomeric 
excess (48% ee) was nearly 6 times higher (Table 5.1, entry 1 and 2), thus demonstrating 
the importance of 3,3'-substituents. We decided to optimize the experimental conditions 
for this reaction. Firstly, we performed a screening of different activators in order to 
improve the catalytic results. 
Table 5.1 Screening of the activators for new cyclopentadienone(iron) complexes.
[a] 
 
Entry Complex Activator Conv. (%)
[b] 
ee (%)
[b,c] 
1 Fe20 K2CO3 62 8 
2 Fe23 K2CO3 54 49 
3 Fe23 Li2CO3 9 52 
4 Fe23 Na2CO3 25 53 
5 Fe23 Cs2CO3 29 51 
6 Fe23 LiOH 49 51 
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7 Fe23 NaOH 35 50 
8 Fe23 KOH 30 52 
9 Fe23 K3PO4 23 53 
10 Fe23 Me3NO 84 50 
[a] 
Reaction conditions: S1/[Fe]/activator = 100:1:2, PH2 = 30 bar, solvent = 5:2 iPrOH/H2O, c0 (S1) = 1.43 M, T = 70 °C, 
time = 18 h. 
[b]
 Determined by GC equipped with a chiral capillary column (MEGADEX DACTBS, diacetyl-t-butylsilyl--
cyclodextrin). 
[c]
 Absolute configuration: S in all cases (assigned by comparison of the optical rotation sign with literature 
data).
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 This screening revealed that the enantiomeric excess is almost independent on 
applied activator (entries 2-10). In terms of conversion, the most efficient inorganic 
activator appeared to be initially selected K2CO3 (entry 2), but the best result was 
obtained with trimethylamine N-oxide (TMNO, entry 11), whose use was firstly reported 
by Renaud and co-workers.99 TMNO oxidatively removes one of CO ligand from Fe23, 
forming a vacant site which is filled with subsequent H2 splitting, compared to the Hieber 
base activation with inorganic bases.  
 After finding the optimal activation pathway for the pre-catalyst Fe23, 
optimization studies continued to assess effects of applied hydrogen pressure, 
temperature and solvent (Table 5.2).  
 
Table 5.2 Optimization of reaction parameters of the AH of acetophenone S1 promoted by pre-catalyst Fe23.
[a]
 
Entry Solvent P (bar) T (°C) Conv. (%)
[b] 
ee (%)
[b,c] 
1 5:2 iPrOH/H2O 30 70 84 50 
2 5:2 iPrOH/H2O 50 70 85 51 
3
 
5:2 iPrOH/H2O 30 80 59 50 
4 5:2 iPrOH/H2O 30 50 33 55 
5
[d]
 5:2 iPrOH/H2O 30 70 100
[e] 
50 
6
[f] 
5:2 iPrOH/H2O 30 70 58 51 
7
[g] 
5:2 iPrOH/H2O -- 70 13 53 
8 iPrOH 30 70 15 54 
9 5:2 EtOH/H2O 30 70 21 49 
10 5:2 CF3CH2OH/H2O 30 70 74 42 
11 5:2 DME/H2O 30 70 56 52 
12 5:2 dioxane/H2O 30 70 56 52 
13 5:2 CH3CN/H2O 30 70 3 53 
14 5:2 DMF/H2O 30 70 26 54 
15 5:2 DCE/H2O 30 70 34 54 
16 5:2 toluene/H2O 30 70 8 53 
 [a] 
Reaction conditions: S1/Fe23/Me3NO = 100:1:2, PH2 = 30 bar, c0 (S1) = 1.43 M 
[b,c]
 See the footnotes of Table 5.1. 
[d]
 2 
mol% CK2 (4 mol% Me3NO) employed. 
[e]
 Yield of the isolated product P1 = 94%. 
[f]
 c0 (S1) = 0.72 M. 
[g]
 no hydrogen was 
applied to perform only ATH 
Chapter 5 
 
 
 Increased pressure (entry 2) or temperature (entry 3) did not lead to full 
conversion. To achieve that, 2 mol% of the Fe23 had to be used (entry 5). A slightly 
increased enantiomeric excess was observed at lower temperature (entry 4), but at the 
cost of the conversion. Additional solvent mixtures were tested (entries 9-16), but none 
of them led to better results than the 5:2 isopropanol/water mixture. Interestingly, the 
presence of water appeared to be crucial for the conversion (entry 8), possibly due to the 
poor solubility of TMNO in isopropanol. Also the substrate concentration appeared be 
important, because when the reaction was diluted twice (entry 6 vs. 1), a remarkable 
erosion of conversion was observed. Pre-catalyst Fe23 was also tested in the absence of 
H2 (entry 7). Under these conditions, a low conversion was obtained, which proves that 
the main catalytic activity is coming from the hydrogenation pathway, although a 
background ATH with isopropanol is also occurring (Scheme 5.12). Nevertheless, obtained 
enantiomeric excess was nearly exactly the same as in the case of the AH and thus it had 
no negative effect on overall results.  
 
Scheme 5.12 Comparison of ATH and AH with Fe23. 
 
5.4 Synthesis of a library of new chiral pre-catalysts  
 The promising enantiomeric excess obtained with Fe23, encouraged us to pursue 
the planned synthetic strategy to prepare complexes bearing different 3,3'-substitutents 
from the common precursor Fe23. We thus tried to demethylate complex Fe23, which 
turned out to be very stable to BBr3. Under typical conditions for the demethylation of 
aryl methyl ethers (0 oC, DCM), no conversion could be achieved, but the unreacted 
substrate gave no sign of decomposition (as expected after initial experiments with 
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similar complexes presented on Scheme 5.8). However, using tetra-n-butylammonium 
iodide (TBAI) as an additive146 and with the reaction temperature raised to 85 °C (in DCE), 
the bis-phenol Fe24 was obtained in good yield of 80% (Scheme 5.13). Again, this harsh 
conditions proved the great stability of cyclopentadienone(iron) complexes. 
 
Scheme 5.13 Demethylation of Fe23. 
 To our delight, we were able to grow a crystal of Fe24 suitable for a single-crystal 
X-ray diffraction analysis (Figure 5.3). 
 
Figure 5.3 ORTEP diagram (CCDC 1037376) of the molecular structure of Fe24  
(thermal ellipsoids set at the 50% probability level). 
 With the "scaffold complex" Fe24 in our hands, we set to pursue our strategy of 
using simple transformation for preparing complexes with more bulky 3,3'-substituents. 
Starting with one of the most trivial chemical transformations, under classical conditions 
for esterification, two new pre-catalysts were obtained in good yields: the bis-acetate 
Fe25 and bis-benzoate Fe26 (Scheme 5.14). 
 
Scheme 5.14 Synthesis of esters Fe25 and Fe26. 
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 Our next goal was to prepare bis-ether derivatives of Fe24. Unfortunately, the 
etherification did not proceed as good as in the previously described esterification. We 
managed to obtain only the bis(benzyl ether) complex Fe27 with a good and useful yield 
(Scheme 5.15). Attempt to use similar conditions for synthesizing the bis(isopropyl ether), 
failed, as efforts in the case of synthesizing the bis(tert-butyl ether) with isobutene or 
(tBuO)2CHNMe2. 
 
Scheme 5.15 Synthesis of 3,3’-bis(benzyl ether) (R)-1c, and attempted preparation of other 3,3’-bis(ether) derivatives. 
 Sulfonylation of Fe24 with methanesulfonyl chloride (MsCl) or p-toluenesulfonyl 
chloride (TsCl) occurred in high yield in the presence of triethylamine (TEA) and catalytic 
amount of 4-dimethylaminopyridine (DMAP), yielding complexes Fe28 and Fe29 (Scheme 
5.16). Surprisingly, the reaction with trifluoromethanesulfonyl chloride (TfCl) or 
trifluoromethanesulfonic anhydride (Tf2O) under analogous conditions did not afford the 
bis-triflate derivative Fe30. To obtain this complex, we used a less common method using 
the Comins’ reagent [N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide)].147 Its 
application led to complex Fe30 in a nearly quantitative way. 
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Scheme 5.16 Synthesis of sulfonyl esters Fe28-30. 
 As the main goal of our synthetic strategy remained the installation of aryl 
substituents in the 3,3'-positions of the binaphthyl moiety, we wanted to use the 
obtained bis-triflate Fe30 in the Suzuki-Miyaura cross-coupling. Under typical conditions 
for this cross-coupling,148 using β-naphtyl boronic acid, only a mono-substituted complex 
Fe31 was obtained with just 17% yield (Scheme 5.17). As the triflate group located nearby 
the Fe(CO)3 group is sterically less accessible, we assigned to the obtained 
monosubstitution product Fe31 the structure shown in Scheme 5.17, where the bulky aryl 
group is located far from the Fe centre. 
 
Scheme 5.17 Suzuki-Miyaura coupling with Fe30. 
 We addressed this low conversion to the steric bulkiness of the β-naphthyl group 
and we decided to carry out further attempts using phenylboronic acid. Application of the 
same conditions led also to only a mono-substituted complex Fe32 (Table 5.3, entry 1), 
but this time in a nearly quantitative way. Slightly modified conditions (Pd(OAc)2/PPh3 
instead of [Pd(PPh3)4]) gave almost the same result, with no sign of the desired complex 
(entry 2). Different conditions were tested, but without success as well (Table 5.3, entry 
3-4).149,150 In general, when using relatively strong bases and/or in the presence of water, 
decomposition of the iron complex was observed. This was most likely caused by the 
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Hieber-base reaction, in which light-sensitive (hydroxycyclopentadienyl)iron complex was 
produced. In total, 24 different palladium and nickel catalyzed cross coupling conditions 
were tested, varying ligands, base, solvent and temperature. In any of them we were able 
to obtain the desired bis-coupled complex Fe33.  
 
Table 5.3 Arylation of bis-triflate Fe30 by Suzuki-Miyaura cross-coupling. 
 
Entry Catalyst 
Equiv. 
PhB(OH)2 
Base 
[equiv.] 
Additive 
[equiv.] 
T 
(°C) 
Solvent 
NMR ratio (%)
[a] 
Fe30 Fe32 Fe33 
1
148 
Pd(PPh3)4 [10%] 2.5 K3PO4 [3] KBr [2.2] 85 dioxane 5 95 (74) 0 
2 
Pd(OAc)2 [20%] 
PPh3 [40%] 
2.5 K3PO4 [3] KBr [2.2] 85 dioxane 2 98 (80) 0 
3
149 Pd(OAc)2 [15%] 
PCy3 [18%] 
2.5 KF [3.3] KBr [2.2] 60 THF 97 3 0 
4
150 
Pd(PPh3)4 [10%] 5 
Ba(OH)2 
·8 H2O [3]  
85 DME/H2O decomposition 
5
149
 
Pd(OAc)2 [15%] 
PCy3 [18%] 
2.5 KF [3.3] 
 
60 THF 97 3 
 
6
151
 
Pd(OAc)2 [25%] 
SPhos [50%] 
3 K3PO4 [4] 
 
85 toluene 
 
100 
 
7 
Pd(OAc)2 [20%] 
PPh3 [40%] 
2.5 K3PO4 [3] KBr [2.2] 85 dioxane 
 
95 (80) 
 
8
152
 Pd(PPh3)4 [5%+5%] 2.5 K3PO4 [3] KBr [2.2] 85 dioxane 
 
93 (74)  
9 Pd(PPh3)4 [10%] 2.5 K3PO4 [3] 
KBr [2.2] 
H2O [6] 
85 dioxane 
 
100  
10 Pd(PPh3)4 [5%] 2.5 K3PO4 [3] KBr [5.6] 110 dioxane 
 
100  
11 Pd(PPh3)4 [5%] 2.5 K3PO4 [5] 
 
100 DMF decomposition 
12 Pd(PPh3)4 [5%] 2.5 K3PO4 [3] TBAB [2.2] 85 dioxane 100 
 
 
13 Pd(PPh3)4 [10%] 5 K3PO4 [6] KBr [2.2] 85 dioxane/H2O decomposition 
14 Pd(PPh3)4 [10%] 5 K3PO4 [6] KBr [2.2] 85 dioxane 
 
100  
15 Pd(PPh3)4 [5%] 2.5 
Ba(OH)2 
·8 H2O [3] 
KBr [2.2] 85 dioxane 
 
100 
 
16
150
 Pd(PPh3)4 [10%] 5 
Ba(OH)2 
·8 H2O [6]  
85 DME/H2O decomposition 
17 Pd(PPh3)4 [10%] 2.5 Ba(OH)2 [3] KBr [2.2] 85 dioxane 65 35 
 
18 Pd(PPh3)4 [5%] 2.5 tBuOK [3] KBr [2.2] 85 dioxane decomposition 
18
153
 PEPPSI-iPr [4%] 2.5 K2CO3 [6] 
 
60 dioxane 100 
  
19 PEPPSI-iPr [5%] 2.5 K3PO4 [3] 
 
85 dioxane 100 
  
20 PEPPSI-iPr [5%] 2.5 tBuOK [2.6] 
 
60 IPA decomposition 
21
154
 
Pd(cinnamyl) 
(IPr*)Cl [5%] 
3 K2CO3 [4] 
 
40 EtOH decomposition 
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22
155
 NiCl2(dppp) [5%] 4 K3PO4 [8] 
 
100 dioxane decomposition 
23 PdCl2(dppp) [10%] 2.5 K3PO4 [3] KBr [2.2] 85 dioxane 50 50 
 
24 PdCl2(dppp) [10%] 2.5 
Ba(OH)2 
·8 H2O [3] 
KBr [2.2] 85 dioxane 50 50 
 
[a] 
Conversion determined by NMR; isolated yields are indicated in brackets. 
  
 Despite the possibility of a non-selective mono cross-coupling on both sides of 
Fe30, NMR studies confirmed that it was occurring only on one side of the molecule. As 
we did not managed to grow a suitable crystal of Fe32, a 100% assessment of which of 
the two diastereotopic OTf groups of Fe30 was substituted, was not possible. We 
postulated that the cross-coupling occurs only on the triflate group located on the 
cyclopentadienone side opposite to Fe(CO)3, as it is sterically less hindered and thus 
allows an easier access for the cross-coupling. 
 We attempted a different approach to obtain the bis-phenyl derivative Fe33. As 
we assumed that the Fe(CO)3 was interfering with Suzuki-Miyaura cross-coupling, we 
decided to remove that obstacle by decomplexation, in order to perform the cross-
coupling just on a 3,3'-substituted cyclopentadienone ligand. We believed that 
subsequent recomplexation of the 3,3'-bisphenyl ligand with Fe2(CO)9 could occur easier 
than the cross-coupling with the metal complex. To asses this proposal, using the 
methodology developed by Knölker,95 we decomplaxated Fe(CO)3 from Fe20 in a 
quantitative manner obaining free ligand 97, and successfully recomplaxate 97 into Fe20 
(Scheme 5.18). 
 
Scheme 5.18 Reversible de-complexation of Fe20  
 We performed the decomplexation directly on the bis-triflate Fe30, as it would 
give us direct access to the Suzuki-Miyaura coupling with obtained ligand 98 (Scheme 
5.19). The reaction worked, although ligand 98 was obtained with only 28% yield. As 
expected, the cross coupling of compound 98 with phenylboronic acid easily afforded 
ligand 99, bearing with two phenyl groups in 3,3'-positions. This results provides indirect 
proof of the fact that, in the mono-substitution products Fe31 and Fe32, the unreacted 
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triflate group is the one located close to the Fe(CO)3 residue. Unfortunately, 
recomplexation of ligand 99 failed, although different iron sources were tried, together 
with higher temperatures and prolonged reaction times. No sign of desired iron complex 
Fe33 was observed. 
 
Scheme 5.19 Attempted synthesis of complex Fe33 from Fe30 by a de-complexation/cross-coupling/re-complexation 
sequence. 
 In summary, our synthetic efforts led us to a new family of chiral iron complexes, 
starting from one "parent scaffold" complex Fe23. Our unprecedented synthetic pathway 
based on the high chemical and thermal stability of cyclopentadienone(iron) complexes 
and their direct modifications, using relatively simple transformations (Scheme 5.20). The 
strategy involved (a) deprotection of Fe23 followed by: (b) esterification, (c) 
etherification, (d) sulfonylation or (e) cross-coupling with the triflate derivative. In this 
way, although synthesis of Fe23 required twelve steps from (R)-BINOL (with overall yield 
of 16%), we were able to synthesize nine of new pre-catalysts with just few synthetic 
steps. In this way we omitted time-consuming parallel synthesis of each new complex and 
possible synthetic complications during multi-step synthesis. 
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Scheme 5.20 Synthetic routs from "parent scaffold" complex Fe23 to 9 different pre-catalysts. 
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5.5 Catalytic test with new chiral cyclopentadienone(iron) complexes 
 Using the optimized conditions found for Fe23, all of the obtained chiral 3,3-
substitued cyclopentadienone(iron) pre-catalysts were tested in the AH of acetophenone. 
 
Table 5.4 Screening of pre-catalysts Fe23-32 in the AH of acetophenone S1.
[a]
 
Entry Pre-catalyst 
Conv.  
(%) 
ee  
(%) 
Entry Pre-catalyst 
Conv.  
(%) 
ee  
(%) 
1 
 
Fe23 
100 50 6 
 
Fe28 
14 39 
2 
 
Fe24 
63 46 7 
 
Fe29 
20 37 
3 
 
Fe25 
3 46 8 
 
Fe30 
7 35 
4 
Fe26 
16 38 9 
 
Fe31 
12 47 
5 
Fe27 
38 39 10 
 
Fe32 
22 52 
 
 [a] 
Reaction conditions: substrate/[Fe]/Me3NO = 100:2:4, PH2 = 30 bar, solvent = 5:2 iPrOH/H2O, c0 (substrate) = 1.43 M, 
T = 70 °C, reaction time = 18 h. 
[b,c]
 See the footnotes of Table 5.1 
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 All of the newly synthesized pre-catalysts showed significantly lower catalytic 
activities and lower strereoselectivity compared to parent pre-catalyst Fe23. A full 
conversion of the substrate S1 was not observed at any case. In terms of catalytic activity, 
the best result was obtained with the dihydroxy-substituted pre-catalyst Fe24, directly 
derived from Fe23. In terms of stereoselectivity, only Fe31 and Fe32 pre-catalysts granted 
the same level as Fe23, whereas the other complexes showed significantly lower ee's 
(entries 3-8). While the slightly decreased enantiomeric excess reached of Fe24 
(compared to Fe23) can be explained by the lesser steric bulk of the 3,3-substituents, the 
low stereoselectivity of the other complexes is not simple to explain, as they bear bigger 
3,3'substituents. In the case of esters Fe25-26, low conversion could be obtained because 
of the possible carbonyl oxygen coordination to the iron centre and its deactivation.156 
Moreover, it is likely that the bulky substituent of ethers and esters tends to stay clear 
from the zone of approach of the substrate because of free rotation of the C-O bond.  
 
5.6 Substrate screening with the best complex 
 As the best catalyst for the AH of acetophenone remained the 3,3'-bis-methoxy 
pre-catalyst Fe23, a substrate screening was performed using that complex (Table 5.5). 
 
Table 5.5 Substrate screening
 
for pre-catalyst Fe23.
[a] 
 
Entry Substrate 
Conv. 
(%)
[b] 
ee (%),
[c] 
 abs. 
conf.
[d] 
Entry Substrate 
Conv. 
(%)
[b]
 
ee (%),
[c] 
 abs. 
conf.
[d]
 
1 
 
100 50, S 8 
 
100 13, R 
2 
 
100 46, S 9 
 
78 59, R 
3 
 
64 50, S 10 
 
76 0 
4 
 
100 51, S 11 
 
43 68, R 
5 
 
99 51, S 12 
 
35 50, S 
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6 
 
97 57, S 13 
 
22 77, S 
7 
 
89 61, S 14
[e]
 
 
25 77, S 
a] 
Reaction conditions: substrate/Fe23/Me3NO = 100:2:4, PH2 = 30 bar, solvent = 5:2 iPrOH/H2O, c0 (substrate) = 1.43 M, 
T = 70 °C, reaction time = 18 h. 
[b]
 Determined by GC equipped with a chiral capillary column (see the Experimental 
section). 
[c]
 Determined by GC or HPLC equipped with a chiral capillary column (see the Experimental section).  
[d]
 Assigned by comparison of the sign of optical rotation with literature data (see the Experimental section).  
[e]
 S14/Fe23/Me3NO = 100:5:10. 
 
 Pre-catalyst Fe23 showed quite a broad application scope. It worked with range of 
acetophenone derivatives (entries 1-6, 9, 11, 14), as well with heteroaromatic (entries 
12), cyclic non aromatic (entries 7, 8) and aliphatic ketones (entries 10, 13). A general 
trend can be observed, as bulkier the substituents next to the carbonyl group, the higher 
ee was observed (up to 77% for S13 and S14) , but along with a decreased conversion as 
well. With a low steric hindrance, low (13% ee for S8) or no enantioselectivity (0% ee for 
S10) was observed, along with good to full conversion (entries 8-10).  
 
5.7 Variation of the 2,5-substituents of the cyclopentadienone ring 
 Although in the substrate scope with 3,3'-substituted pre-catalyst Fe23, we 
obtained up to 77% ee, they came along with quite low conversions of 22-25%. The most 
commonly used substrate in ketone hydrogenation, acetophenone S1, was fully 
hydrogenated with 50% ee. According to our initial speculation, also 2,5-substituents of 
the cyclopentadienone ring could influence the transmission of stereochemical 
information and thus affect the catalytic performance of the iron complex. Therefore, we 
decided to modify the best working pre-catalyst Fe23, by replacing its TMS groups in the 
2,5-positions with other groups. In particular, we selected the TIPS group, because of its 
increased steric bulk compared to TMS, and the flat phenyl group, which could possibly 
allow to install bulky 3,3’-substituents by cross-coupling reaction. The last investigated 
option was just the removal of any substituents from the 2,5-positions.  
 Previously synthesized advanced intermediates were used for the synthesis of the 
new derivatives. We functionalized the bis-iodide 95 with different ethynyl-lithium 
compounds in analogous way to described before (Scheme 5.21a). Upon treatment of 95 
with [(TIPS)ethynyl)]lithium and [(phenyl)ethynyl]lithium, new diyne compounds 100 and 
101 were obtained. However, the following cyclization of the TIPS derivative 100 in the 
presence of Fe2(CO)9 gave no conversion, most likely due to the excessive steric bulk of 
the TIPS groups. The 2,5-bis-phenyl-substituted derivative 101 did cyclize with Fe2(CO)9 
and afforded the new chiral iron complex Fe34. In order to obtain 2,5-unsubstituted 
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complex, we removed the TMS groups from diyne 96, in the presence of sodium 
carbonate in methanol (Scheme 5.21b). In these mild conditions we obtained quantitative 
conversion to diyne 102, which unfortunately was not stable enough under the cyclization 
conditions, so that only decomposition was observed. 
 
Scheme 5.21 Synthesis of Fe23 analogs modified at the 2,5-positions of the cyclopentadienone ring. 
 The new complex Fe34 was tested in the AH of acetophenone, applying our 
optimized conditions for Fe23 (Scheme 5.22). 
 
Scheme 5.22 Test of pre-catalyst Fe34 in the AH of acetophenone S1. 
 To our disappointment, newly prepared pre-catalyst Fe34 presented very low 
catalytic activity. Only 6% of the substrate S1 was converted to (R)-phenylethanol, with 
only 11% ee. A possible rationalization of that result, might be that the phenyl groups on 
the cyclopentadienone ring are not bulky enough to prevent dimerization of the activated 
hydride of Fe34, which could lead to a decomposition as reported by Guan and co-
workers for a related iron complex.157 Additionally, computational studies on a related 
achiral cyclopentadienone(iron) complex with 2,5-phenyl groups, confirmed that phenyl 
groups lead to an increase of the activation energy of the hydrogenation process.158 
 Despite this negative result, we still attempted to install 3,3'-phenyl substituents 
and to verify if bulky 2,5-TMS groups are really interfering with the Suzuki-Miyaura cross-
coupling or not. Complex Fe34 was subjected to deprotection at room temperature in the 
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presence of BBr3 (Scheme 5.23). The reaction did not proceed to the dihydroxy derivative 
Fe37 and, as in the synthesis if Fe24, use of very harsh conditions for a long period of time 
was required. After 3 days of reflux, only a small amount of the desired product was 
obtained (15% yield), thus suggesting that, in the case of Fe23, the TMS groups exert also 
some stabilizing effect on the cyclopentadienone ring. Fe37 was converted in the 
corresponding triflate Fe38 using the Comin's reagent. Subjecting Fe38 into the Suzuki-
Miyaura cross-coupling with phenylboronic acid under the best conditions found for Fe30 
(Table 5.3), afforded a mixture of mono and bis-substituted products Fe39 and Fe40. This 
result proved that, together with the Fe(CO)3 group, also the bulky TMS groups interfered 
with the Suzuki-Miyaura coupling during our attempts to synthesize Fe33. The flat phenyl 
group allowed the cross-coupling to occur on the both sides of the molecule, although 
reaction was very sluggish. 
 
Scheme 5.23 Synthesis of 3,3-bisphenyl (cyclopentadienone)iron complex Fe40. 
 The catalytic activity of complexes Fe34, Fe39 and Fe40 in the AH of 
acetophenone S1 was studied (Table 5.6).  
 
Table 5.6 Screening of pre-catalysts in the AH of acetophenone S1.
[a] 
 
Entry Pre-catalyst 
Conv. 
(%)
[b] 
ee (%),
[c]
 abs. 
conf.
[d] 
1 Fe34 
 
6 11, R 
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2 Fe39 
 
10 16, R 
3 Fe40 
 
20 24, R 
[a] 
Reaction conditions: substrate/[Fe]/Me3NO = 100:2:4, PH2 = 30 bar, solvent = 5:2 iPrOH/H2O, c0 (substrate) = 1.43 M, 
T = 70 °C, reaction time = 18 h. 
[b,c]
 See the footnotes of Table 5.1 
 
 In comparison to the bis-methoxy pre-catalyst Fe34, both new catalyst revealed 
increased catalytic activity. The best result was obtained with catalyst Fe40, which led to 
20% conversion of acetophenone with 24% ee. With Fe39, lower conversion (10%) and ee 
(16%) were obtained. Interestingly, complexes with 2,5-phenyl substituents (Fe34, Fe39, 
Fe40) produced (R)-phenylethanol, whereas use of 2,5-TMS pre-catalysts (Fe20, Fe23-32) 
led to the (S)-enantiomer. This inversion in the stereochemical preference demonstrates 
that the cyclopentadienone 2,5-substituents play an important role in the transmission of 
the stereochemical information to the substrate, not less than the binaphthyl 3,3’-
substituents. As we were not able to grow crystals of any of the 2,5-phenyl catalysts, it is 
not certain how phenyls are positioned and how this effect the reverse enantioselectivity 
of these catalysts.  
 
5.8 Cyclopentadienone(iron) complexes bearing chiral 2,5-substituents 
 We decided to investigate also a new approach to the development of chiral 
(cyclopentadienone)iron pre-catalysts, which consists in the introduction of chiral 
substituents at the 2,5-positions of the cyclopentadienone ring, rather than employing a 
chiral cyclopentadienone backbone as was done in the examples described above. In 
particular, we envisaged the possibility of using chiral silyl groups easily prepared from 
(R)-BINOL (Figure 5.4).  
 
Figure 5.4 New ideas for the development of chiral (cyclopentadienone)iron complexes. 
 The new chiral iron complex Fe41 was prepared as shown in the Scheme 5.24. 
Previously synthesized (R)-2,2'-dimethyl-1,1'-binaphthalene 76, was dilithiated using 
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nBuLi/TMEDA complex and subsequently treated with trimethoxy(methyl)silane to afford 
the methoxysilacycle 103. Diyne 104 was obtained from 103 and dilithiated octa-1,7-
diyne, and subsequently cyclized in the presence of Fe2(CO)9 to afford the new complex 
Fe41. 
 
Scheme 5.24 Synthesis of new complex Fe41. 
 The new complex Fe41, was tested in the AH of acetophenone, applying our 
optimized conditions for Fe24 (Scheme 5.25).  
 
Scheme 5.25 Hydrogenation of acetophenone S1 using pre-catalyst Fe41. 
 Pre-catalyst Fe41 proved to be active in the AH of S1 and the phenylehtanol P1 
was obtained with a good conversion (under conditions optimized for a different 
catalysts). Remarkably there was almost no transfer of stereochemical information from 
the chiral fragments of the complex as the product P1 was nearly a racemate (just 2% ee). 
This outcome is probably due to the free rotation of the C-Si bond connecting the 
cyclopentadienone ring to the chiral silacycles. This result discouraged us from any 
further investigations of chiral 2,5-substituents on the cyclopentadienone ring. 
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5.9 Complexes derived from chiral diamines 
 The new diamine-derived (cyclopentadienone)iron complex 45 and its use as a 
pre-catalyst for reductive amination and NaHCO3 hydrogenation was reported by Renaud 
and co-workers (see Paragraph 2.5.1).111 Thanks to the 3,4-ethylenediamino-substitution, 
complex 45 possesses a more electron-rich cyclopentadienone framework compared to 
37, which was enhancing the overall Lewis base character of the carbonyl group in the 
cyclopentadienone ligand. Using DFT calculations, Renaud and co-workers proved that 
their new complex, after de-complexation of a CO ligand, had a lower energy barrier to 
split H2 and to form the active hydride species. Considering that a number of chiral 1,2-
diamine are commercially available or synthetically accessible, we decided to synthesized 
new chiral analogues of 45 bearing a chiral diamino moiety, hoping to achieve new 
effective chiral iron pre-catalysts (Figure 5.5). 
 
Figure 5.5 Idea for new chiral iron pre-catalysts. 
 Using Claisen condensation of commercially available 1,3-diphenylpropan-2-one 
with diethyl oxalate we obtained 105, which reacted with (S,S)-N,N'-dimethyl-1,2-
cyclohexanediamine to afford ligand 106 (Scheme 5.26). Subsequent cyclisation with 
Fe2(CO)9 allowed to obtain a new chiral complex Fe42. 
 
Scheme 5.26 Synthesis of a new chiral pre-catalyst Fe42. 
 We tried to apply this methodology with two other commercially available amines 
but, unfortunately, no sign of reaction was observed between them and 105, and thus 
the corresponding complexes Fe43 and Fe44 could not be prepared (Scheme 5.27). 
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Scheme 5.27 Unaccomplished plans for synthesizing new chiral complexes a) Fe43 and b) Fe44. 
 We also tried to synthesize a new chiral complex similar to Fe42 but with TMS 
groups at the 2,5-positions (Scheme 5.28). (TMS)acetyl chloride 108 was obtained from 
corresponding carboxylic acid using thionyl chloride. Using prepared in situ prepared 
(TMS)magnesium chloride, TMS-acetone 109 was obtained with a good yield. 
Unfortunately it appeared to be very sensitive and it underwent decomposition shortly 
after being prepared. For this reason, the synthesis of a Fe42 analogue bearing TMS 
groups could not be carried out. 
 
Scheme 5.28 Attempt to synthesize new complex Fe45. 
 Complex Fe42 was tested in the AH of acetophenone, applying our optimized 
conditions for Fe23 (Scheme 5.29). 
 
Scheme 5.29 Hydrogenation of acetophenone S1 using pre-catalyst Fe42. 
 Pre-catalyst Fe42 was found to be catalytically active, giving 80% conversion of 
acetophenone, but with only low enantiomeric excess (8% ee). A plausible reason for such 
low enantiocontrol is that the catalyst’s stereocenters are too remote from the zone from 
where the reaction occurs, thus preventing an efficient transfer of the stereochemical 
information. To tackle this issue, the synthesis of new pre-catalysts bearing bulkier 
substituents in the 2,5-positions of the cyclopentadienone ring is currently underway. 
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5.10 Summary of chiral (cyclopentadienone)iron complexes  
 In our studies we developed a series of new chiral cyclopentadienone(iron) 
complexes (Figure 5.6). We were confident that with their advantages (like easy synthesis 
or working with them without a glove-box), they can bring a positive contribution to the 
field of iron catalysis. In our research towards new, effective chiral iron complexes, we 
focused our attention to investigate various structural modifications of the 
cyclopentadienone ring. 
 
 
Figure 5.6 Summary of obtained new chiral (cyclopentadienone)iron pre-catalysts for ketone hydrogenation. 
 The most extensive research was directed towards new pre-catalysts derived from 
(R)-BINOL (Figure 5.6a). In total 16 novel iron complexes for ketone hydrogenation were 
obtained and the best one, Fe23, allowed to get up to 77% ee in ketone AH. In our 
research, we found out that 3,3'-substituents play a crucial role in the transfer of 
stereogenic information to the reaction centre, although the range of suitable 3,3'-
substituents was found to be rather limited. They should not possess heteroatoms which 
might coordinate to the iron centre and deactivate the catalyst. Moreover, we were not 
able to install really bulky substituents like phenyl or 2-naphthyl when 2,5-positions of the 
cyclopentadienone rings were substituted with TMS groups. Replacing them with phenyl 
groups allowed to install phenyl substituents at the 3,3'-positions, but the catalytic 
studies revealed that overall results of the asymmetric hydrogenation, are also 
dependent on the cyclopendadienone 2,5-substituents. Thus, replacement of TMS groups 
with phenyl groups led to decrease of catalytic activity of (cyclopentadienone)iron pre-
catalysts even in the presence of bulky 3,3'-substituents.  
 Following an alternative approach aimed at bringing the stereogenic units closer 
to the reaction centre, we introduced chiral substituents at 2,5-postionstions of the 
cyclopentadienone ring (Figure 5.6b). However, almost no ee was observed with Fe41, 
most probably due to the conformational flexibility of the new complex. 
 With a different synthetic route, we tried to obtain a new family of chiral diamine-
derived (cyclopentadienone)iron complexes, but we managed to synthesize just the iron 
pre-catalyst Fe42 (Figure 5.6c). In the hydrogenation of acetophenone, the obtained ee 
was low - just 8%, most probably due to the long distance between the catalyst’s 
stereocentres and the reaction site, typical problem met with chiral 
(cyclopentadienone)iron complexes. 
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5.11 Experimental section 
General Remarks 
 All reactions were carried out in flame-dried glassware with magnetic stirring under 
nitrogen or argon atmosphere, unless otherwise stated. 
 The solvents for reactions were distilled over the following drying agents and transferred 
under nitrogen: CH2Cl2 (CaH2), MeOH (CaH2), THF (Na), dioxane (Na), Et3N (CaH2). Dry Et2O, 
acetone and CHCl3 (over molecular sieves in bottles with crown cap) were purchased from Sigma 
Aldrich and stored under nitrogen.  
 The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution. Flash 
column chromatography was performed using silica gel (60 Å, particle size 40-64 μm) as 
stationary phase, following the procedure by Still and co-workers.159 
 Proton NMR spectra were recorded on a spectrometer operating at 400.13 MHz. Proton 
chemical shifts are reported in ppm (δ) with the solvent reference relative to tetramethylsilane 
(TMS) employed as the internal standard (CDCl3 δ = 7.26 ppm; CD2Cl2, δ = 5.32 ppm; [D]6acetone, 
δ = 2.05 ppm; [D]6DMSO, δ = 2.50 ppm; CD3OD, δ = 3.33 ppm). The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br 
= broad signal, dd = doublet-doublet, td = triplet-doublet. 13C-NMR spectra were recorded on a 
400 MHz spectrometer operating at 100.56 MHz, with complete proton decoupling. Carbon 
chemical shifts are reported in ppm (δ) relative to TMS with the respective solvent resonance as 
the internal standard (CDCl3, δ = 77.16 ppm; CD2Cl2, δ = 54.00 ppm; [D]6acetone, δ = 29.84 ppm, 
206.26 ppm; [D]6DMSO, δ = 39.51 ppm; CD3OD, δ = 49.05 ppm). The coupling constant values are 
given in Hz.  
 Infrared spectra were recorded on a standard FT/IR spectrometer. Optical rotation values 
were measured on an automatic polarimeter with a 1 dm cell at the sodium D line (λ = 589 nm).  
Gas chromatography was performed on a GC instrument equipped with a flame ionization 
detector, using a chiral capillary column.  
 High resolution mass spectra (HRMS) were performed on a Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker Daltonics) – 
4.7 T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro Interdipartimentale 
Grandi Apparecchiature) c/o Università degli Studi di Milano.  
 Low resolution mass spectra (MS) were acquired either on a Thermo-Finnigan LCQ 
Advantage mass spectrometer (ESI ion source) or on a VG Autospec M246 spectrometer (FAB ion 
source). 
 Elemental analyses were performed on a Perkin Elmer Series II CHNS/O Analyzer 2000. X-
ray intensity data were collected with a Bruker Apex II CCD area detector by using graphite 
monochromated Mo-Kα radiation. 
Materials 
 Commercially available reagents were used as received. While both (R)-(+)-1,1′-bi(2-
naphthol) (BINOL) and (R)-3,3'-dibromo-[1,1'-binaphthalene]-2,2'-diol are commercially available,  
(R)-2,2′-bis(bromomethyl)-1,1′-binaphthyl 77 and (R)-2'',3'-bis(bromomethyl)-2,2':4',1'':3'',2'''-
Chiral (cyclopentadienone)iron complexes 
 
quaternaphthalene 84 were synthesized from BINOL according to the procedure described by Ooi 
et al. 160 (R)-2,2'-bis(bromomethyl)-3,3'-dimethoxy-1,1'-binaphthyl 94 was synthesized according 
to the procedure described by Crammer and co-workers.138 4-Hydroxy-2,5-diphenylcyclopent-4-
ene-1,3-dione 105 was synthesized following the procedure by Claisen et al.161 1,3-
Bis(trimethylsilyl)propan-2-one 109 was synthesized according to the paper of Hosomi et al.162 
Ethynyltrimethylsilane, ethylmagnesium bromide (1 m in THF), n-BuLi (1.6 m in hexanes), BBr3 (1 
m in DCM), Bu4NI, NaI, CuI, Fe2(CO)9, DMAP, acetyl chloride, benzoyl chloride, benzyl bromide, 
methanesulfonyl chloride, p-tolueneslufonyl chloride, N-(5-chloro-2-pyridyl)bis(trifluoromethane-
sulfonimide), Pd(OAc)2, K3PO4, PPh3, KBr, phenylboronic acid, PCy3, SPhos, Pd(cinnamyl)(IPr)Cl, 
PdCl2(dppp), NiCl2(dppp), Ba(OH)2·H2O, Ba(OH)2 anhydrous, Bu4NBr, KF, K2CO3, tBuOK, 1-
iodopentane, ethynyltriisopropylsilane, ethynylbenzene and the ketones used in the substrate 
screening were purchased from commercial suppliers (TCI Chemicals, ACROS, Sigma Aldrich) and 
used as received. 
(R)-2,2'-Bis(iodomethyl)-1,1'-binaphthyl 78 
Under nitrogen in a Schlenk tube fitted with a Teflon screw cap, NaI (13.6 g. 91 
mmol, 10 eq) was added to a stirred suspension of compound 77138 (4.01 g, 9.1 
mmol) in acetone (50 mL). The Schlenk was sealed and the mixture was heated 
to 58 °C and stirred overnight. To prevent possible photodegradation of 78, the 
reaction vessel was covered tightly with aluminum foil and the reaction workup 
was done in the presence of the smallest possible amount of light. After cooling down to 40 °C, 
acetone was removed in vacuo, and the obtained solid was dried under high vacuum for 30 min. 
Water (100 mL) was added, and the obtained suspension was stirred for 30 min. The mixture was 
filtered on a ceramic frit, and the crude product 78 was washed with water (100 mL), sat. aq. 
Na2S2O3 (100 mL), water (100 mL), and ice-cold 2:1 MeOH/hexane mixture (100 mL). Product 78 – 
a pale yellow powder – was dried on the frit and then under high vacuum. Yield: 3.89 g (80%); 
m.p. = 130-132 °C (dec.); []D
24 = + 112.81 (c = 0.345 in DCM); 1H NMR (400 MHz, [D6]acetone): δ 
= 7.34 (d, 3J(H,H) = 8.6 Hz, 2H), 7.25 (d, 3J(H,H) = 8.2 Hz, 2H), 7.06 (d, 3J(H,H) = 8.6 Hz, 2H), 6.77 
(td, 3J(H,H) = 8.2 Hz, 4J(H,H) = 1.1 Hz, 2H), 6.55 (td, 3J(H,H) = 8.2 Hz, 4J(H,H) = 1.2 Hz, 2H), 6.25 (d, 
3J(H,H) = 8.6 Hz, 2H), 3.62 (d, 2J(H,H) = 9.5 Hz, 2H, AB system), 3.51 (d, 2J(H,H) = 9.5 Hz, 2H, AB 
system); 13C NMR (100 MHz, [D6]acetone): δ = 136.2, 134.1, 133.0, 130.3, 129.2, 129.1, 127.8, 
127.5, 127.3, 5.7; IR (film): ν = 2292.2, 1461.9, 1377.3, 1156.6 cm-1; elemental analysis (%): C 
49.26, H 3.03 (calcd. for C22H16I2: C 49.47, H 3.02). 
(R)-2,2'-Bis(3-(trimethylsilyl)prop-2-ynyl)-1,1'-binaphthyl 79.  
A solution of ethynyltrimethylsilane (0.565 mL, 4.0 mmol, 4 eq) in THF 
(5 mL) was added dropwise to a 1 M solution of ethylmagnesium 
bromide in THF (4.0 ml, 4.0 mmol, 4 eq) kept at 0 °C. The reaction 
mixture was heated to reflux and stirred for 1 h. After cooling to room 
temperature, CuI (0.095 g, 0.500 mmol, 0.5 eq) and compound 78 
(0.534 g, 1.0 mmol, 1 eq) were added. The mixture was heated to reflux and stirred overnight. 
After cooling down to R.T., the reaction was quenched with sat. aq. NH4Cl (5 mL), and the 
obtained aqueous phase was extracted with AcOEt (3 × 25 mL). The organic layer was washed 
with H2O (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Purification by 
column chromatography (95:5 hexane/DCM) gave the product 79 as a light yellow oil. Yield: 0.38 g 
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(80%); m.p. = 56 °C; []D
24 = + 134.55 (c = 0.348 in DCM); 1H NMR (400 MHz, CD2Cl2): δ = 8.03 (d, 
3J(H,H) = 8.5 Hz, 2H), 7.95 (d, 3J(H,H) = 8.2 Hz, 2H), 7.89 (d, 3J(H,H) = 8.5 Hz, 2H), 7.45 (td, 3J(H,H) = 
8.2 Hz, 4J(H,H) = 1.1 Hz, 2H), 7.24 (td, 3J(H,H) = 8.2 Hz, 4J(H,H) = 1.3 Hz, 2H), 6.99 (d, 3J(H,H) = 8.5 
Hz, 2H), 3.35 (d, 2J(H,H) = 19 Hz, 2H, AB system), 3.22 (d, 2J(H,H) = 19 Hz, 2H, AB system), 0.12 (s, 
18H); 13C NMR (100 MHz, CD2Cl2): δ = 134.2, 133.7, 133.4, 133.0, 129.1, 128.7, 127.2, 127.2, 
126.3, 126.0, 104.5, 87.6, 25.1, 0.3; IR (film): ν = 3059.0, 2959.8, 2174.8, 1484.9, 1265.1, 1249.8 
cm-1; HRMS (ESI+): m/z 497.20980 [M + Na]+ (calcd. for C32H34Si2Na: 497.20913). 
Complex Fe20.  
Under argon, diyne 79 (0.510 g, 1.07 mmol, 1 eq) and Fe2(CO)9 (0.781 g, 
2.14 mmol, 2 eq) were dissolved in dry toluene (9 mL) and heated to 90 
°C for 4 h. After cooling down to room temperature, the reaction 
mixture was filtered through a pad of Celite (rinsing with DCM). The 
filtrate was concentrated in vacuo, and the residue was purified by flash 
column chromatography (8:2 hexane/DCM) to obtain (R)-Fe20 as a pale 
yellow solid. Yield: 0.320 g (46%); m.p. = 209 °C (dec.); []D
19 = -32.24 (c = 0.9 in DCM); 1H NMR 
(400 MHz, CD2Cl2): δ = 8.04 (d, 
3J(H,H) = 8.5 Hz, 2H), 7.99 (d, 3J(H,H) = 8.8 Hz, 1H), 7.97 (d, 3J(H,H) 
= 8.8 Hz, 1H), 7.68 (d, 3J(H,H) = 8.5 Hz, 1H), 7.55 (d, 3J(H,H) = 8.5 Hz, 1H), 7.52-7.45 (m, 2H), 7.30 
(td, 3J(H,H) = 8.5 Hz, 4J(H,H) = 1.1 Hz, 1H), 7.25 (td, 3J(H,H) = 8.5 Hz, 4J(H,H) = 1.1 Hz, 1H), 7.20 (d, 
3J(H,H) = 8.5 Hz, 1H), 7.09 (d, 3J(H,H) = 8.5 Hz, 1H), 3.76 (d, 2J(H,H) = 15.7 Hz, 1H), 3.67 (d, 2J(H,H) = 
14.1 Hz, 1H), 3.45 (d, 2J(H,H) = 15.7 Hz, 1H), 3.38 (d, 2J(H,H) = 14.1 Hz, 1H), 0.41 (s, 9H), 0.26 (s, 
9H); 13C NMR (100 MHz, CD2Cl2): δ = 209.8, 181.4, 137.0, 135.6, 135.0, 134.6, 133.4, 132.5, 130.0, 
129.7, 128.9, 128.7, 127.5, 127.3, 127.1, 127.0, 126.9, 126.5, 113.1, 111.5, 76.0, 74.0, 34.8, 32.8, 
0.9, 0.5; IR (film): ν = 3054.69, 2953.93, 2060.1, 2005.1, 1985.4, 1626.2, 1507.6, 1429.5, 1264.1, 
1248.7, cm-1; HRMS (ESI+): m/z 643.14164 [M + H]+ (calcd. for C36H35O4Si2Fe: 643.14294). 
(R)-2'',3'-bis(iodomethyl)-2,2':4',1'':3'',2'''-quaternaphthalene 85 
Under nitrogen in a Schlenk tube fitted with a Teflon screw cap, NaI (1.33 g, 8.9 
mmol, 8 eq) was added to a stirred suspension of (R)-2,2'-bis(bromomethyl)-
3,3'-dimethoxy-1,1'-binaphthyl 84 (0.77 g, 1.1 mmol, 1 eq) in acetone (6 mL). 
The Schlenk was sealed and the mixture was heated to 58 °C and stirred 
overnight. To prevent possible photodegradation of 84, the reaction vessel was 
covered tightly with aluminum foil and the reaction workup was done in the presence of the 
smallest possible amount of light. After cooling down to 40 °C, acetone was removed in vacuo, 
and the obtained solid was dried under high vacuum for 30 min. Water (100 mL) was added, and 
the obtained suspension was stirred for 30 min. The mixture was filtered on a ceramic frit, and 
the crude product 84 was washed with water (15 mL), sat. aq. Na2S2O3 (15 mL), water (15 mL), 
and ice-cold 2:1 MeOH/hexane mixture (15 mL). Product 84 – a pale yellow powder – was dried 
on the frit and then under high vacuum. Yield: 0.83 g (95%); 1H NMR (400 MHz, CD2Cl2): δ = 8.24 
(s, 2H), 7.97-8.07 (10 H, m), 7.89 (d, 2H, 3J(H,H) = 8.0 Hz), 7.58-7.65 (6H, m), 7.31-7.43 (4H, m), 
4.52 (d, 2J(H,H) = 12 Hz, 2H, AB system), 4.41 (d, 2J(H,H) = 8.0 Hz, 2H, AB system). 
(R)-2,2'-Bis(iodomethyl)-3,3'-dimethoxy-1,1'-binaphthyl 95. 
Under nitrogen in a Schlenk tube fitted with a Teflon screw cap, NaI (16.5 g, 
110 mmol, 10 eq) was added to a stirred suspension of (R)-2,2'-
bis(bromomethyl)-3,3'-dimethoxy-1,1'-binaphthyl 94138 (5.50 g, 11.0 mmol) in 
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acetone (55 mL). The Schlenk was sealed and the mixture was heated to 58 °C and stirred 
overnight. To prevent possible photodegradation of 95, the reaction vessel was covered tightly 
with aluminum foil and the reaction workup was done in the presence of the smallest possible 
amount of light. After cooling down to 40 °C, acetone was removed in vacuo, and the obtained 
solid was dried under high vacuum for 30 min. Water (100 mL) was added, and the obtained 
suspension was stirred for 30 min. The mixture was filtered on a ceramic frit, and the crude 
product 95 was washed with water (100 mL), sat. aq. Na2S2O3 (120 mL), water (150 mL), and ice-
cold 2:1 MeOH/hexane mixture (100 mL). Product 95 – a pale yellow powder – was dried on the 
frit and then under high vacuum. Yield: 5.94 g (91%); m.p. = 169-173 °C (dec.); []D
24 = +133.48 (c 
= 0.52 in acetone); 1H NMR (400 MHz, [D6]acetone): δ = 7.93 (d, 
3J(H,H) = 8.2 Hz, 2H), 7.57 (s, 2H), 
7.47 (td, 3J(H,H) = 8.1 Hz, 4J(H,H) = 1.1 Hz, 2H), 7.13 (td, 3J(H,H) = 8.1 Hz, 4J(H,H) = 1.2 Hz, 2H), 6.9 
(d, 3J(H,H) = 8.1 Hz, 2H), 4.28 (d, 2J(H,H) = 8.9 Hz, 2H, AB system), 4.20 (d, 2J(H,H) = 8.9 Hz, 2H, AB 
system), 4.15 (s, 6H); 13C NMR (100 MHz, [D6]acetone): δ = 156.5, 136.1, 135.7, 128.1, 128.1, 
128.0, 127.9, 127.6, 125.1, 107.6, 56.3, 0.1; IR (film): ν = 3060.5, 2959.7, 2935.6, 1618.0, 1597.7, 
1570.7, 1445.9, 1422.7, 1327.3, 1158.0 cm-1; HRMS (ESI+): m/z 616.94566 [M + Na]+ (calcd. for 
C24H20I2O2Na: 616.94449). 
(R)-(3,3'-(3,3'-dimethoxy-1,1'-binaphthyl-2,2'-diyl)bis(prop-1-yne-3,1-diyl))bis(trimethylsilane) 96 
n-BuLi (1.6 M hexane solution, 11.6 mL, 18.5 mmol, 3 eq) was added 
dropwise to a solution of ethynyltrimethylsilane (1.82 g, 2.62 mL, 18.5 
mmol, 3 eq) in THF (12 mL) kept at -60 °C. The obtained mixture was 
allowed to warm to 0 °C and stirred for 30 min at this temperature, then 
it was cooled down again to -60 °C. A solution of bis-iodide 95 (3.63 g, 
6.11 mmol, 1 eq) in THF (45 mL) was added and then the mixture was allowed to warm to R.T. 
and stirred overnight. The reaction was quenched with sat. aq. NH4Cl (50 mL) and extracted with 
Et2O (3  20 mL). The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. Diyne 96 can be either purified by flash column chromatography (8:2 hexane/DCM) or 
used in the following step without further purification. Yield after chromatography: 2.61 g (80%); 
m.p. = 75-83 °C; []D
24 = +55.56 (c = 0.555 in CHCl3); 
1H NMR (400 MHz, CDCl3): δ = 7.81 (d, 
3J(H,H) 
= 8.2 Hz, 2H), 7.40 (t, 3J(H,H) = 8.2 Hz, 2H), 7.32 (s, 2H), 7.09-7.02 (m, 4H), 4.08 (s, 6H), 3.40 (d, 
2J(H,H) = 16.6 Hz, 2H, AB system), 3.29 (d, 2J(H,H) = 16.6 Hz, 2H, AB system), 0.00 (s, 18H); 13C 
NMR (100 MHz, CDCl3): δ = 155.9, 136.1, 134.0, 128.3, 126.9, 126.6, 126.6, 126.3, 124.0, 106.0, 
104.5, 83.6, 55.8, 19.6, 0.16; IR (film): ν = 3062.9, 2958.3, 2898.0, 2173.9, 1620.4, 1597.7, 1446.8, 
1327.3, 1248.7, 1109.8 cm-1; HRMS (ESI+): m/z 557.23139 [M + Na]+ (calcd. for C34H38O2Si2Na: 
557.23025).  
Complex Fe23 
Under argon, diyne 96 (3.27 g, 6.11 mmol, 1 eq) and Fe2(CO)9 (4.55g, 
12.5 mmol, 2 eq) were dissolved in dry toluene (45 mL) and heated to 
90 °C for 4.5 h. After cooling down to room temperature, the reaction 
mixture was filtered through a pad of Celite (rinsing with DCM). The 
filtrate was concentrated in vacuo, and the residue was purified by flash 
column chromatography (93:7 hexane/AcOEt) to obtain (R)-Fe23 as a 
pale yellow solid. Yield: 2.88 g (67% yield); m.p. = 233-237 °C (dec.); []D
23 = -129.38 (c = 0.41 in 
DCM); 1H NMR (400 MHz, CDCl3): δ = 7.84 (m, 2H), 7.42 (t, 
3J(H,H) = 7.2 Hz, 2H), 7.33 (s, 1H), 7.30 
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(s, 1H), 7.11-7.03 (m, 2H), 6.92 (d, 3J(H,H) = 8.4 Hz, 2H), 4.37 (d, 2J(H,H) = 15.5 Hz, 1H), 4.15 (d, 
2J(H,H) = 13.7 Hz, 1H), 4.04 (s, 3H), 3.94 (s, 3H), 3.26 (d, 2J(H,H) = 13.7 Hz, 1H), 3.12 (d, 2J(H,H) = 
15.5 Hz, 1H), 0.43 (s, 9H), 0.32 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 208.7, 181.1, 155.1, 154.8, 
138.6, 137.2, 133.9, 133.8, 127.4, 127.2, 127.1, 127.0, 126.9, 126.8, 126.6, 126.5, 126.4, 124.3, 
124.1, 115.4, 107.8, 106.3, 105.7, 75.2, 74.9, 55.6, 54.8, 26.3, 26.2, 0.7, 0.2; IR (film): ν = 3059.5, 
2960.2, 2169.0, 2059.6, 2004.2, 1987.3, 1620.4, 1598.7, 1454.1, 1246.3, 1111.3 cm-1; HRMS 
(ESI+): m/z 703.16264 [M + H]+ (calcd. for C38H39O6Si2Fe: 703.16410). 
Complex Fe24 
Under nitrogen in a Schlenk tube fitted with a Teflon screw cap, BBr3 (1 
M DCM solution, 14.0 mL, 14.0 mmol, 10 eq) was added dropwise to a 
stirred solution of (R)-Fe23 (0.99 g, 1.41 mmol, 1 eq) and Bu4NI (1.30 g, 
3.52 mmol, 2.5 eq) in DCE (40 mL) kept at 0 °C. The Schlenk was sealed 
and the mixture was heated to 84 °C and stirred for 3 days. After this 
time, the reaction was cooled down to 0 °C and ice-cold H2O (50 mL) 
was added. The mixture was extracted with DCM (3  20 mL), washed with brine (30 mL) and then 
dried over Na2SO4. Filtration of the DCM solution through a short pad of silica allowed to remove 
the ammonium salts (which eluted before the product), then complex (R)-Fe24 – a pale yellow 
solid – was purified by flash column chromatography (83:17 to 77:23 hexane/AcOEt). Yield: 0.762 
g (80%); m.p. = 187-195 °C (dec.); []D
23 = -115.07 (c = 0.515 in DCM); 1H NMR (400 MHz, CDCl3): δ 
= 7.71 (d, 3J(H,H) = 8.2 Hz, 2H), 7.39-7.35 (m, 3H), 7.31 (s, 1H), 7.06 (t, 3J(H,H) = 7.5 Hz, 2H), 6.98 
(dd, 3J(H,H) = 8.3 Hz, 4J(H,H) = 2.3 Hz, 2H), 6.32 (br s, 2H), 4.34 (d, 2J(H,H) = 15.6 Hz, 1H), 4.14 (d, 
2J(H,H) = 13.8 Hz, 1H), 3.24 (d, 2J(H,H) = 13.8 Hz, 1H), 3.11 (d, 2J(H,H) = 15.5 Hz, 1H), 0.41 (s, 9H), 
0.31 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 208.4, 180.3, 152.3, 152.2, 138.9, 137.7, 134.0, 133.9, 
127.3, 127.3, 127.1, 126.4, 126.1, 125.5, 123.8, 123.6, 114.7, 110.4, 109.5, 76.3, 75.4, 29.8, 26.4, 
0.9, 0.5; IR (film): ν = 3236.0, 2953.4, 2852.7, 2065.9, 2010.4, 1996.9, 1575.1, 1342.2, 1248.2 cm-
1; HRMS (ESI+): m/z 675.13152 [M + H]+ (calcd. for C36H35O6Si2Fe: 675.13277). 
X-Ray Crystal Structure Analysis Of Complex Fe24 
Crystals suitable for X-ray diffraction analysis have been obtained by slow diffusion of hexane into 
a DCM solution of complex (R)-Fe24. Crystal data and details of data collection and refinement are 
given in Table 5.7. Intensity data were collected with a Bruker Apex II CCD area detector by using 
graphite monochromated Mo-Kα radiation. Data reduction was performed with SAINT, and 
absorption corrections based on multiscan were obtained with SADABS.163 The structure was 
solved by direct methods using SHELXS-97 and refined by SHELXL-2013. 164 The program ORTEPIII 
was used for graphics.165 Anisotropic thermal parameters were used for all non-hydrogen atoms. 
The isotropic thermal parameters of H atoms were fixed at 1.2 (1.5 for methyl groups) times 
those of the atom to which they were attached. All H atoms were placed in calculated positions 
and refined using a riding model with freely rotating methyl groups. 
Table 5.7 Details of the Crystal Data and Structure Refinement for Compound (R)-Fe24 
Crystal Data   
Empirical formula  C40H44FeO8Si2 
Moiety formula  C36H34FeO6Si2·C4H10O·H2O 
Formula weight 764.78 
Chiral (cyclopentadienone)iron complexes 
 
Crystal system  Orthorhombic 
Space group  P212121 
a/Å 11.1452(5) 
b/Å 16.4340(7) 
c/Å 22.8671(10) 
V/Å3  4188.3(3)Å3 
Z 4 
Temperature/K  130(2) 
Density (calculated) Dx/Mg m
-3  1.213 
Absorption coefficient μ/mm-1 0.464  
Color, habit orange, prism 
Dimensions /mm 0.300.300.20 
Data Collection   
radiation,  /Å Mo K, 0.71073 
2 max/º  49.34 
h range  -1313 
k range  -1919 
l range  -2626 
Measured reflections  55474 
Independent reflections 7102 
Reflections with I>2(I)  6162 
Rint  0.0577 
Refinement on F2  
Data, restraints, parameters 7102, 1, 488 
S 1.049 
Final R, wR [F2>2(F2)] 0.0377, 0.0920 
Final R, wR (all data) 0.0478, 0.0985 
Flack parameter 0.000(7) 
(/)max 0.001 
max, min /eÅ
3 0.359, -0.270 
An ORTEP view of the complex is presented in Figure 5.7 and selected geometrical parameters are 
collected in Table 5.8. The structure includes one water molecule, disordered over three positions 
labeled Ow1, Ow2 and Ow3 with occupancies 0.4, 0.4 and 0.2, respectively (only Ow1 is shown in 
Figure 5.7 for clarity) and one Et2O molecule. The latter, which is strongly hydrogen-bonded to 
one hydroxyl group (O1–H1) of the complex through its oxygen atom O7 (O1···O7, 2.752 Å; O1–
H1···O7, 164.4°), was probably bonded to the complex during solubilization attempts made before 
the crystallization. 
The crystal structure of (R)-Fe24 shows typical geometrical parameters observed in related 
structures. In particular, the cyclopentadienone ring strongly deviates from planarity, with atom 
C24 significantly bent away from the iron atom (see Table 5.8). The dihedral angle between the 
l.s. plane through the coordinated butadiene and the plane defined by C23, C24 and C25, 
13.9(2)°, is typical for cyclopentadienone-iron complexes.95 The dihedral angle between the l.s. 
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planes through the carbon atoms of the naphthyl moieties, 67.9(1)°, is quite similar to that found 
in other binaphthyl derivatives where the ortho positions are connected through a 
(diyldimethylene)cyclopentadienyl group.166 In Table 5.8 are also reported the relevant distances 
concerning atom O2, which remarkably affects the level of enantioselectivity in ketone 
hydrogenation, as discussed in the article.  
CCDC 1037376 contains the supplementary crystallographic data for this structure. These data 
can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Figure 5.7 ORTEP view of the asymmetric unit of Fe24.Et2O
.H2O. Thermal ellipsoids are drawn at 
the 50% probability level. 
Table 5.8 Selected interatomic distances (Å) for Fe24. 
Fe–C22  2.095(4) O2···C29  5.356(3) 
Fe–C26  2.115(4) O2···O5  6.296(3) 
Fe–C23 2.139(4) O2···Fe 4.016(2) 
Fe–C25 2.145(4) O2···O3 6.429(2) 
Fe–C24 2.310(4) O2···Si2 4.408(2) 
  O2···C36 3.641(4) 
Complex Fe25 
Acetyl chloride (32 µL, 0.44 mmol, 3 eq) was slowly added to a stirred 
solution of Fe24 (100 mg, 0.15 mmol, 1 eq), Et3N (83 µL, 0.59 mmol, 4 
eq) and DMAP (1.6 mg, 0.015 mmol, 0.1 eq) in THF (2 mL), then the 
mixture was refluxed for 3 h. After this time, the mixture was diluted 
DCM and washed with 0.5 M HCl (2  5 mL), sat. aq. NaHCO3 (5 mL) and 
brine (5 mL). The organic phase was then dried over Na2SO4. Complex 
Fe25 – a pale yellow solid – was purified by flash column chromatography (90:10 to 85:15 
hexane/AcOEt). Yield: 103.3 g (92%); m.p. = 162-166 °C; [α]D
22 = + 19.37 (c = 0.51 in DCM); 1H 
Chiral (cyclopentadienone)iron complexes 
 
NMR (400 MHz, CDCl3) δ 7.90 (d, 
3J(H,H) = 8.2 Hz, 1H), 7.87 (d, 3J(H,H) = 8.2 Hz, 1H), 7.80 (s, 1H), 
7.73 (s, 1H), 7.52-7.43 (m, 2H), 7.25-7.17 (m, 2H), 6.99 (d, 3J(H,H) = 8.4 Hz, 1H), 6.85 (d, 3J(H,H) = 
8.4 Hz, 1H), 4.00 (d, 2J(H,H) = 16.0 Hz, 1H), 3.89 (d, 2J(H,H) = 14.3 Hz, 1H), 3.36 (d, 2J(H,H) = 14.3 
Hz, 1H), 3.34 (d, 2J(H,H) = 16.0 Hz, 1H), 2.45 (s, 3H), 2.39 (s, 3H), 0.45 (s, 9H), 0.32 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ 208.2, 181.0, 170.1, 169.8, 146.1, 138.8, 137.5, 133.0, 132.9, 130.2, 130.1, 
128.7, 127.9, 127.8, 127.5, 127.0, 126.8, 126.7, 126.6, 121.6, 121.1, 112.0, 110.2, 74.9, 74.6, 27.5, 
26.6, 22.3, 21.9, 0.9, 0.5; IR (film): ν = 3062.4, 2953.9, 2923.6, 2903.3, 2852.7, 2062.5, 2007.5, 
1989.7, 1768.4, 1624.25, 1189.4, 1155.6, 1087.7, 849.0 cm-1; HRMS (ESI+): m/z 759.15207 [M + 
H]+ (calcd. for C50H43O8Si2Fe: 759.15395). 
Complex Fe26 
Benzoyl chloride (26 µL, 0.22 mmol, 3 eq) was slowly added to a stirred 
solution of Fe24 (50 mg, 0.07 mmol, 1 eq), Et3N (41 µL, 0.3 mmol, 4 eq) 
and DMAP (0.8 mg, 0.007 mmol, 0.1 eq) in THF (1 mL), then the mixture 
was refluxed for 4 h. After this time, the mixture was diluted with DCM 
and washed with 0.5 M HCl (2  5 mL), sat. aq. NaHCO3 (5 mL) and brine 
(5 mL). The organic phase was then dried over Na2SO4. After 
concentration, the pure complex (R)-1e - a pale yellow solid - was purified by flash column 
chromatography (95:5 to 9:1 hexane/AcOEt). Yield: 53 mg (81%); m.p. = 176 °C (dec.); [α]436
27 = – 
108.6 (c = 0.25 in DCM); 1H NMR (400 MHz, CDCl3) δ 8.26 (m, 1H), 8.24 (m, 1H), 8.21 (m, 1H), 8.19 
(m, 1H), 7.92 (d, 3J(H,H) = 4.7 Hz, 1H), 7.90 (d, 3J(H,H) = 4.6 Hz, 1H), 7.83 (s, 1H), 7.82 (s, 1H), 7.72-
7.64 (m, 2H), 7.59-7.46 (m, 6H), 7.31-7.26 (m, 2H), 7.01 (dd, 3J(H,H) = 8.4, 4J(H,H) = 0.6 Hz, 1H), 
6.97 (dd, 3J(H,H) = 8.5, 4J(H,H) = 0.6 Hz, 1H), 4.01 (d, 2J(H,H) = 14.5 Hz, 1H), 3.98 (d, 2J(H,H) = 16.1 
Hz, 1H), 3.58 (d, 2J(H,H) = 14.6 Hz, 1H), 3.49 (d, 2J(H,H) = 16.1 Hz, 1H), 0.10 (s, 9H), 0.03 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 208.1, 181.0, 167.0, 166.6, 147.3, 147.1, 139.0, 137.8, 134.2, 134.1, 
133.3, 131.1, 130.7, 129.7, 129.7, 129.5, 129.2, 128.7, 127.8, 127.1, 126.9, 126.7, 121.1, 120.7, 
113.2, 109.1, 75.7, 74.8, 27.7, 27.2, 0.7, 0.3; IR (film): ν = 3062.9, 2953.9, 2897.5, 2062.0, 2007.5, 
1990.2, 1740.4, 1624.7, 1266.0, 1246.3, 1090.1, 1022.1, 847.1, 711.1 cm-1; HRMS (ESI+): m/z 
883.187411 [M + H]+ (calcd. for C50H43O8Si2Fe: 883.18537). 
Complex Fe27 
Benzyl bromide (53 µL, 0.45 mmol, 6 eq) was slowly added to a stirred 
solution of Fe24 (50 mg, 0.07 mmol, 1 eq) and K2CO3 (41 mg, 0.30 
mmol, 4 eq) in DMF (0.37 mL) and stirred at 70 °C overnight. After this 
time, the reaction was cooled down to R.T. and diluted with Et2O (8 
mL). The mixture was washed with H2O (3  5 mL) and the organic 
phase dried over Na2SO4. Complex Fe27 – a pale yellow solid – was 
purified by flash column chromatography (9:1 DCM/hexane). Yield: 42 mg (70%); m.p. = 155 °C 
(dec.); [α]D
32 = – 20.6 (c = 0.92 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.80 (d, 
3J(H,H) = 8.1 Hz, 1H), 
7.71 (d, 3J(H,H) = 8.1 Hz, 1H), 7.46-7.23 (m, 14H), 7.11-7.03 (m, 2H), 6.91-6.84 (m, 2H), 5.51 (d, 
2J(H,H) = 13.5 Hz, 1H), 5.46 (d, 2J(H,H) = 13.5 Hz, 1H), 5.26 (d, 2J(H,H) = 11.3 Hz, 1H), 5.17 (d, 
2J(H,H) = 11.3 Hz, 1H), 4.38 (d, 2J(H,H) = 15.6 Hz, 1H), 4.29 (d, 2J(H,H) = 13.8 Hz, 1H), 3.35 (d, 
2J(H,H) = 13.8 Hz, 1H), 3.15 (d, 2J(H,H) = 15.6 Hz, 1H), 0.32 (s, 9H), 0.08 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 208.6, 181.1, 154.1, 153.6, 139.0, 137.6, 136.7, 136.1, 133.8, 133.6, 129.1, 128.9, 128.7, 
128.5, 128.1, 127.4, 127.4, 127.2, 127.1, 127.1, 127.0, 126.9, 126.9, 126.6, 126.4, 124.3, 124.3, 
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114.8, 108.7, 108.6, 107.3, 75.8, 75.1, 70.5, 70.1, 26.4, 26.2, 0.8, 0.2; IR (film): ν = 3063.4, 3034.4, 
2953.0, 2899.0, 2060.1, 2004.2, 1987.3, 1757.3, 1620.9, 1596.8, 1246.3, 1105.5, 850.5, 738.1 cm -
1; HRMS (ESI+): m/z 855.22583 [M + H]+ (calcd. for C50H47O6Si2Fe: 855.22685). 
Complex Fe28 
Methanesulfonyl chloride (17 µL, 0.22 mmol, 3 eq) was slowly added to 
a stirred solution of Fe24 (50 mg, 0.07 mmol, 1 eq), Et3N (41 µL, 0.30 
mmol, 4 eq) and DMAP (0.8 mg, 0.007 mmol, 0.1 eq) in THF (1 mL), 
then the mixture was refluxed for 5 h. After this time, the reaction was 
cooled down to R.T., diluted with AcOEt (5 mL) and washed with 0.5 M 
HCl (2  5 mL), sat. aq. NaHCO3 (5 mL) and brine (5 mL). The organic 
phase was dried over Na2SO4. After concentration, the pure complex Fe28 was obtained as a pale 
yellow solid. Yield: 40 mg (65%); m.p. = 172 °C (dec.); [α]D
27 = – 6.8 (c = 1.4 in DCM); 1H NMR (400 
MHz, CDCl3) δ 8.12 (s, 1H), 8.09 (s, 1H), 7.99 (d, 
3J(H,H) = 8.3 Hz, 1H), 7.96 (d, 3J(H,H) = 8.3 Hz, 1H), 
7.56 (dd, 3J(H,H) = 8.3 Hz, 3J(H,H) = 7.0 Hz, 1H), 7.53 (dd, 3J(H,H) = 8.3 Hz, 3J(H,H) = 6.9 Hz, 1H), 
7.33 (dd, 3J(H,H) = 8.4 Hz, 3J(H,H) = 7.0 Hz, 1H), 7.28 (dd, 3J(H,H) = 8.5 Hz, 3J(H,H) = 6.9 Hz, 1H), 
6.99 (d, 3J(H,H) = 8.4 Hz, 1H), 6.85 (d, 3J(H,H) = 8.5 Hz, 1H), 4.25 (d, 2J(H,H) = 16.2 Hz, 1H), 4.15 (d, 
2J(H,H) = 14.4 Hz, 1H), 3.35 (d, 2J(H,H) = 14.4 Hz, 1H), 3.33 (d, 2J(H,H) = 16.2 Hz, 1H), 3.31 (s, 3H), 
3.29 (s, 3H), 0.45 (s, 9H), 0.33 (m, 9H); 13C NMR (100 MHz, CDCl3) δ 208.2, 181.4, 144.4, 143.5, 
139.3, 138.0, 132.8, 132.7, 130.5, 130.5, 128.8, 128.5, 128.4, 128.2, 128.0, 127.8, 127.8, 127.7, 
126.6, 126.3, 121.9, 121.4, 111.1, 110.1, 75.5, 75.1, 38.8, 38.6, 27.7, 26.7, 0.7, 0.5; IR (film): ν = 
3054.2, 2986.7, 2066.4, 2010.4, 1994.5, 1617.5, 1265.6, 739.1, 705.3 cm-1; HRMS (ESI+): m/z 
853.06820 [M + Na]+ (calcd. for C38H38O10S2Si2FeNa: 853.06985). 
Complex Fe29 
p-Toluenesulfonyl chloride (43 mg, 0.22 mmol, 3 eq) was slowly added 
to a stirred solution of Fe24 (50 mg, 0.07 mmol, 1 eq), Et3N (41 µL, 0.03 
mmol, 4 eq) and DMAP (0.8 mg, 0.007 mmol, 0.1 eq) in THF (1 mL), 
then the mixture was refluxed overnight. The reaction was cooled 
down to R.T., diluted with AcOEt (5 mL) and washed with 0.5 M HCl (2  
5 mL), sat. aq. NaHCO3 (5 mL) and brine (5 mL). The organic phase was 
dried over Na2SO4 and then concentrated. Complex Fe29 – a pale yellow solid – was purified by 
flash column chromatography (8:2 hexane/AcOEt). Yield: 63 mg (96%); m.p. = 166-168 °C (dec.); 
[α]D
23 = + 168.6 (c = 1.2 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.85 (d, 
3J(H,H) = 8.3 Hz, 
1H), 7.82 (d, 3J(H,H) = 8.3 Hz, 1H), 7.79 (s, 1H), 7.70 (d, 3J(H,H) = 8.0 Hz, 2H), 7.65 (d, 3J(H,H) = 8.0 
Hz, 2H), 7.51 (t, 3J(H,H) = 7.5 Hz, 2H), 7.29-7.19 (m, 6H), 6.65 (d, 3J(H,H) = 8.4 Hz, 1H), 6.54 (d, 
3J(H,H) = 8.5 Hz, 1H), 3.93 (d, 2J(H,H) = 16.1 Hz, 1H), 3.92 (d, 2J(H,H) = 14.3 Hz, 1H), 3.01 (d, 2J(H,H) 
= 14.3 Hz, 1H), 2.86 (d, 2J(H,H) = 16.1 Hz, 1H), 2.40 (s, 3H), 2.37 (s, 3H), 0.43 (s, 9H), 0.27 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 208.0, 181.3, 145.9, 145.9, 145.0, 145.0, 138.8, 137.3, 132.7, 132.5, 
132.4, 130.2, 130.1, 130.0, 129.9, 129.3, 128.9, 128.8, 128.5, 128.4, 128.3, 127.4, 127.3, 127.3, 
126.2, 126.1, 121.2, 121.2, 111.5, 108.6, 75.3, 74.9, 27.3, 26.4, 21.9, 21.9, 0.6, 0.6. IR (film): ν = 
3054.2, 2986.7, 2916.8, 2066.4, 2010.9, 1422.2, 1265.6, 895.8, 740.5, 705.3 cm-1; HRMS (ESI+): 
m/z 983.14923 [M + H]+ (calcd. for C50H47O10S2Si2Fe: 983.15069). 
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Complex Fe30 
N-(5-Chloro-2-pyridyl)bis(trifluoromethanesulfonimide) (1.2 g, 3.0 
mmol, 3 eq) was added to a stirred solution of Fe24 (670 mg, 1.0 mmol, 
1 eq), Et3N (550 µL, 4.0 mmol, 4 eq) and DMAP (12 mg, 0.1 mmol, 0.1 
eq) in DCM (30 mL) and stirred at R.T. overnight. The reaction was 
diluted with DCM (30 mL) and washed with 0.5 M HCl (2  50 mL), 0.5 M 
NaOH (2  50 mL) and brine (50 mL). The organic phase was then dried 
over Na2SO4. Complex Fe30 – a pale yellow solid – was purified by flash column chromatography 
(10:1 hexane/AcOEt). Yield: 882 mg (94%); m.p. = 142-143 °C (dec.); [α]D
24 = + 43.9 (c = 1.9 in 
DCM); 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 8.12 (s, 1H), 8.03 (d, 
3J(H,H) = 8.5 Hz, 1H), 8.01 (d, 
3J(H,H) = 8.3 Hz, 1H), 7.62 (t, 3J(H,H) = 7.5 Hz, 1H), 7.61 (t, 3J(H,H) = 7.5 Hz, 1H), 7.40 (t, 3J(H,H) = 
8.2 Hz, 1H), 7.38 (t, 3J(H,H) = 8.1 Hz, 1H), 6.90 (d, 3J(H,H) = 8.5 Hz, 1H), 6.84 (d, 3J(H,H) = 8.5 Hz, 
1H), 4.18 (d, 2J(H,H) = 16.2 Hz, 1H), 4.13 (d, 2J(H,H) = 14.6 Hz, 1H), 3.40 (d, 2J(H,H) = 14.7 Hz, 1H), 
3.35 (d, 2J(H,H) = 16.2 Hz, 1H), 0.41 (s, 9H), 0.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 207.9, 181.3, 
145.2, 144.9, 139.4, 137.9, 132.7, 132.6, 130.8, 130.7, 128.9, 128.8, 128.8, 128.7, 128.4, 128.3, 
127.8, 127.1, 126.2, 126.0, 120.9, 120.8, 119.0 (q, 1J(C,F) = 324.5 Hz), 118.9 (q, 1J(C,F) = 324.5 Hz), 
110.7, 108.7, 75.5, 75.5, 27.6, 26.8, 0.5, 0.4; 19F NMR (282 MHz, CDCl3) δ -71.7, -72.7; IR (film): ν = 
3066.7, 2954.9, 2925.5, 2903.3, 2852.7, 2065.4, 2011.9, 1993.6, 1629.1, 1427.6, 1245.8, 1212.5, 
1138.3, 915.5, 883.2, 844.7, 822.0 cm-1; HRMS (ESI+): m/z 961.01272 [M + Na]+ (calcd. for 
C38H32O10F6S2Si2FeNa: 961.01332). 
Complex Fe31 
Fe30 (100 mg, 0.1 mmol, 1 eq), Pd(OAc)2 (4.5 mg, 0.02 mmol, 0.2 eq), 
PPh3 (10.5 mg, 0.04 mmol, 0.4 eq), K3PO4 (63 mg, 0.3 mmol, 3 eq), KBr 
(26 mg, 0.22 mmol, 2.2 eq) and phenylboronic acid (30.5 mg, 0.25 
mmol, 2.5 eq) were dissolved in dioxane (2.5 mL). The reaction was 
heated to 85 °C and stirred overnight. The mixture was diluted with 
DCM (5 mL) and washed with 1 M NaOH (5 mL), H2O (5 mL) and brine (5 
mL), then dried over Na2SO4. Complex Fe31 – a yellow solid – was purified by flash column 
chromatography (DCM/hexane 7:3). Yield: 15 mg (17%); 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 
7.89-8.02 (m 6H), 7.81 (m, 2H), 7.62 (t, 3J(H,H) = 8.0 1H), 7.54 (m, 3H), 7.41 (m 2H), 7.29 (t, 3J(H,H) 
= 8.0 Hz,1 H), 7.09 (m, 1H), 6.74 (d, 3J(H,H) = 8.0 Hz, 1H), 4.24 (d, 2J(H,H) = 14.8 Hz, 1H), 4.13 (d, 
2J(H,H) = 15.8 Hz, 1H), 3.64 (d, 2J(H,H) = 14.8 Hz, 1H), 3.52 (d, 2J(H,H) = 15.8 Hz, 1H), 0.34 (s, 9H), -
0.40 (s, 9H); ESI-MS in CH3CN: [M+H]
2+ m/z 917.2 
Complex Fe32 
Fe30 (100 mg, 0.1 mmol, 1 eq), Pd(OAc)2 (4.5 mg, 0.02 mmol, 0.2 eq), 
PPh3 (10.5 mg, 0.04 mmol, 0.4 eq), K3PO4 (63 mg, 0.3 mmol, 3 eq), KBr 
(26 mg, 0.22 mmol, 2.2 eq) and phenylboronic acid (30.5 mg, 0.25 
mmol, 2.5 eq) were dissolved in dioxane (2.5 mL). The reaction was 
heated to 85 °C and stirred overnight. The mixture was diluted with 
DCM (5 mL) and washed with 1 M NaOH (5 mL), H2O (5 mL) and brine (5 
mL), then dried over Na2SO4. Complex Fe32 – a yellow solid – was purified by flash column 
chromatography (6:4 to 8:2 DCM/hexane). Yield: 69 mg (80%); m.p. = 157-158 °C (dec.); [α]D
21 = + 
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88.3 (c = 0.6 in DCM); 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 8.01 (d, 
3J(H,H) = 8.2 Hz, 1H), 7.93 
(d, 3J(H,H) = 8.2 Hz, 1H), 7.90 (s, 1H), 7.63-7.31 (m, 8H), 7.26 (dd, 3J(H,H) = 8.5 Hz, 3J(H,H) = 7.3 Hz, 
1H), 7.02 (d, 3J(H,H) = 8.5 Hz, 1H), 6.70 (d, 3J(H,H) = 8.5 Hz, 1H), 4.27 (d, 2J(H,H) = 14.8 Hz, 1H), 
4.11 (d, 2J(H,H) = 15.8 Hz, 1H), 3.58 (d, 2J(H,H) = 14.8 Hz, 1H), 3.50 (d, 2J(H,H) = 15.8 Hz, 1H), 0.33 
(s, 9H), -0.15 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 208.1, 180.8, 144.9, 141.6, 141.3, 139.4, 136.1, 
132.7, 132.5, 132.5, 132.1, 131.1, 130.9, 128.6, 128.3, 128.1, 127.9, 127.6, 127.4, 127.0, 126.4, 
125.7, 120.0, 118.9 (q, 1J(C,F) = 321.3 Hz), 111.8, 111.2, 75.9, 75.5, 29.5, 27.5, 0.5, 0.4; 19F NMR 
(282 MHz, CDCl3) δ -72.1; IR (film): ν = 3054.7, 2987.2, 2065.4, 2009.5, 1639.7, 1421.8, 1265.6, 
744.4, 705.3 cm-1; HRMS (ESI+): m/z 889.10212 [M + Na]+ (calcd. for C43H37O7F3S1Si2FeNa: 
889.10049). 
1,3-bis(trimethylsilyl)-4,17-dihydro-2H-cyclopenta[6,7]cycloocta[2,1-a:3,4-a']dinaphthalen-2-one 97 
A solution of complex Fe20 (104 mg, 0.16 mmol, 1 eq), in THF (2.7 mL) 
and aqueous 1 M NaOH (1.3 mL) was stirred for 2.5 h under an argon 
atmosphere. Then 1-iodopentane was added (50 µL, 0.38 mmol, 2.4 eq) 
and the yellow solution turned brown. After stirring the mixture for an 
additional 15 min under argon, H3PO4 (85%, 50 µL) was added, the 
reaction stirred for 5 min and the organic layer separated. The aqueous layer was extracted with 
Et2O (2  7 mL). The combined organic layers were dried over Na2SO4 and filtered through a short 
path of silica gel. After addition of Na2S2O3·5 H2O (105 mg) and Celite (65 mg) the filtrate was 
stirred slowly in the air for 16 h in the presence of daylight. Filtration through a short path of 
Celite, evaporation of the solvent, and flash chromatography (9:1 hexane/DCM) of the residue on 
silica gel provided the free ligand 97. Yield: 79 mg (99%) 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 
8.4 Hz, 4H), 7.53 (d, J = 8.4 Hz, 2H), 7.51 – 7.46 (m, 2H), 7.30 (d, J = 3.6 Hz, 4H), 4.02 (d, J = 14.8 
Hz, 2H), 3.22 (d, J = 14.8 Hz, 2H), 0.27 (s, 18H). 
(R)-2-Oxo-1,3-bis(trimethylsilyl)-4,17-dihydro-2-cyclopenta[6,7]cycloocta[2,1-a:3,4-a']-
dinaphthalene-5,16-diyl bis(trifluoromethanesulfonate) 98 
A solution of complex Fe30 (150 mg, 0.16 mmol, 1 eq), in THF (2.7 mL) 
and aqueous 1 M NaOH (1.3 mL) was stirred for 2.5 h under an argon 
atmosphere. Then 1-iodopentane was added (50 µL, 0.38 mmol, 2.4 eq) 
and the yellow solution turned brown. After stirring the mixture for an 
additional 15 min under argon, H3PO4 (85%, 50 µL) was added, the 
reaction stirred for 5 min and the organic layer separated. The aqueous layer was extracted with 
Et2O (2  7 mL). The combined organic layers were dried over Na2SO4 and filtered through a short 
path of silica gel. After addition of Na2S2O3·5 H2O (105 mg) and Celite (65 mg) the filtrate was 
stirred slowly in the air for 16 h in the presence of daylight. Filtration through a short path of 
Celite, evaporation of the solvent, and flash chromatography (9:1 hexane/DCM) of the residue on 
silica gel provided the free ligand 98. Yield: 35 mg (28%); m.p. = 204-207 °C; [α]D
21 = + 112.4 (c = 
0.6 in DCM); 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 2H), 8.01 (d, 
3J(H,H) = 8.3 Hz, 2H), 7.62 (dd, 
3J(H,H) = 8.3, 6.4 Hz, 1H), 7.41 (dd, 3J(H,H) = 8.4, 6.4 Hz, 1H), 7.20 (d, 3J(H,H) = 8.5 Hz, 2H), 4.36 (d, 
2J(H,H) = 15.6 Hz, 2H), 3.06 (d, 2J(H,H) = 15.6 Hz, 2H), 0.22 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 
209.6, 164.7, 147.5, 138.9, 132.8, 132.1, 130.6, 129.1, 128.8, 128.3, 128.0, 126.7, 119.0, 118.9 (q, 
1J(C,F) = 321.5 Hz), 30.1, 0.2; 19F NMR (282 MHz, CDCl3) δ -72.75; IR (film): ν = 2953.5, 2906.2, 
1685.0, 1426.1, 1241.0, 1214.0, 1138.8, 847.1 cm-1; HRMS (ESI+): m/z 821.08966 [M + Na]+ (calcd. 
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for C35H32O7F6S2Si2Na: 821.09244). 
(R)-5,16-Diphenyl-1,3-bis(trimethylsilyl)-4,17-dihydro-2H-cyclopenta[6,7]cycloocta[2,1-a:3,4-
a']dinaphthalen-2-one 99  
98 (35 mg, 0.044 mmol, 1 eq), Pd(OAc)2 (2 mg, 0.009 mmol, 0.2 eq), 
PPh3 (4.6 mg, 0.018 mmol, 0.4 eq), K3PO4 (37 mg, 0.18 mmol, 3 eq), KBr 
(12 mg, 0.10 mmol, 2.2 eq) and phenylboronic acid (16 mg, 0.13 mmol, 
3 eq) were dissolved in dioxane (1 mL). The reaction was stirred at 85 °C 
overnight. The mixture was diluted with DCM (5 mL) and washed with 1 M NaOH (5 mL), H2O (5 
mL) and brine (5 mL), then dried over Na2SO4. Ligand 99 – a yellow solid – was purified by flash 
column chromatography (29:1 hexane/DCM). Yield: 25 mg (86%); m.p. = 264-266 °C; [α]D
20 = + 
150.5 (c = 0.5 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.92 (d, 
3J(H,H) = 8.2 Hz, 2H), 7.79 (s, 2H), 7.51 
(ddd, 3J(H,H) = 8.1, 6.7 Hz, 4J(H,H) = 1.2 Hz, 2H), 7.45-7.38 (m, 6H), 7.38-7.29 (m, 6H), 7.24 (d, 
3J(H,H) = 8.4 Hz, 2H), 4.00 (d, 2J(H,H) = 15.4 Hz, 2H), 3.30 (d, 2J(H,H) = 15.4 Hz, 2H), -0.20 (s, 18H); 
13C NMR (100 MHz, CDCl3) δ 210.8, 169.5, 142.1, 141.7, 137.7, 134.1, 132.3, 131.5, 129.9, 129.6, 
128.6, 128.1, 127.5, 126.9, 126.5, 126.4, 33.8, 0.0.; IR (film): ν = 3058.6, 2958.8, 2896.1, 1679.7, 
1542.3, 1245.3, 850.5, 748.2, 701.0 cm-1; HRMS (ESI+): m/z 655.28304 [M + H]+ (calcd. for 
C45H43O1Si2: 655.28470). 
(R)-((3,3'-Dimethoxy-[1,1'-binaphthalene]-2,2'-diyl)bis(prop-1-yne-3,1-diyl))bis-(triiso-
propylsilane)100 
n-BuLi (1.6 M hexane solution, 560 µL, 0.9 mmol, 3 eq) was added 
dropwise to a solution of ethynyltriisopropylsilane (200 µL, 0.9 mmol, 3 
eq) in THF (1 mL) kept at -60 °C. The obtained mixture was allowed to 
warm to 0 °C and stirred for 30 min at this temperature, and then it 
was cooled down again to -60 °C. A solution of bis-iodide 95 (178 mg, 0.3 mmol, 1 eq) in THF (3 
mL) was added and then the mixture was allowed to warm to R.T. and stirred overnight. The 
reaction was quenched with sat. aq. NH4Cl (5 mL) and extracted with Et2O (3  5 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo. Diyne 100 was 
purified by flash column chromatography (8:2 hexane/DCM). Yield: 86 mg (41%); m.p. = 61-62 °C; 
[α]D
20 = + 22.4 (c = 0.6 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.80 (d, 
3J(H,H) = 8.1 Hz, 2H), 7.40 
(ddd, 3J(H,H) = 8.1, 6.6 Hz, 4J(H,H) = 1.4 Hz, 2H), , 7.29 (s, 2H), 7.10-6.99 (m, 4H), 4.05 (s, 6H), 3.34 
(s, 4H), 0.98-0.92 (m, 36H); 13C NMR (100 MHz, CDCl3) δ 156.2, 135.8, 133.9, 128.5, 127.1, 127.0, 
126.6, 126.2, 124.2, 106.4, 105.6, 79.3, 55.5, 20.1, 18.7, 11.4; IR (film): ν = 2962.1, 2941.9, 
2862.8, 2171.5, 1260.3, 1092.5, 1020.2, 799.4 cm-1; HRMS (ESI+): m/z 725.41937 [M + Na]+ (calcd. 
for C46H62O2Si2Na: 725.41806). 
(R)-3,3'-Dimethoxy-2,2'-bis(3-phenylprop-2-yn-1-yl)-1,1'-binaphthalene 101 
n-BuLi (1.6 M hexane solution, 790 µL, 1.26 mmol, 3 eq) was added 
dropwise to a solution of ethynylbenzene (140 µL, 1.26 mmol, 3 eq) in 
THF (1.5 mL) kept at -60 °C. The obtained mixture was allowed to warm 
to 0 °C and stirred for 30 min at this temperature, and then it was cooled 
down again to -60 °C. A solution of bis-iodide 95 (250 mg, 0.42 mmol, 1 
eq) in THF (4 mL) was added and then the mixture was allowed to warm 
to R.T. and stirred overnight. The reaction was quenched with sat. aq. NH4Cl (5 mL) and extracted 
with Et2O (3  5 mL). The combined organic extracts were dried over Na2SO4 and concentrated in 
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vacuo. Diyne 101 was purified by flash column chromatography (8:2 hexane/DCM). Yield: 180 mg 
(79%); m.p. = 94-95 °C; [α]D
16 = – 20.9 (c = 0.7 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.82 (d, 
3J(H,H) 
= 8.2 Hz, 2H), 7.39 (ddd, 3J(H,H) = 8.1, 6.5 Hz, 4J(H,H) = 1.4 Hz, 2H), 7.35 (s, 2H), 7.21-7.12 (m, 
10H), 7.12-7.02 (m, 4H), 4.10 (s, 6H), 3.64 (d, 2J(H,H) = 16.5 Hz, 2H), 3.51 (d, 2J(H,H) = 16.5 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 156.0, 136.3, 134.0, 131.7, 128.5, 128.0, 127.4, 126.9, 126.7, 126.7, 
126.4, 124.2, 124.0, 106.0, 88.2, 80.0, 55.9, 19.0.; IR (film): ν = 3060.5, 2934.2, 2365.3, 1619.0, 
1596.8, 1422.2, 1107.9, 1020.2, 755.0, 691.4 cm-1; HRMS (ESI+): m/z 565.21535 [M + Na]+ (calcd. 
for C40H30O2Na: 565.21380). 
Complex Fe34 
Diyne 101 (271 mg, 0.50 mmol, 1 eq) and Fe2(CO)9 (455 mg, 1.25 
mmol, 2.5 eq) were dissolved in toluene (6 mL) and stirred to 90 °C 
overnight. After cooling down to room temperature, the reaction 
mixture was filtered through a pad of Celite (rinsing with DCM). The 
filtrate was concentrated in vacuo, and the residue was purified by 
flash column chromatography (8:2 hexane/DCM) to obtain Fe34 as a 
pale yellow solid. Yield: 201 mg (57% yield); m.p. = 156-158 °C; [α]D
17 = – 92.1 (c = 0.4 in DCM); 1H 
NMR (400 MHz, CDCl3) δ 7.85 (d, 
3J(H,H) = 8.2 Hz, 1H), 7.80 (d, 3J(H,H) = 8.2 Hz, 1H), 7.46-7.30 (m, 
5H), 7.30 (s, 1H), 7.26 (s, 1H), 7.21-7.01 (m, 9H), 6.91 (m, 1H), 6.81 (m, 1H), 3.97 (d, 2J(H,H) = 15.2 
Hz, 1H), 3.96 (s, 3H), 3.86 (d, 2J(H,H) = 14.3 Hz, 1H), 3.80 (s, 3H), 3.08 (d, 2J(H,H) = 15.1 Hz, 1H), 
2.99 (d, 2J(H,H) = 14.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 213.8, 212.2, 205.9, 204.7, 183.1, 
167.3, 155.6, 155.1, 148.7, 148.6, 138.6, 138.4, 134.0, 133.8, 132.7, 129.8, 128.6, 128.2, 128.0, 
127.5, 127.2, 127.0, 127.0, 127.0, 126.9, 126.6, 126.5, 126.4, 126.4, 126.3, 124.1, 123.9, 105.9, 
105.6, 55.1, 54.8, 30.2, 29.3; IR (film): ν = 3055.7, 2919.7, 2858.0, 2061.5, 1985.4, 2024.9, 1599.6, 
1451.2, 1111.8, 1025.9 cm-1; HRMS (ESI+): m/z 733.13041 [M + Na]+ (calcd. for C40H30O2Na: 
733.12972).  
(R)-3,3'-Dimethoxy-2,2'-di(prop-2-yn-1-yl)-1,1'-binaphthalene 102 
A solution of 96 (244 mg, 0.34 mmol, 1 eq) in MeOH (5 mL) and DCM (2.5 
mL) was treated with K2CO3 (276 mg, 2 mmol, 5.9 eq) and stirred at 30 °C 
overnight. After this time, H2O (10 mL) were added and the mixture was 
extracted with DCM. The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. Diyne 102 was recrystallized from a 
mixture hexane/DCM (9:1) Yield: 120 mg (90%); m.p. = 150-152 °C; [α]D
16 = 
+ 112.0 (c = 0.5 in DCM); 1H NMR (400 MHz, CDCl3) δ 7.81 (d, 
3J(H,H) = 8.2 Hz, 2H), 7.40 (ddd, 
3J(H,H) = 8.2 Hz, 3J(H,H) = 6.7 Hz, 4J(H,H) = 1.4 Hz, 2H), 7.32 (s, 2H), 7.07 (ddd, 3J(H,H) = 8.4 Hz, 
3J(H,H) = 6.7 Hz, 4J(H,H) = 1.2 Hz, 2H), 7.01 (d, 3J(H,H) = 8.4 Hz, 2H), 4.09 (s, 6H), 3.36 (dd, 2J(H,H) = 
16.5 Hz, 4J(H,H) = 2.7 Hz, 2H), 3.24 (dd, 2J(H,H) = 16.5 Hz, 4J(H,H) = 2.7 Hz, 2H), 1.71 (t, 4J(H,H) = 
2.7 Hz, 2H).; 13C NMR (100 MHz, CDCl3) δ 155.8, 136.2, 134.0, 128.3, 126.9, 126.7, 126.5, 126.3, 
124.0, 106.0, 82.2, 67.8, 55.9, 18.3; IR (film): ν = 3290.9, 3058.6, 2934.2, 2118.4, 1619.0, 1597.7, 
1447.3, 1422.2, 1326.8, 1217.8, 1108.9, 1020.2 cm-1; HRMS (ESI+): m/z 413.15186 [M + Na]+ 
(calcd. for C40H30O2Na: 413.15120). 
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Complex Fe37 
Under argon in a Schlenk tube fitted with a Teflon screw cap, BBr3 (1 M 
DCM solution, 10.0 mL, 10.0 mmol, 10 eq) was added dropwise to a 
stirred solution of (R)-Fe34 (0.71 g, 1.0 mmol, 1 eq) and Bu4NI (0.92 g, 
2.5 mmol, 2.5 eq) in DCE (25 mL) kept at 0 °C. The Schlenk was sealed 
and the mixture was heated to 84 °C and stirred for 3 days. After this 
time, the reaction was cooled down to 0 °C and ice-cold H2O (30 mL) 
was added. The mixture was extracted with DCM (3  15 mL), washed with brine (25 mL) and then 
dried over Na2SO4. Filtration of the DCM solution through a short pad of silica allowed to remove 
the ammonium salts (which eluted before the product), then complex (R)-Fe37 – a pale yellow 
solid – was purified by flash column chromatography (7:3 heptane/AcOEt). Yield: 0.105 g (15%); 
1H NMR (300 MHz, CDCl3): δ = 7.72 (d, 
3J(H,H) = 9 Hz, 1H), 7.80 (d, 3J(H,H) = 9 Hz, 1H), 7.38-7.21 
(m, 5H), 7.16-6.97 (m, 11 H), 6.89 (m, 1H), 6.79 (m, 1H), 5.11 (bs, 1H), 5.02 (bs, 1H), 3.92 (d, 
2J(H,H) = 15 Hz, 1H), 3.65 (d, 2J(H,H) = 15 Hz, 1H), 3.12 (d, 2J(H,H) = 15 Hz, 1H), 3.02 (d, 2J(H,H) = 15 
Hz, 1H). 
Complex Fe38 
N-(5-Chloro-2-pyridyl)bis(trifluoromethanesulfonimide) (0.12 g, 0.3 
mmol, 3 eq) was added to a stirred solution of Fe37 (68 mg, 0.1 mmol, 1 
eq), Et3N (55 µL, 0.4 mmol, 4 eq) and DMAP (1.2 mg, 0.01 mmol, 0.1 eq) 
in DCM (3 mL) and stirred at R.T. overnight. The reaction was diluted 
with DCM (5 mL) and washed with 0.5 M HCl (2  10 mL), 0.5 M NaOH (2 
 10 mL) and brine (20 mL). The organic phase was then dried over 
Na2SO4. Complex Fe38 – a pale yellow solid – was purified by flash column chromatography (10:2 
heptane/AcOEt). Yield: 91 mg (96%). 1H NMR (300 MHz, CDCl3) δ 
1H NMR (300 MHz, CD2Cl2) δ 
8.25 (s, 1H), 8.07 (t, J = 4.0 Hz, 2H), 8.03 (d, J = 8.3 Hz, 1H), 7.61 (dd, J = 15.8, 7.8 Hz, 2H), 7.48 – 
7.25 (m, 5H), 7.25 – 7.09 (m, 5H), 7.04 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.93 – 6.81 (m, 
1H), 6.75 – 6.66 (m, 1H), 3.98 (d, J = 11.8 Hz, 1H), 3.93 (d, J = 12.1 Hz, 1H), 3.31 (d, J = 15.6 Hz, 
1H), 3.12 (d, J = 15.3 Hz, 1H). 19F NMR (282 MHz, CDCl3) δ -73.3, -74.1. 
Complexes Fe39 and Fe40 
Fe38 (90 mg, 0.1 mmol, 1 eq), Pd(OAc)2 (4.5 mg, 0.02 mmol, 0.2 eq), 
PPh3 (10.5 mg, 0.04 mmol, 0.4 eq), K3PO4 (63 mg, 0.3 mmol, 3 eq), KBr 
(26 mg, 0.22 mmol, 2.2 eq) and phenylboronic acid (30.5 mg, 0.25 
mmol, 2.5 eq) were dissolved in dioxane (3 mL). The reaction was 
heated to 85 °C and stirred overnight. The mixture was diluted with 
DCM (5 mL) and washed with 1 M NaOH (5 mL), H2O (5 mL) and brine 
(10 mL), then dried over Na2SO4. Mixture of complexes Fe39 and Fe40 – 
a yellow solid – was purified by flash column chromatography (7:3 
heptane/AcOEt). Yield Fe39: 25 mg (30%). 1H NMR (600 MHz, CD2Cl2) δ 
8.07 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.83 (s, 1H), 
7.63 (t, J = 7.2 Hz, 1H), 7.60 – 7.57 (m, 1H), 7.56 – 7.50 (m, 3H), 7.44 – 
7.41 (m, 2H), 7.40 – 7.37 (m, 2H), 7.36 (t, J = 6.9 Hz, 2H), 7.28 – 7.26 (m, 
1H), 7.24 – 7.20 (m, 4H), 7.02 – 6.94 (m, 3H), 6.88 (d, J = 8.8 Hz, 1H), 6.86 – 6.83 (m, 1H), 3.96 (d, J 
= 15.9 Hz, 1H), 3.87 (d, J = 15.4 Hz, 1H), 3.40 (d, J = 12.5 Hz, 1H), 3.17 (d, J = 15.9 Hz, 1H). ESI-MS: 
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m/z 897.0 [M + Na]+ (calcd. for C49H29F3FeO7S: 874.1). Yield Fe40: 28 mg (35%).
1H NMR (600 MHz, 
CD2Cl2) δ 7.98 (s, 1H), 7.97 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.71 (s, 1H), 7.53 – 7.48 (m, 1H), 7.48 – 
7.44 (m, 1H), 7.40 – 7.32 (m, 4H), 7.32 – 7.28 (m, 3H), 7.27 – 7.18 (m, 6H), 7.09 (dt, J = 19.9, 7.1 
Hz, 3H), 7.00 (dd, J = 15.3, 7.9 Hz, 2H), 6.96 (d, J = 8.1 Hz, 2H), 6.94 – 6.89 (m, 2H), 6.84 (t, J = 7.3 
Hz, 1H), 6.80 (d, J = 7.4 Hz, 1H), 4.16 (d, J = 15.7 Hz, 1H), 4.03 (d, J = 15.0 Hz, 1H), 3.41 (d, J = 15.0 
Hz, 1H), 3.31 (d, J = 15.7 Hz, 1H). ESI-MS: m/z 825.2 [M + Na]+ (calcd. for C54H34FeO4: 802.2). 
4-methoxy-4-methyl-4,5-dihydro-3H-dinaphtho[2,1-c:1',2'-e]silepine 103 
Adapting the procedure described by Mattson and co-workers,167 under 
argon a Schlenk flask was charged with n-BuLi (2.7 M heptane solution, 8.3 
mL, 22.5 mmol, 3 eq) and cooled to 0 oC. 76 (2.12 g, 7.5 mmol) was 
dissolved in dry Et2O (25 mL) and added dropwise to the Schlenk tube. The 
solution was stirred at 0 0C for 10 minutes, then dry N,N,N,N-
tetramethylethylenediamine (TMEDA, 3.5 mL, 22.5 mmol, 3 eq) was added dropwise at 0 oC. 
Solution changed color to yellow and it was stirred for 24 h at R.T. The resulting dark red mixture 
was cooled to 0 oC and trimethoxy(methyl)silane (4.2 mL, 29.2 mmol, 3.9 eq) in dry Et2O (25 mL) 
was added dropwise. The mixture was stirred overnight at R.T. The solution was concentrated and 
purified using column chromatography (95:5 heptane/AcOEt). Yield 53% (1.4 g). 1H NMR (300 
MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 
8.4 Hz, 1H), 7.37 (t, J = 9.0 Hz, 2H), 7.18 (t, J = 9.0 Hz, 2H), 7.12-7.08 (m, 2H), 3.40 (s, 3H), 2.24-
2.07 (m, 3 H), 1.89 (d, J = 15 Hz, 1 H), 0.13 (s, 3H). 
1,8-bis((4S,11bR)-4-methyl-4,5-dihydro-3H-dinaphtho[2,1-c:1',2'-e]silepin-4-yl)octa-1,7-diyne 104 
Under argon, in a Schlenk flask, a stirred solution of with 
1,7-octadiyne (0.09 mL, 0.66 mmol, 0.45 eq) in THF (2.5 
mL) was cooled to -78 oC. n-BuLi (2.7 M heptane solution, 
0.5 mL, 1.35 mmol, 0.93 eq) was added dropwise and the 
reaction was stirred for 10 min. at -78 oC and then 30 min. 
at 0 0C. A THF solution (2.5 mL) of 103 (0.52 g, 1.46 mmol, 
1 eq) was added dropwise at 0 oC. After addition, mixture was stirred for 2 h at R.T. and quenched 
with 1 M HCl (5 mL) at 0 oC. Organic materials were extracted with Et2O (2x 10 mL) and washed 
with water (2x 15 mL) and brine (1x 20 mL). After drying over anhydrous Na2SO4 the solvent was 
removed in vacuo, and the residue was purified by flash column chromatography (7:3 
heptane/DCM) to obtain 104 as a white foamy solid. Yield 80 mg (36% when calculated from 
diyne). 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 4H), 7.84 (d, J = 8.4 Hz, 4H), 7.48 (d, J = 8.4 
Hz, 2H), 7.39-7.32 (m, 6H), 7.19-7.08 (m, 8H), 2.12-2.04 (m, 6 H), 1.87 (d, J = 15 Hz, 2 H), 1.59-1.54 
(m, 4H), 0.91-0.86 (m, 4H), 0.17 (s, 6H). ESI-MS m/z 773.6 [M + Na]+ (calcd. for C54H46Si2: 750.3). 
Complex Fe41 
Under argon, diyne 104 (153 mg, 0.2 mmol, 1 eq) and 
Fe2(CO)9 (185 mg, 0.5 mmol, 2.5 eq) were dissolved in 
dry toluene (3 mL) and heated to 90 °C for 6 h. After 
cooling down to room temperature, the reaction 
mixture was filtered through a pad of Celite (rinsing 
with DCM). The filtrate was concentrated in vacuo, 
and the residue was purified by flash column chromatography (9:1 heptane/AcOEt) to obtain Fe41 
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as a pale yellow solid. Yield: 130 mg (70%). 1H NMR (300 MHz, CDCl3) δ 7.89-7.84 (m, 8H), 7.52-
7.33 (m, 8H), 7.23-7.03 (m, 8H), 2.35-2.19 (m, 4H), 2.07-1.93 (m, 4H), 1.40-1.33 (m, 4H), 1.30-1.25 
(m 4H), 0.43 (s, 3H), 0.28 (s, 3H). ESI-MS m/z 941.3 [M + Na]+ (calcd. for C58H46FeO4Si2: 918.2). 
(4S,8S)-4,9-dimethyl-1,3-diphenyl-4,4,5,6,7,8,8,9-octahydro-2H-cyclopenta[b]quinoxalin-2-one 106 
Adapting the procedure described by Renoud and co-workers,
111
 in a 
Shlenk tube, the diphenylcyclopentanetrione 105 (500 mg, 1.90 mmol, 1 
eq) and (R,R)-N,N-dimethylcyclohexane-1,2-diamine (280 mg, 1.90 mmol, 1 
eq) were mixed in methanol (10 mL). The reaction mixture was heated under reflux for 3 h. After 
removing solvent in vacuo, the pure 106 was obtained as a dark purple powder. Yield 660 mg 
(92%). 1H NMR (300 MHz, CDCl3) δ 7.30-7.25 (m, 8H), 7.16-7.12 (m, 2H), 3.13 (m, 2H), 2.78 (s, 6H), 
1.90-1.83 (m, 4H), 1.40-1.35) (m, 4H). 
Complex Fe42 
Under argon, the cyclopentadienone derivative 106 (0.66 g, 1.75 mmol, 1 
eq) and Fe2(CO)9 (1.25 g, 3.5 mmol, 2 eq) were dissolved in dry toluene (12 
mL) and heated to 90 °C for 4 h. After cooling down to room temperature, 
the reaction mixture was filtered through a pad of Celite (rinsing with 
DCM). The filtrate was concentrated in vacuo, and the residue was purified 
by flash column chromatography (9:1 heptane/EtOAc) to obtain Fe42. Yield: 0.50 g (54%). 1H NMR 
(300 MHz, CDCl3) δ 7.28-7.23 (m, 8H), 7.12-7.08 (m, 2H), 3.25 (m, 2H), 2.37 (s, 6H), 1.99-1.89 (m, 
4H), 1.45-1.40) (m, 4H). ESI-MS m/z 533.1 [M + Na]+ (calcd. for C28H26FeN2O4: 510.1). 
General Procedure for the Asymmetric Hydrogenation 
Hydrogenations were run in a 450 mL Parr autoclave equipped with a removable aluminum block 
that can accommodate up to fifteen magnetically stirred 7 mL glass vials. The catalyst [0.01 mmol 
(2 mol-%)] was weighed in glass vials, which were accommodated in the aluminum block after 
adding magnetic stir bars in each of them. The block was placed in a Schlenk tube, where it was 
subjected to three vacuum/nitrogen cycles. iPrOH (0.25 mL) was added to each vial, and stirring 
was started. Me3NO [0.02 mmol (4 mol-%)] was added to each vial as an H2O solution (0.1 mL). 
After stirring at room temperature under nitrogen for 10 min, the substrate (0.5 mmol) was 
added to the mixtures. Each vial was capped with a Teflon septum pierced by a needle, the block 
was transferred into the autoclave, and stirring was started. After purging four times with 
hydrogen at the selected pressure, heating was started. The reactions were stirred under 
hydrogen pressure overnight and then analyzed for conversion and ee determination. 
Conditions for conversion and ee determination 
Products’ absolute configurations were assigned by comparison of the sign of optical rotation 
with literature data (see the references cited for each compound). 
(S)-1-Phenylethanol P1 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--
cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 
bar; oven temperature: 95 °C for 20 min: tsubstrate = 6.0 min; tR = 13.2 min; tS = 15.1 min.
168 
(S)-1-(4-(Trifluoromethyl)phenyl)ethanol P2 (GC): capillary column: MEGADEX DACTBS, diacetyl-
tert-butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; 
inlet pressure: 1 bar; oven temperature: 110 °C for 20 min: tsubstrate = 6.4 min; tR = 14.3 min; tS = 
15.4 min.169 
(S)-1-(4-Methoxyphenyl)ethanol P3 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-
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butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet 
pressure: 1 bar; oven temperature: 110 °C for 10 min; 30 °C/min gradient; 120 °C for 10 min; 30 
°C/min gradient; 130 °C: tsubstrate = 20.1 min; tR = 21.1 min; tS = 22.6 min.
170 
(S)-1-(4-Chlorophenyl)ethanol P4 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-
butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet 
pressure: 1 bar; oven temperature: 110 °C for 10 min; 30 °C/min gradient; 120 °C for 10 min; 30 
°C/min gradient; 130 °C: tsubstrate = 12.8 min; tR = 23.4 min; tS = 24.3 min.
170 
(S)-1-(Naphthalen-2-yl)ethanol P5 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-
butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet 
pressure: 1 bar; oven temperature: 150 °C for 20 min: tsubstrate = 10.6 min; tR = 16.9 min; tS = 17.9 
min.170 
(S)-1-Phenylpropan-1-ol P6 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--
cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 
bar; oven temperature: 95 °C for 20 min: tsubstrate = 9.4 min; tR = 16.6 min; tS = 18.5 min.
171 
(S)-1-Cyclohexylethanol P7 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--
cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 
bar; oven temperature: 120 °C for 20 min: tsubstrate = 4.9 min; tS = 6.2 min; tR = 7.6 min.
172 
(R)-1,2,3,4-Tetrahydronaphthalen-2-ol P8 (GC): the product was derivatized as acetate before 
injection. Capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--cyclodextrin, 0.25 μm; 
diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 bar; oven temperature: 
110 °C for 40 min: tR = 29.3 min; tS = 30.3 min; tsubstrate = 35.1 min.
173 
(R)-2,3-Dihydro-1H-inden-1-ol P9 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-
butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet 
pressure: 1 bar; oven temperature: 110 °C for 20 min: tsubstrate = 12.9 min; tS = 11.8 min; tR = 14.2 
min.174 
rac-4-Methylpentan-2-ol P10 (GC): capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--
cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 
bar; oven temperature: 120 °C for 20 min): tsubstrate = 10.6 min; ten.1 = 11.6 min; ten.2 = 13.5 min. 
(S)-1-(Naphthalen-1-yl)ethanol P11 (GC and HPLC): GC conditions for conversion determination: 
capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--cyclodextrin, 0.25 μm; diameter = 
0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 bar; oven temperature: 150 °C for 15 
min): tsubstrate = 8.0 min; tR+S = 10.4 min. HPLC conditions of ee determination: column: Daicel 
Chiralcel OD-H; eluent: 9:1 n-hexane/i-PrOH; flow: 1 mL/min; λ = 210 nm; tsubstrate = 7.1 min; tS = 
9.3 min; tR = 13.3 min.
170 
(S)-1-(Pyridin-3-yl)ethanol P12 (GC and HPLC): GC conditions for conversion determination: 
capillary column: MEGADEX DACTBS, diacetyl-tert-butylsilyl--cyclodextrin, 0.25 μm; diameter = 
0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1 bar; oven temperature: 130 °C for 15 
min: tsubstrate = 3.4 min; tR+S = 12.0 min. HPLC conditions of ee determination: column: Daicel 
Chiralcel OB-H; eluent: 9:1 n-hexane/i-PrOH; flow: 0.8 mL/min; λ = 210 nm; tS = 10.6 min; tR = 17.4 
min; tsubstrate = 20.1 min.
170 
(S)-3,3-Dimethylbutan-2-ol P13 (GC): capillary column: CP-Chirasil-Dex CB, 0.25 μm; diameter = 
0.25 mm; length = 25 m; carrier: hydrogen; inlet pressure: 1.89 bar; oven temperature: 60 °C for 
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11 min: tsubstrate = 3.3 min; tS = 10.1 min; tR = 10.6 min.
175 
(S)-1,2,3,4-Tetrahydronaphthalen-1-ol P14 (GC): capillary column: MEGADEX DACTBS, diacetyl-
tert-butylsilyl--cyclodextrin, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: hydrogen; 
inlet pressure: 1 bar; oven temperature: 120 °C for 20 min: tsubstrate = 9.5 min; tR = 11.0 min; tS = 
12.2 min.176 
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6 New application of cyclopentadienone(iron) 
complexes 
6.1 Ester hydrogenation with (cyclopentadienone)iron complex 
 Until 2014, application of iron catalysts for ester hydrogenation was unreported. 
As described in Paragraph 2.5.2, this situation changed thanks to contribution made by 
three research groups. Firstly, Milstein and co-workers proved that the P,N,P-complex 47 
(Figure 6.1a) could be applied in the hydrogenation of strongly activated trifluoroacetic 
esters.119Although the reduction of trifluoroacetates is not particularly appealing from the 
synthetic point of view, this was the first report of an iron-catalytic methodology for the 
ester reduction. Shortly after the Milstein’s seminal report, important contributions were 
made, nearly simultaneously, by the research groups of Beller120 and 
Guan/Fairweather.121 Using catalyst 49 (Figure 6.1b) both groups were able to 
hydrogenate various esters, including fatty esters under base-free, neat conditions. 
Catalysts 47 and 49 clearly opened a new chapter in the ester hydrogenation, proving 
that it can be accomplished using complexes with a cheap and abundant metal such as 
iron. Yet, in order for these catalysts to become really suitable for industrial use, their 
catalytic activity still has to be improved and the pincer P,N,P-ligands ideally should be 
replaced with less expensive and easy-to-handle ones. 
 
Figure 6.1 Catalysts used for hydrogenation of a) activated and b) "normal" esters. 
 As described in Chapter 5, during my research, I deeply investigated asymmetric 
hydrogenations using various (cyclopentadienone)iron complexes. As I had become quite 
familiar with their synthesis and setting up catalytic reactions with them, I started to 
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wonder if we can find a new field to apply them. As discussed in Paragraph 2.4.7, 
(cyclopentadienone)iron complexes are especially effective in ketone and imine 
hydrogenation, but they were also found active in the hydrogenation of sodium 
bicarbonate. They were also used in reductive amination or hydrogen borrowing 
reactions. What was for sure unaccomplished with them was the ester hydrogenation, 
and we decided approach this challenging field with them. (Cyclopentadienone)iron 
complexes for sure would be much welcome in ester hydrogenation as, compared to 
P,N,P-pincer ligands, they are easier to synthesize and to handle.  
 It was decided to carry out the initial experiments with the activated ester 2,2,2-
trifluoroethyl 2,2,2-trifluoroacetate E1 (Scheme 6.1). We chose to work with the most 
well studied iron complex 37 and to activate it using Me3NO to form the Knölker-Casey 
catalyst 38 in situ. Knowing the high thermal stability of (cyclopentadienone)iron 
complexes, we decided to start our catalytic experiments using rather harsh conditions: 
110 oC and 70 bar H2. We did that as we rather wanted to see some conversion and 
possibly lower the temperature and hydrogen pressure in course of the optimization of 
the reaction's conditions, than not to observe any conversion because of the mild 
conditions applied. 1,4-Dioxane was selected as a higher-boiling surrogate of 
tetrahydrofuran (b.p. = 101 °C vs. 66 °C), which is commonly used in ester hydrogenation. 
A co-solvent was also employed to dissolve Me3NO, which is poorly soluble in 1,4-
dioxane, thus ensuring the possibility to work with stock solutions while preparing the 
reaction. 
 
Scheme 6.1 Hydrogenation of 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate with complex 37. 
 Delightfully, the first attempt, carried out using 1,2-dichloroethane (DCE) as co-
solvent, led to full conversion. As the 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate or 2,2,2-
trifluoroethanol (TFE) have too low boiling point to be detected by GC, we measured the 
ester conversion using 19F NMR analysis of the reaction crude. This method allowed us to 
measure the conversion and the yield of TFE, but also to detect possible fluorine 
byproducts such as the 2,2,2-trifluoroacetic acid (TFA) potentially formed by ester 
hydrolysis (Figure 6.2).  
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Figure 6.2 An exemplary 
19
F NMR spectra (decoupled) of α,α,α-trifluorotoluene (used as 
19
F NMR shift reference),  
2,2,2-trifluoroethyl trifluoroacetate (substrate), trifluoroacetic acid (possible by-product) 
 and 2,2,2-trifluoroethanol (product). 
6.2 Conditions screening  
 We decided to test this new methodology for ester hydrogenation using 
(cyclopentadienone)iron pre-catalyst 37 with more challenging substrates - 
cyclohexylmethyl 2,2,2-trifluoroacetate E2 and hexyl 2,2,2-trifluoroacetate E3 (Table 6.1).  
Table 6.1 Solvent screening with esters E2 and E3. 
 
Entry Solvent 
Yield (%)
[a] 
Substrate E2 Substrate E3
 
 
 
 
 
1 1,4-Dioxane/DCE 75:25 77 82 
2 1,4-Dioxane/DCE 85:15 94 88 
3 1,4-dioxane 100 100 
4 DCE 89 90 
5 CPME 100 100 
6 Toluene 100 100 
[a] Yield of TFE by 
19
F NMR. 
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 Upon applying for esters E2 and E3 the same conditions as for substrate E1, we 
were positively surprised upon obtaining high yields for both esters (entry 1). The bulky 
cyclohexylmethyl group clearly was not an obstacle during the hydrogenation. When we 
tried to lower the amount of co-solvent (DCE), we were able to obtain higher yields (entry 
2). As we observed that the amount of DCE clearly affected the results, we tried to run 
catalytic tests without using any co-solvent, despite the bad solubility of Me3NO in most 
common solvents. Remarkably, using pure 1,4-dioxane led to 100% yield (entry 3), 
whereas the use of pure DCE afforded slightly lower yields, 89% for E1 and 90% for E3 
(entry 4). Following the lead of pure solvents we tested also cyclopentyl methyl ether 
(CPME) and toluene, obtaining in every case 100% yield in each case. 
 As we did not see any difference between two substrates E2 and E3, we run the 
further optimization study using only E3, together with three best solvents - 1,4-dioxane, 
CPME and toluene (Table 6.2). We wanted to evaluate the effects of lowering catalyst 
loading, temperature and pressure. 
Table 6.2 Optimization of the ester hydrogenation using complex 37. 
 
Entry 
Temp  
(
o
C) 
Pressure 
(bar) 
Yield (%)
[a]
 
1,4-dioxane CPME toluene 
1 110 70 100 100 100 
2 90 70 98 100 100 
3 90 35 91 99 98 
4 70 70 83 96 99 
[a] Yield of TFE by 
19
F NMR. 
 We started our optimization by lowering the catalyst loading from 2.5% to 1% 
which did not affect results at all (entry 1 from Table 6.2 vs. entries 3, 5-6 from Table 6.1). 
Decrease of the temperature by 20 oC, lowered the yield only in the case of 1,4-dioxane, 
but only by 2% (entry 2). Moreover, lowering the pressure (35 bar vs. 70 bar) led to lower 
yields, but the most significant change was observed again with 1,4-dioxane (entry 3). 
Keeping the original pressure (70 bar), but lowering the temperature to 70 oC, led to 
lower yields, most distinguishable in the case of 1,4-dioxane (entry 4). Overall, reactions 
performed in toluene were the least affected by changes of pressure or temperature. 
However, we did not undertake further reaction optimization, but rather used the best 
conditions (i.e. with 100% yield) for a substrate screening in which we wanted to include 
also more challenging "non-activated" esters. Before carrying out the solvent screening, 
we decided to test two other (cyclopentadienone)iron pre-catalysts (Scheme 6.2). 
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Scheme 6.2 Additional screening of two other (cyclopentadienone)iron complexes in ester hydrogenation. 
 With complex 39, the reaction worked as good as with the pre-catalyst 37, but 
complex 45 lowered the yield to 78%. We decided to keep the pre-catalyst 37 for the 
substrate screening, as it is the most commonly used (cyclopentadienone)iron pre-
catalyst.  
 
6.3 Substrate screening 
 In the substrate screening (Table 6.3), besides testing other 2,2,2-trifluoroacetic 
esters, we wanted to verify whether CF3 group on the acyl group is indispensable to 
observe conversion (substrates E5-6). Also esters derived from 2,2,2-trifluoroethanol 
were synthesized (E7 and E17), to test if their CF3 group can affect the hydrogenation. 
Besides that we included other, more classical "non-activated" esters (E18-19) and 2,2,2-
trifluoroactic acid (E20). 
 
Table 6.3 Substrate screening for ester hydrogenation, using pre-catalyst 37. 
 
Entry Substrate Yield (%)
 Milstein's 
yield (%)
[a]
 
Entry Substrate Yield (%) 
Milstein's 
yield (%)
[a]
 
1 E1 
 
100
 
>99 11 E11 
 
100 >99 
2 E2 
 
100 52, 95
[b] 
12 E12 
 
0  
3 E3 
 
100  13 E13 
 
0  
4 E4 
 
100  14 E14 
 
100 78 
5 E5 
 
0 0 15 E15 
 
100 >99 
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6 E6 
 
0 0 16 E16 
 
100 97 
7 E7 
 
0 0 17 E17 
 
0  
8 E8 
 
100 25, 77
[c]
 18 E18 
 
0  
9 E9 
 
100 95 19 E19 
 
0  
10 E10 
 
100 77 20 E20 
 
0  
[a] Yields reported by Milstein and co-workers with iron catalyst 47 (conditions: 1 mol% catalyst, 5 mol% NaOMe, 16h, 
40 
o
C); [b] higher yield required 48 h reaction time [c] higher yield required 3 mol% catalyst, 15 mol% NaOMe, 60h) 
 
 Remarkably, the hydrogenation did either not work at all or lead to 100% yield. 
None of the "non-activated" esters was hydrogenated (entries 7, 17-19), as well as "less-
activated" substrates E5 and E6 featuring a CHF2 group instead of CF3 (entries 5-6). Also 
2,2,2-trifuloroacetic acid E20 did not react (entry 20). On the contrary, the activated 
esters all gave full conversion with the exception of esters E12 and E13, featuring 
electron-poor phenol groups (entries 12-13). We tried to hydrogenate them using pre-
catalyst 39 and 45, but also without obtaining any conversion. Upon comparison with iron 
catalyst 47 used by Milstein and co-workers for hydrogenation of majority of tested here 
esters, it can be clearly seen that (cyclopentadienone)iron catalyst 37 is having a broader 
scope of substrates, being able to hydrogenate esters with the bulky alkoxy groups (entry 
2 and 8) without prolonged reaction times or increased catalyst loading. 
 
6.4 Tentative mechanism of ester hydrogenation 
 Based on the outcome of the ester hydrogenation experiments and on the 
commonly accepted mechanism of the hydrogenation of carbonyl compound promoted 
by the Knölker-Casey catalyst, a tentative mechanism can be proposed for the ester 
hydrogenation with the pre-catalyst 37 (Scheme 6.3). After removal of a CO ligand by 
Me3NO and subsequent hydrogen splitting, the catalyst 38 is able to promote the 
reduction of ester C=O group according to a concerted outer-sphere mechanism, in which 
its OH group is activating the ester by a hydrogen-bonding. As the ester C=O group is 
poorly reactive, a strong electron withdrawing group such as CF3 is indispensable to make 
it more electrophilic and thus activate it towards the nucleophilic attack of the hydride in 
the pericyclic transition state 38.1. Formed 2,2,2-trifluorohemiacetal A is then converted 
into the corresponding 2,2,2-trifuloroaldehyde B, which then is hydrogenated by the 
regenerated iron hydride 38 to form TFE. 
New application of cyclopentadienone(iron) complexes 
 
 
Scheme 6.3 Plausible mechanism of activated ester hydrogenation with pre-catalyst 37. 
 This proposed mechanism explains why the hydrogenation is not working with 
other than 2,2,2-trifluoroacetic esters, as in "non-activated" esters, the carbonyl carbon is 
a weaker electrophile. Nor hemiacetal or aldehyde intermediates are observed by 19F 
NMR, suggesting that the hemiacetal dissociation and subsequent hydrogenation of 
2,2,2-trifuloroaldehyde take place with a fast rate. 
 
6.5 Summary 
 In summary, a new reactivity of (cyclopentadienone/hydroxycyclopentadienyl)iron 
complexes has been discovered. Ester hydrogenation promoted by these complexes has 
been investigated and shown to work with trifluoroacetic esters. It has been shown that 
(cyclopentadienone)iron complexes, upon activation with Me3NO, can catalyze 
hydrogenation of variety of trifluoroacetic esters, almost independently on alcohol part of 
the ester (with the exception of phenyl esters bearing electron-poor substituents, which 
did not reacted). Unfortunately, up to date we have been unable to perform the 
hydrogenation of more "typical" esters E18 and E19, and for this reason the outcome of 
this research has mostly academic impact, without possible industrial applications. 
Nevertheless, the catalytic performances obtained on trifluoroacetate esters are superior 
to those previously reported by Milstein (with catalyst 47) and co-workers on this narrow 
class of substrates.  
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6.6 Experimental section 
General Remarks 
 Dry toluene and tetrahydrofuran were obtained from MBraun SPS system. Dry diethyl 
ether, dichloroethane, CPME and 1,4-dioxane (over molecular sieves in bottles with crown cap) 
were purchased from Sigma Aldrich and stored under nitrogen. 
 The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution. Flash 
column chromatography was performed using Grace Reveleris® X2 Flash Chromatography System 
(silica gel cartridges with particle size 40 µm). 
 Proton NMR spectra were recorded on a spectrometer operating at 300 MHz. Proton 
chemical shifts are reported in ppm (δ) with the solvent reference relative to tetramethylsilane 
(TMS) employed as the internal standard (CDCl3 = 7.26 ppm). The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd 
= doublet-doublet. 13C NMR spectra were recorded on a 300 MHz spectrometer operating at 75 
MHz, with complete proton decoupling. Carbon chemical shifts are reported in ppm (δ) relative to 
TMS with the respective solvent resonance as the internal standard (CDCl3, δ = 77.2 ppm). The 
coupling constant values are given in Hz. 
 Gas chromatography was performed on a Hewlett Packard 6890 instrument, equipped 
with a flame ionization detector, using capillary columns. Mass analysis was performed using a 
Hewlett Packard 6890 instrument coupled with a mass spectrometer. 
Materials 
 The following substrates were obtained from commercial sources (Sigma and VWR): 
2,2,2-trifluoroethyl trifluoroacetate E1, ethyl 2,2,2-trifluoroacetate E4, ethyl difluoroacete E5, 
ethyl bromodifluoroacete E6, 2,2,2-trifluoroethyl acetate E7, i-propyl trifluoroacetate E8, allyl 
trifluoroacetate E9, butyl 2,2,2-trifluoroacetate E10, phenyl 2,2,2-trifluoroacetate E11, 4-
nitrophenyl 2,2,2-trifluoroacetate E12, perfluorophenyl 2,2,2-trifluoroacetate E13, methyl 
benzoate E18, methyl hexanoate E19, 2,2,2-trifluoroacetic acid E20. Esters: cyclohexylmethyl 
2,2,2-trifluoroacetate E2, phenethyl 2,2,2-trifluoroacetate E14, benzyl 2,2,2-trifluoroacetate E15, 
4-fluorobenzyl 2,2,2-trifluoroacetate E16 were prepared as reported by Milstein and co-
workers.119 2,2,2-Trifluoroethyl benzoate E17 was prepared using the procedure reported by 
Studer and co-workers.177 Complexes 37 and 45 were prepared following procedures reported by 
Renaud and co-workers.111 Complex 39 was prepared as described by Wills and co-workers.105 
Hexyl 2,2,2-trifluoroacetate E3 
Under argon, 1-hexanol (0.06 mol, 7.5 mL, 1 eq) was diluted with dry 
Et2O (60 mL) and cooled down to 0 
oC. 2,2,2-Trifluoroacetic anhydride 
(0.072 mol, 10 mL, 1.2 eq) was slowly added and the reaction mixture 
was stirred for 0.5 h at 0 oC. Then the ice bath was removed and the reaction was stirred for 2 h. 
GC-MS and 19F NMR analysis confirmed full conversion of 1-hexanol to hexyl 2,2,2-trifluoroacetate 
E3. The reaction mixture was diluted with ether (50 mL). The organic layer was washed with 
NaHCO3 saturated solution (2x 100 mL) and with brine (1x 100 mL). The organic phases were 
combined and filtered using phase-separation paper. Ester E3 was purified by distillation (boiling 
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point 145 oC). Yield 84%. 1H NMR (300 MHz) δ 4.34 (t, 3J(H,H) = 6.7 Hz, 2H), 1.76-1.69 (m, 2H), 
1.39-1.30 (m, 6H), 0.90 (t, 3J(H,H) = 6.7 Hz, 3H). 19F NMR (282 MHz, CDCl3) δ -75.72. 
13C NMR (75 
MHz) δ 157.8 (q, 2J(C,F) = 42.0 Hz), 114.8 (q, 1J(C,F) = 285.6 Hz), 68.5, 31.4, 28.2, 25.3, 22.6, 14.0. 
GCI-MS m/z 198 [M] (calcd. for C8H13F3O2: 198.1). 
General Procedure for the Hydrogenation 
In a nitrogen filled mBraun glovebox, a solution of catalyst (0.01 mmol, 1 mol% in 0.25 mL solvent) 
was dispensed to a glass vial with solid Me3NO (0.02 mmol, 2 mol%). Vial was capped and solution 
was stirred for 1h at 30 OC. After that vial was opened and ester substrate (1 mmol) was added. 
Vial was capped again and put inside the Premex 96er Reactor. The system was purged three 
times with 10 bar of nitrogen and three times with 10 bar of hydrogen. Catalytic reactions were 
stirred overnight under selected pressure and temperature. After this time, the reaction crudes 
were directly analyzed by 19F NMR with α,α,α-trifluorotoluene (1 mmol in 0.5 mL solvent) as 19F 
NMR internal shift reference. 
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7 Conclusions and perspectives 
 
 In my thesis Reductions catalyzed by first-row transition metals, I decided to 
particularly focus on the most abundant transition metal – iron. In the last 15 years, this 
cheap and non-toxic metal is becoming the object of increasing interest in the scientific 
community, and a remarkable progress has been made in the development of iron-
catalyzed reactions. The new iron catalysts started to reach activities reported so far only 
for noble metal complexes. Nevertheless, there is still much room for improvement, as 
many of these iron catalysts are highly air- and/or moisture-sensitive, and their synthesis 
can be very difficult. In order for the homogeneous iron catalysts to become industrially 
relevant, more easy-to-prepare and stable catalysts have to be developed. My thesis 
contributes particularly to the field of asymmetric catalysis, seen often as a domain of 
noble metals. 
 In Chapter 3 iron complexes with N,N,N,N-ligands are described (Figure 7.1). 
Eleven iron complexes were synthesized and tested in catalytic reductions. The negative 
results obtained with N,N,N,N-ligand complexes in the hydrogenation of C=C and C=O 
double bonds indicate that N-based tetradentate ligands, despite being an effective 
option for stabilizing the Fe(II) metal centre, are not particularly good candidates for 
promoting Fe-catalyzed reductions. In addition to the N-based tetradentate ligand, they 
require strong π-acceptors like CO, to stabilize the low-valent iron species produced in 
the course of the reaction. 
 
Figure 7.1 Examples of synthesized iron complexes with N,N,N,N-ligands. 
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 In Chapter 4 new iron complexes with isonitrile ligands are described. Overall, 
three families of iron complexes were synthesized and tested in asymmetric transfer 
hydrogenation of ketones. The best catalyst, Fe17 (Figure 7.2), was able to induce up to 
29% ee in transfer hydrogenation of acetophenone. In order to improve the transfer of 
the stereochemical information from the (R)-BINOL derived backbone, the introduction 
of steric bulk in different positions of the molecule was investigated, but no 
improvement could be obtained. Research towards more effective catalysts is still 
underway in Gennari group. 
 
Figure 7.2 The most effective tetra(isonitrile) complex for ketone transfer-hydrogenation. 
 In Chapter 5, chiral cyclopentadienone(iron) complexes are presented, which 
represent the core of my PhD work. Compared to other iron complexes used for 
homogenous asymmetric hydrogenation, (cyclopentadienone)iron complexes have the 
advantage of being easy to synthesize and stable to air, water and light. By reaction with 
bases or Me3NO, these complexes can be activated in situ and converted in catalysts for 
reduction reactions such as the hydrogenation of ketones and imines. A series of 
eighteen new chiral (cyclopentadienone)iron pre-catalysts were developed. Most of 
these complexes are derived from (R)-BINOL and differ one from the other in the 
substitution at the 3,3'-positions of the dinaphthalene backbone, as well as at the 2,5-
positions of the cyclopentadienone ring. Among these (R)-BINOL-derived iron complexes, 
the best one, Fe23 (Figure 7.3), allowed to obtain up to 77% ee in the asymmetric 
hydrogenation of ketones. Remarkably, this result was nearly three times higher than 
previously reported in the literature for chiral (cyclopentadienone)iron derivatives.  
 
Figure 7.3 The most effective chiral cyclopentadienone(iron) complexes for ketone hydrogenation. 
 Other approaches to the development of chiral cyclopetadienone(iron) 
complexes were also investigated, such as replacement of the (R)-BINOL-derived 
backbone with chiral diamine-derived one, and introduction of stereocentres at the 2,5-
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positions of the cyclopentadienone ring. However, these approaches did not lead to any 
improvement, in terms of stereocontrol, with respect to the (R)-BINOL-derived 
complexes. 
 Building on the expertise achieved with cyclopentadienone(iron) complexes, it 
was decided to use the most well-known complex 37 to investigate the reduction of 
substrates different from ketones and imines. In Chapter 6, ester hydrogenation with 
iron complex 37 is described (Scheme 7.1). Hydrogenation of a variety of 2,2,2-
trifluoroacetate esters could be achieved with a 100% yield, although classical esters 
remained inactive under these reaction conditions.  
 
Scheme 7.1 Ester hydrogenation with cyclopentadienone(iron) complex 37. 
 To conclude, in my work of thesis nearly 40 iron complexes have been developed 
and tested in catalytic hydrogenation reactions, giving in some cases very promising 
results, and providing new knowledge and directions for future developments in this 
field. 
 
  
  
8 List of publications 
 
1. Chiral (Cyclopentadienone)iron Complexes for the Catalytic Asymmetric 
Hydrogenation of Ketones, P. Gajewski, M. Renom-Carrasco, S. Vailati Facchini, L. 
Pignataro, L. Lefort, J. G. de Vries, R. Ferraccioli, A. Forni, U. Piarulli and C. 
Gennari, Eur. J. Org. Chem. 2015, 1887-1893. 
In this thesis, research from this paper is presented under copyright license with 
John Wiley and Sons – license number 3773900427152 from 21st December 
2015. 
This communication was highlighted as Iron-Catalyzed Asymmetric Hydrogenation 
of Ketones, SynFacts 2015, 11, 626.  
 
2. Synthesis of (R)-BINOL-Derived (Cyclopentadienone)iron Complexes and Their 
Application in the Catalytic Asymmetric Hydrogenation of Ketones, P. Gajewski, M. 
Renom-Carrasco, S. Vailati Facchini, L. Pignataro, L. Lefort, J. G. de Vries, R. 
Ferraccioli, U. Piarulli and C. Gennari, Eur. J. Org. Chem. 2015, 5526–5536. 
In this thesis, research from this paper is presented under copyright license with 
John Wiley and Sons – license number 3773900159497 from 21st December 
2015. 
 
3. Assisted Tandem Catalysis: Metathesis Followed by Asymmetric Hydrogenation 
from a Single Ruthenium Source, M. Renom-Carrasco, P. Gajewski, L. Pignataro, J. 
G. de Vries, U. Piarulli, C. Gennari and L. Lefort. Adv. Synth. Catal. 2015, 10, 2223-
2228. 
 
4. Asymmetric Transfer Hydrogenation of Ketones with modified Grubbs Metathesis 
Catalysts: On the Way to a Tandem Process, M. Renom-Carrasco, P. Gajewski, L. 
Pignataro, J. G. de Vries, U. Piarulli, C. Gennari and L. Lefort. Adv. Synth. Catal. 
2016, DOI: 10.1002/adsc.201500933, in press. 
 
  
  
9 Acknowledgments  
 
I sincerely acknowledge my supervisors, Prof. Cesare Gennari and Prof. Johanes de Vries, for 
giving me the opportunity to work on a challenging and multidisciplinary project, for their 
steady support, and for their huge contribution to my scientific education. 
I thank Dr. Laurent Lefort for giving me insights into working in the industry, and Prof. 
Umberto Piarulli for the copious advice about my project. 
I do not thank Dr. Luca Pignataro. I simply do not know how. Words cannot express my 
gratitude for his excellent support, advice on every topic, innumerable visits to the university 
bar, and countless ridiculously bad small jokes.  
Words of appreciation go to Allegra, with whom I started my iron adventure. Cheers to 
Alberto, my party-hard companion! Dottore, dottore, dottore...! I hope that you were right 
and I will return to Italy someday! Salute to Simone, a quiet and self-possessed member of 
the group. Congratulations to my first student Marco, who somehow survied my supervison 
and decided to return to Gennari Group! Many thanks also to Sofia for her input to my 
project. 
Last from the University of Milan, but definitely not least – Marc. We started together and 
we will finish together, but we never really worked together. A unique collaboration which 
will always stay in my memory. And what an outcome! Seven papers (fingers crossed!), two 
weeks in Poland and one week in Spain! It was great to have you as my tandem co-worker! 
From my stay at DSM I would like to thank Joanne, as she was always there to chat about 
chemistry, and not only that (and I hope I did not bore you to death with my trivial 
problems!). I cannot forget about Mr. Mike! It was a pleasure to work with you. You work 
very hard, but you never forget about other people – this truly makes you a great person! 
Besides that, I would like to thank Felix for all the tips and tricks, from chemistry to cycling 
and climbing. Thanks to the whole deparment of Innovative Synthesis for a warm welcome 
and see you all on the next ODS!  
I dedicate this work to my parents, Joanna (pomijając to ziewanie przed Skypem, to chyba 
jednak całkiem dobrze mnie wychowałaś skoro kończę doktorat!) and Tadeusz (chemia nie 
jest programowaniem, ale też jest fajna), my sister Eliza (I still believe that art is a little bit 
more joyful for the soul than chemistry, so keep it up!), and to my beloved wife – Agnieszka. 
Without Agnieszka, this thesis would not have been written, and even this PhD would not 
have been started. If this doctorate was our honeymoon, what will happen next? For sure, 
the future is bright! 
PS: To everyone who arrived on this page after reading my thesis – many thanks! But if you 
have not read it and skipped straight to acknowledgments, think about your actions, your 
life, and the Universe – and then return to page 1! May the iron be with you! 
  
  
10  Bibliography 
                                                     
1 J. J. Berzelius, Årsberättelsen om framsteg i fysik och kemi [Annual report on progress in physics and 
2 P. T. Anastas, J. Warner, Green chemistry: theory and practice, Oxford University Press, Oxford, 1988. 
3 (a) A. Corma, S. Iborra and A. Velty, Chem. Rev., 2007, 107, 2411; (b) J. G. de Vries, C. J. Elsevier, 
Handbook of Homogeneous Hydrogenation, Wiley-VCH, Weinheim, 2007.  
4 E. Bauer, Iron Catalysis II, Top Organomet Chem 2015, 50. 
5 G. Patrick, Instant Notes in Medicinal Chemistry, BIOS Scientific Publishers, 2001. 
6 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm 
7 V. Farina, J. T. Reeves, C. H. Senanayake, J. J. Song, Chem. Soc. Rev. 2006, 106, 2734-2793. 
8 M. Calvin, J. Am. Chem. Soc. 1939, 61, 2230-2234. 
9 J. A. Osborn, F. H. Jardine, J. F. Young, G. Wilkinson, J. Chem. Soc. A 1966, 12, 1711-1732. 
10 (a) W. S. Knowles, M. J. Sabacky, Chem. Commun. 1968, 22, 1445-1446; (b) W. S. Knowles, M. J. 
Sabacky, B. D. Vineyard, J. Chem. Soc., Chem. Commun. 1972, 10-11. 
11 L. Horner, H. Siegel, H. Büthe, Angew. Chem., Int. Ed. Engl. 1968, 7, 941. 
12 Berry, A. J.: Modern Chemistry, Cambridge, University Press, 1946. 
13 H. B. Kagan, T. P. Dang, J. Am. Chem. Soc. 1972, 94, 6429-6433.  
14 B. D. Vineyard, W. S. Knowles, M. J. Sabacky, G. L. Bachman, D. J. Weinkauff, J. Am. Chem. Soc. 1977, 
99, 5946–5952. 
15(a) R. Noyori, H. Takaya, Acc. Chem. Res. 1990, 23, 345-350; (b) R. Noyori, M. Kitamura, T. Ohkuma, 
Proc. Natl. Ac. Sci. U. S. A. 2004, 101, 5356-5362. 
16 R. Noyori, Angew. Chem. Int. Ed. 2002, 41, 2008-2022. 
17 W. S. Knowles, Angew. Chem. Int. Ed. 2002, 41, 1998-2007.  
18 K. B. Sharpless Angew. Chem. Int. Ed. 2002, 41, 2024-2032. 
19(a) Hydrogenation of olefins: R. Noyori, T. Ohkuma, M. Kitamura, J. Am. Chem. Soc. 1987, 109, 5856-
5858; (b) Hydrogenation of functionalised ketones: M. Kitamura, T. Ohkuma, S. Inoue, N. Sayo, H. 
Kumobayashi, S. Akutagawa, T. Ohta, H. Takaya, R. Noyori, J. Am. Chem. Soc. 1988, 110, 629-631; (c) 
Hydrogenation of unfunctionalised ketones: T. Ohkuma, H. Ooka, S. Hashiguchi, T. Ikariya, R. Noyori, J. 
Am. Chem. Soc. 2005, 117, 2675-2676. 
20 (a) A. Gillon, K. Heslop, D. J. Hyett, A. Martorell, A. G. Orpen, P. G. Pringle, C. Claver, E. Fernandez, 
Chem. Commun. 2000, 961-962; (b) M. T. Reetz, G. Mehler, Angew. Chem. Int. Ed. 2000, 39, 3889-
3890; (c) F. Guillen, J.-C. Fiaud, Tetrahedron Lett. 1999, 40, 2939-2942; (d) M. van den Berg, A. J. 
Minnaard, E. P. Schudde, J. van Esch, A. H. M. de Vries, J. G. de Vries, B. L. Feringa, J. Am. Chem. Soc. 
2000, 122, 11539-11540; (e) A. Börner, Phosphorus Ligands in Asymmetric Catalysis: Synthesis and 
Applications, Wiley-VCH, 2008. 
21 M. T. Reetz, T. Sell, A. Meiswinkel, G. Mehler, Angew. Chem. Int. Ed. 2003, 42, 790-793. 
22 D. Peña, A. J. Minnaard, J. A. F. Boogers, A. H. M. de Vries, J. G. de Vries, B. L. Feringa, Org. Biomol. 
Chem. 2003, 1, 1087-1089. 
23 Schneider, H.-J.; Yatsimirsky, A. K., Principles and Methods in Supramolecular Chemistry, Wiley-VCH, 
New York, 2000 
24 B. Plietker Iron Catalysis in Organic Chemistry, Wiley-VCH Verlag, Weinheim, 2008. 
25 For reviews on asymmetric homogeneous hydrogenation, see: (a) D. J. Ager, A. H. M. de Vries, J. G. 
de Vries, Chem. Soc. Rev. 2012, 41, 3340-3380; (b) H. U. Blaser, C. Malan, B. Pugin, F. Spindler, H. 
Steiner, M. Studer, Adv. Synth. Catal. 2003, 345, 103-151; (c) J. G. de Vries, C. J. Elsevier, Handbook of 
  
                                                                                                                                                             
Homogeneous Hydrogenation, Wiley-VCH, 2006; (d) G. Shang, W. Li, X. Zhang, Transition metal-
catalyzed homogeneous asymmetric hydrogenation, in Catalytic Asymmetric Synthesis, 3rd ed., Wiley-
VCH, 2010, 343-436. 
26 S. Gladiali, E. Alberico, Chem. Soc. Rev. 2006, 35, 226-236. 
27 H.U. Blaser, H.-J. Federsel Asymmetric Catalysis on Industrial Scale, 2nd ed. Challenges, Approaches, 
Solutions, Wiley-VCH, Weinheim, 2010 
28 Prices obtained on http://www.infomine.com/investment/metal-prices/ as for 1.12.2015. 
29 R. M. Bullock, Catalysis without Precious Metals, Wiley-VCH, 2010. 
30 (a) M. Darwish, M. Wills, Catal. Sci. Technol. 2012, 2, 243-255; (b) specifically on Fe-catalysed 
reduction methodologies: R. H. Morris, Chem. Soc. Rev. 2009, 38, 2282-2291; (c) K. Gopalaiah, Chem. 
Rev. 2013, 113, 3248−3296; (d) I. Bauer, H. J. Knolker Chem. Rev. 2015, 115, 3170–3387; (e) D. S. 
Mérela, M. Loan Tran Doa, S. Gaillarda, P. Dupaud, J. L. Renauda, Coord. Chem. Rev. 2015, 288, 50-68; 
(f) A. Pinaka, G.C. Vougioukalakis Coord. Chem. Rev. 2015, 288, 69–97; (g) L. C. Misal Castro, H. Li, J. B. 
Sortais, C. Darcel, Green Chem. 2015, 17, 2283–2303. 
31 (a) B. Plietker, A. Dieskau Eur. J. Org. Chem. 2009, 775 (b) O. G. Manchegno Angew. Chem., Int. Ed. 
2011, 50, 2216. (c) I. Bauer, H.-J. Knolker Chem. Rev. 2015, 115, 3170–3387. 
32 S. J. Lippard, J. M. Berg Principles of Bioinorganic Chemistry, University Science Books , Mill Valley, 
1994. 
33 F. Naud, F. Spindler, C. J. Rueggeberg, A. T. Schmidt, H. U. Blaser, Org. Process Res. Dev., 2007, 11, 
519. 
34 C. Bolm Nat. Chem. 2009, 1, 420. 
35 P. J. Chirik, J. Am. Chem. Soc. 2009, 131, 3788-3789. 
36 H. U. Blaser, C. Malan, B. Pugin, F. Spindler, H. Steiner and M. Studer, Adv. Synth. Catal., 2003, 345, 
103; J. I. van der Vlugt, J. N. H. Reek, Angew. Chem., Int. Ed., 2009, 48, 8832. 
37 B. de Bruin Eur. J. Inorg. Chem. 2012, 340-342. 
38 K. Jørgensen, Coord. Chem. Rev. 1966, 1, 164–178. 
39 H. Grützmacher, Angew. Chem. Int. Ed. 2008, 47, 1814; J. I. van der Vlugt, J. N. H. Reek, Angew. 
Chem. Int. Ed. 2009, 48, 8832. 
40 J. R. Partington A History of Chemistry, MacMillan & Co, New York, 1964. 
41 L. Mond, F. Quinke, J. Chem. Soc. 1891, 59,604. 
42 For early studies using iron salts activated by aluminum compounds see: Y. Takegami, T. Ueno, T. 
Fujii Bull. Chem. Soc. Jpn 1969, 42 , 1663. 
43 E. N. Frankel, E. A. Emken, H. M.Peters, V. K. Davison, R. O. and Butterfield J. Org. Chem. 1964, 29 , 
3292. 
44 R. Noyori, I. Umeda, T. Ishigami J. Org. Chem., 1972, 37, 1542. 
45 M. A. Schroeder, M. S. Wrighton, J. Am. Chem. Soc., 1976, 98, 551. 
46 (a) B. H. Weiller, M. E. Miller, E. R. Grant J. Am. Chem. Soc., 1987, 109 , 352; (b)  
B. H. Weiller, E. R. Grant J. Am. Chem. Soc., 1987, 109 , 1051; (c) M. E. Miller, E. R. Grant J. Am. Chem. 
Soc., 1987, 109 , 7951. 
47 K. Kano, M. Takeuchi, S. Hashimoto, Z. I. Yoshida, J. Chem. Soc., Chem. Commun., 1991, 1728. 
48 (a) S. Sakaki, T. Sagura, T. Arai, T. Kojima, T. Ogata and K. Ohkubo, J. Mol. Catal., 1992, 75, L33; (b) S. 
Sakaki, T. I. Kojima and T. Arai, J. Chem. Soc., Dalton Trans., 1994, 7. 
49 (a) H. Inoue, M. Sato, J. Chem. Soc., Chem. Commun. 1983, 983–984; (b) H. Inoue, M. Suzuki, J. 
  
                                                                                                                                                             
Chem. Soc., Chem. Commun. 1980, 817–818. 
50 C. Bianchini, A. Meli, M. Peruzzini, P. Frediani, C. Bohanna, M. A. Esteruelas and L. A. Oro, 
Organometallics, 1992, 11, 138. 
51 E. J. Daida, J. C. Peters, Inorg. Chem. 2004, 43, 7474-7485. 
52 H. Fong, M. Moret, Y. Lee, J. C. Peters, Organometallics, 2013, 32, 3053. 
53 G. Wienhofer, F. Westerhaus, R. V. Jagadeesh, K. Junge, H. Junge, M. Beller Chem. Commun. 2012, 
48, 4827. 
54 D. Srimani, Y. Diskin-Posner, Y. Ben-David, D. Milstein, Angew. Chem., Int. Ed. 2013, 52, 14131. 
55 D. J Frank,L. Guiet, A. Kaslin, E. Murphy, S. P. Thomas, RSC Adv. 2013, 3, 25698. 
56 M. Kamitani, Y. Nishiguchi, R. Tada, M. Itazaki, H. Nakazawa, Organometallics 2014, 33, 1532. 
57 S. C. Bart, E. Lobkovsky, P. J. Chirik, J. Am. Chem. Soc. 2004, 126, 13794-13807. 
58 (a)G. J. P. Britovsek, V. C. Gibson, B. S. Kimberley, P. J. Maddox, S. J. McTavish, G. A. Solan, A. J. P. 
White, D. J. Williams Chem. Commun. 1998, 59, 849-850; (b) B. L. Small, M. Brookhart, A. M. A. 
Bennett J. Am. Chem. Soc. 1998, 120, 4049-4050. 
59 V. C. Gibson, C. Redshaw, G. A. Solan Chem. Rev. 2007, 107, 1745−1776. 
60 S. C. Bart, K. Chlopek, E. Bill, M. W. Bouwkamp, E. Lobkovsky, F. Neese, K. Wieghardt and P. J. Chirik, 
J. Am. Chem. Soc., 2006, 128, 13901. 
61 Studies on the non-innocent nature of the bis(imino)pyridine ligand: (a) S. Stieber, E. Chantal, C. 
Milsmann, J. M. Hoyt, Z. R. Turner, K. D. Finkelstein, K. Wieghardt, S. DeBeer, J. P. Chirik, Inorg. Chem. 
2012, 51, 3770-3785; (b) A. M. Tondreau, S. Stieber, E. Chantal, C. Milsmann, E. Lobkovsky, T. 
Weyhermuller, S. Semproni, J. P. Chirik, Inorg. Chem. 2013, 52, 635-646. 
62 R. J. Trovitch, E. Lobkovsky, P. J. Chirik, Inorg. Chem. 2006, 45, 7252–7260. 
63 S. C. Bart, E. J. Hawrelak, E. Lobkovsky, Organometallics 2005, 24, 5518–5527. 
64 P. Phua, L. Lefort, J. A. F. Boogers, M. Tristany and J. G. de Vries, Chem. Commun., 2009, 3747. 
65 R. Bedford, M.. Betham, D. Bruce, S. Davis, R. Frost and M. Hird, Chem. Commun., 2006, 1398. 
66 M. Stein, J. Wieland, P. Steurer, F. Teolle, R. Moulhaupt, B. Breit, Adv. Synth. Catal. 2011, 353, 523. 
67 T. N. Gieshoff, A. Welther, M. T. Kessler, M. H. G. Prechtl, A. von Wangelin, J. Chem. Commun. 2014, 
50, 2261. 
68 V. Kelsen, B. Wendt, S. Werkmeister, K. Junge, M. Beller, B. Chaudret, Chem. Commun. 2013, 49, 
3416. 
69 (a) L. Markó , M. A. Radhi J. Organomet. Chem. 1981, 218, 369; (b) L. Markó, J. Pala, Transition Met. 
Chem. 1983, 8,207. 
70 J.-S. Chen, L.-L. Chen, Y. Xing, G. Chen, W.-Y. Shen, Z.-R. Dong, Y.-Y. Li, J.-X. Gao Acta Chim. Sin. 2004, 
62, 1745.  
71 C. Sui-Seng, F. Freutel, A. Lough, R. H. Morris, Angew. Chem., Int. Ed. 2008, 47, 940. 
72 J. F. Sonnenberg, R. H. Morris, ACS Catal. 2013, 3, 1092−1102. 
73 (a) A. A. Mikhailine, E. Kim, C. Dingels, A. J. Lough, R. H. Morris, Inorg. Chem., 2008, 47, 6587−6589; 
(b) A. A. Mikhailine, A. J. Lough, R. H. Morris, J. Am. Chem. Soc. 2009, 131, 1394−1395; (c) P. O. 
Lagaditis, A. A. Mikhailine, A. J. Lough, R. H. Morris, Inorg. Chem. 2010, 49, 1094−1102. 
74 P. E. Sues, A. J. Lough, R. H. Morris , Organometallics 2011, 30, 4418−4431. 
75 A. A. Mikhailine, M. I. Maishan, A. J. Lough, R. H. Morris, J. Am. Chem. Soc. 2012, 134, 12266−12280. 
76 (a) W. W. Zuo, A. J. Lough, Y. F. Li, R. H. Morris, Science 2013, 342, 1080−1083; (b) W. Zuo, S. Tauer, 
D. E. Prokopchuk, R. H. Morris, Organometallics 2014, 33, 5791−5801; (c) 
  
                                                                                                                                                             
S. A. M. Smith, R. H. Morris, Synthesis 2015, DOI: 10.1055/s-0034-1380147. 
77 (a) C. A. Sandoval, T. Ohkuma, K. Muniz, R. Noyori, J. Am. Chem. Soc. 2003, 125, 13490-13503; (b) R. 
Noyori, M. Kitamura, T. Ohkuma, Proc. Natl. Ac. Sci. 2004, 101, 5356-5362. 
78 (a) W. Zuo, Y. Li,A. J. Lough, R. H. Morris Science 2013, 342, 1080; (b)W. Zuo, S. Tauer, D. E. 
Prokopchuk, R. H. Morris Organometallics 2014, 33, 5791; (c) S. A. M. Smith, R. H. Morris Synthesis 
2015, 47, 1775–1779. 
79 P. O. Lagaditis, P. E. Sues, J. F. Sonnenberg, K. Y. Wan, A. J. Lough, R. H. Morris J. Am. Chem. Soc. 
2014, 136, 1367−1380. 
80 S. L. Yu, W. Y. Shen,Y. Y. Li, Z. R. Dong, Y. Q. Xu, Q. Li.;J. N. Zhang, J. X. Gao Adv. Synth. Catal. 2012, 
354, 818−822. 
81 Y. Y. Li, S. L. Yu, X. F. Wu, J. L. Xiao, W. Y. Shen, Z. Dong, J. X. Gao J. Am. Chem. Soc. 2014, 136, 
4031−4039. 
82 M. Ranocchiari, A. Mezzetti Organometallics 2009, 28, 1286–1288. 
83 R. Bigler, E. Otth, A. Mezzetti Organometallics 2014, 33, 4086−4099. 
84 R. Bigler, A. Mezzetti Org. Lett. 2014, 16, 6460−6463. 
85 R. Bigler, R. Huber, A. Mezzetti Angew. Chem. Int. Ed. 2015, 54, 5171 –5174. 
86 (a) R. Langer, G. Leitus, Y. Ben-David, D. Milstein Angew. Chem. Int. Ed. 2011, 50, 2120-2124; (b) R. 
Langer, M. A. Iron, L. Kostantinovski, Y. Diskin-Posner, G. Leitus, Y. Ben-David, D. Milstein, Chem. Eur. 
J. 2012, 18, 7196-7209. 
87 R. Langer, M. A. Iron, L. Konstantinovski, Y. Diskin-Posner, G. Leitus, Y. Ben-David, D. Milstein 
Chem.—Eur. J. 2012, 18, 7196. 
88 S. Enthaler, B. Hagemann, G. Erre, K. Junge, M. Beller Chem.—Asian J. 2006, 1, 598. 
89 S. Enthaler, G. Erre, M. K. Tse, K. Junge, M. Beller Tetrahedron Lett. 2006, 47, 8095. 
90 G. Wienhofer, F. A. Westerhaus, K. Junge, R. Ludwig, M. Beller Chem.—Eur. J. 2013, 19, 7701. 
91 A. Naik, T. Maji, O. Reiser, Chem. Commun. 2010, 46, 4475-4477. 
92 W. Reppe, H. Vetter, Liebigs Ann. Chem. 1953, 582, 133. 
93 (a) H.-J. Knolker, J. Heber, C. H. Mahler, Synlett 1992, 1002; (b) H.-J. Knolker, J. Heber, Synlett 1993, 
924; (c) H.-J. Knolker, E. Baum, R. Klauss, Tetrahedron Lett. 1995, 36, 7647. 
94 (a) A. J. Pearson, R. A. Dubbert J. Chem. Soc. Chem. Commun. 1991, 202; (b) A. J. Pearson, R. J. 
Shively, Jr., R. A. Dubbert, Organometallics 1992, 11, 4096; (c) A. J. Pearson, R. J. Shively, Jr., 
Organometallics 1994, 13, 578; (d) A. J. Pearson, A. Perosa, Organometallics 1995, 14, 5178; (e) A. J. 
Pearson, X. Yao, Synlett 1997, 1281. 
95 (a) H.-J. Knolker, E. Baum, H. Goesmann, R. Klauss, Angew. Chem. 1999, 111, 2196; Angew. Chem. 
Int. Ed. 1999, 38, 2064. 
96 (a) C. P. Casey, H. Guan, J. Am. Chem. Soc. 2007, 129, 5816; For an highlight on this discovery: (b) R. 
M. Bullock, Angew. Chem. 2007, 119, 7504; Angew. Chem. Int. Ed. 2007, 46, 7360. 
97 For the first preparation of Shvo complex: (a) Y. Blum, D. Czarkie, Y. Rahamim, Y. Shvo, 
Organometallics 1985, 4, 1459; (b) Y. Shvo, D. Czierkie, Y. Rahamin, D. F. Ghodosh, J. Am. Chem. Soc. 
1986, 108, 7400; For reviews on the Shvo catalyst: (c) R. Prabhakaran, Synlett 2004, 2048; (d) R. 
Karvembu, R. Prabhakaran, K. Natarajan, Coord. Chem. Rev. 2005, 249, 911; (e) B. L. Conley,M. K. 
Pennington-Boggio, E. Boz, T. J.Williams, 
Chem. Rev. 2010, 110, 2294. 
98 X. Lu, R. Cheng, N. Turner, Q. Liu, M. Zhang, X. Sun J. Org. Chem. 2014, 79, 9355−9364. 
  
                                                                                                                                                             
99 (a) S. Moulin, H. Dentel, A. Pagnoux-Ozherelyeva, S. Gaillard, A. Poater, L. Cavallo, J.-F. Lohier, J.-L. 
Renaud, Chem. Eur. J. 2013, 19, 17881-17890; (b) D. S. Mérel, M. Elie, J.-F. Lohier, S. Gaillard, J.-L. 
Renaud, ChemCatChem 2013, 5, 2939-2945; (c) A. Pagnoux-Ozherelyeva, N. Pannetier, M. D. Mbaye, 
S. Gaillard, J.-L. Renaud, Angew. Chem. 2012, 124, 5060-5064; Angew. Chem. Int. Ed. 2012, 51, 4976-
4980; (d) J. P. Hopewell, J. E. D. Martins, T. C. Johnson, J. Godfrey, M. Wills, Org. Biomol. Chem. 2012, 
10, 134-145; (e) T.-T. Thai, D. S. Mérel, A. Poater, S. Gaillard, J.-L. Renaud, Chem. Eur. J. 2015, 21, 
7066-7070. 
100 A. Berkessel, S. Reichau, A. von der Höh, N. Leconte, J.-M. Neudörfl, Organometallics 2011, 30, 
3880–3887. 
101 (a) S. Fleischer, S. Zhou, K. Junge, M. Beller, Angew. Chem. 2013, 125, 5224-5228; Angew. Chem. 
Int. Ed. 2013, 52, 5120-5124; (b) A. Tlili, J. Schranck, H. Neumann, M. Beller, Chem. Eur. J. 2012, 18, 
15935-15939. 
102 For a recent review on (cyclopentadienone)iron complexes, see: A. Quintard, J. Rodriguez, Angew. 
Chem. 2014, 126, 4124-4136; Angew. Chem. Int. Ed. 2014, 53, 4044-4055. 
103 S. Fleischer, S. S. Zhou, K. Junge,M. Beller, Angew. Chem. 2013, 125, 5224; Angew. Chem. Int. Ed. 
2013, 52, 5120. 
104 A. Berkessel, S. Reichau, A. von der Höh, N. Leconte, J.-M. Neudörfl, Organometallics 2011, 30, 
3880–3887. 
105 J. P. Hopewell, J. E. D. Martins, T. C. Johnson, J. Godfrey, M. Wills, Org. Biomol. Chem. 2012, 10, 
134–145. 
106 S. Zhou, S. Fleischer, K. Junge, M. Beller, Angew. Chem., Int. Ed. 2011, 50, 5120. 
107 S. Fleischer, S. Zhou, S. Werkmeister, K. Junge, M. Beller Chem.—Eur. J. 2013, 19, 4997. 
108 S. Zhou, S. Fleischer, H. Jiao, K. Junge, M. Beller Adv. Synth. Catal. 2014, 356, 3451 – 3455. 
109 S. Fleischer, S. Werkmeister, S. Zhou, K. Junge, M. Beller Chem.—Eur. J. 2012, 18, 9005. 
110 A. Pagnoux-Ozherelyeva, N. Pannetier, M. D. Mbaye, S. Gaillard, J.-L. Renaud Angew. Chem., Int. 
Ed. 2012, 51, 4976. 
111 T.-T. Thai, D. S. Merel, A. Poater, S. Gaillard, J. -L. Renaud Chem. Eur. J. 2015, 21, 7066 – 7070. 
112 T. Yan, B. L. Feringa, K. Barta Nat. Commun. 2014 5:5602 doi: 10.1038/ncomms6602. 
113 H.-J. Pan, T. Wei Ng, Y. Zhao Chem. Commun., 2015, 51, 11907-11910. 
114 C. Federsel, A. Boddien,R. Jackstell, R. Jennerjahn, P. Dyson, R. Scopelliti, G. Laurenczy, M. Beller, 
Angew. Chem. Int. Ed. 2010, 49, 9777. 
115 C. Ziebart, C. Federsel, P. Anbarasan, R. Jackstell, W. Baumann, A. Spannenberg, M. Beller J. Am. 
Chem. Soc. 2012, 134, 20701. 
116 R. Langer,Y. Diskin-Posner, G. Leitus, L. J. W. Shimon, Y. Ben-David,D. Milstein, Angew. Chem., Int. 
Ed. 2011, 50, 9948. 
117 F. Bertini, I. Mellone, A. Ienco, M. Peruzzini, L. Gonsalvi ACS Catal. 2015, 5, 1254−1265. 
118 F. Zhu, L. Zhu-Ge, G. Yang, S. Zhou ChemSusChem 2015, 8, 609 – 612. 
119 T. Zell, Y. Ben-David, D. Milstein, Angew. Chem., Int. Ed. 2014, 53, 4685. 
120 S. Werkmeister, K. Junge, B. Wendt, E. Alberico, H. Jiao, W. Baumann, H. Junge, F. Gallou, M. Beller 
Angew. Chem., Int. Ed. 2014, 53, 8722. 
121 S. Chakraborty, H. Dai, P. Bhattacharya, N. T. Fairweather, M. S. Gibson, J. A. Krause, H. Guan, J. 
Am. Chem. Soc. 2014, 136, 7869. 
122 (a) D. Spasyuk, D. G. Gusev, Organometallics 2012, 31, 5239; (b) A. Acosta-Ramirez, M. Bertoli, D. 
  
                                                                                                                                                             
G. Gusev, M. Schlaf, Green Chem. 2012, 14, 1178. 
123 N. Ségaud, J.-N. Rebilly, K. Sénéchal-David, R. Guillot, L. Billon, J.-P. Baltaze, J. Farjon, O. Reinaud, F. 
Banse, Inorg. Chem. 2013, 52, 691-700. 
124 (a) M. Costas, K. Chen,L. Jr Que Coord. Chem. Rev. 2000, 200–202, 517–544; (b) L. Jr Que, W.B. 
Tolman Nature 2008, 455,333–340; (c) A. C. Mayer, C. Bolm Iron-catalyzed Oxidation Reactions. 
Oxidation of C-H and C = C bonds. 2008, 73-92, in: B. Plietker Iron Catalysis in Organic Chemistry, 2008, 
Wiley, Weinheim. 
125 M. Grau, G. J.P. Britovsek Top Organomet Chem 2015, 50, 145–172. 
126 (a) M. S. Chen, M. C. White, Science 2007, 318, 783-787; (b) M. S. Chen, M. C. White, Science 2010, 
327, 566-570. 
127 S. E. Denmark, J. Fu, M. J. Lawler, S. Lee, E. Huntsman, E. J. J. Grabowski, Org. Synth. 2006, 83, 121-
130. 
128 (a) Classical preparation of NaBArF: M. Brookhart, B. Grant, A. F. Volpe, Organomeallics 1992, 11, 
3920-3922; (b) Alternative preparation of NaBArF: N. A. Yakelis, R. G. Bergman, Organometallics 2005, 
24, 3579-3581; (c) Preparation of KBArF and AgBArF: . E. Buschmann, J. S. Miller, K. Bowman-James, C. 
N. Miller, Inorg. Synth. 2002, 33, 83. 
129 (a) R. Langer, G. Leitus, Y. Ben-David, D. Milstein, Angew. Chem. Int. Ed. 2011, 50, 2120-2124. 
130 W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923-2925. 
131 A. Dömling, I. Ugi, Angew. Chem. Int. Ed. 2000, 39, 3168-3210. 
132 F. E. Hahn, Angew. Chem. Int. Ed. 1993, 32, 650–665. 
133 W. Kandatege; K. Alliston, Journal of the American Chemical Society, 1995 , 117, 1220 - 1224. 
134 P. Bertus, J. Szymoniak, Chem. Commun. 2001, 1792-1793. 
135 W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923-2925. 
136 (a) J. M. Grill, J. H. Reibenspies, S. A. Miller, J. Organomet. Chem. 2005, 690, 3009-3017; (b) M. 
Hatano, T. Asai, K. Ishihara, Tetrahedron Lett. 2008, 49, 379-382. 
137 P. Gajewski, M. Renom-Carrasco, S. Vailati Facchini, L. Pignataro, L. Lefort, J. G. de Vries, R. 
Ferraccioli, A. Forni, U. Piarulli and C. Gennari, Eur. J. Org. Chem. 2015, 1887-1893. 
138 (a) B. Ye, N. Cramer, Angew. Chem. 2014, 126, 8030-8033; Angew. Chem. Int. Ed. 2014, 53, 7896-
7899; (b) B. Ye, N. Cramer, J. Am. Chem. Soc. 2013, 135, 636-639. 
139 Estimated price per gram upon purchase of 1 kg of (R)-BINOL from Reuter Chemischer 
Apparatebau KG. 
140 (a) D. Kampen, C. Reisinger, B. List, Top. Curr. Chem. 2009, 291, 1-37; (b) M. Terada, Chem. 
Commun. 2008, 4097-4112. 
141 T. Ooi, M. Kameda, K. Maruoka, J. Am. Chem. Soc. 2003, 125, 5139-5151. 
142 M. Ikunaka, K. Maruoka, Y. Okuda, T. Ooi, Org. Process Res. Dev. 2003, 7, 644. 
143 T. Hameury, J. Guillemont, L. van Hijfte, V. Bellosta, J. Cossy Org. Lett. 2009, 11, 2397-2400. 
144 P. Gajewski, M. Renom-Carrasco, S. Vailati Facchini, L. Pignataro, L. Lefort, J. G. de Vries, R. 
Ferraccioli, U. Piarulli and C. Gennari, Eur. J. Org. Chem. 2015, 5526–5536. 
145 T. Ooi, M. Kameda, K. Maruoka, J. Am. Chem. Soc. 2003, 125, 5139. 
146 (a) G. A. Olah,S. C. Narang,L. D. Field,R. Karpeles,. J. Org. Chem. 1981, 46, 2408; (b) P. R. Brooks, M. 
C. Wirtz, M. G. Vetelino, D. M. Rescek, G. F. Woodworth, B. P. Morgan, J. W. Coe, J. Org. Chem. 1999, 
64, 9719-9721. 
147 D. L. Comins, A. Dehghani, Tetrahedron Letters 1992, 33, 6299–6302. 
  
                                                                                                                                                             
148 T. Ohe, N. Miyaura, A. Suzuki, J. Org. Chem. 1993, 58, 2201-2208. 
149 A. F. Littke, C. Dai, G. C. Fu, J. Am. Chem. Soc. 2000, 122, 4020-4028. 
150 T. Watanabe, N. Miyaura, A. Suzuki, Synlett 1992, 1992, 207-210. 
151 R. A. Altman, S. Buchwald, Nat. Protoc. 2007, 2, 3115-3121. 
152 T. Ohe, N. Miyaura, A. Suzuki, J. Org. Chem. 1993, 58, 2201-2208. 
153 C. J. O'Brien, E. A. B. Kantchev, C. Valente, N. Hadei, G. A. Chass, A. Lough, A. C. Hopkinson, M. G. 
Organ, Chem. Eur. J. 2006, 12, 4743-4748. 
154 Hruszkewycz, D. P.; Balcells, D.; Guard, L. M.; Hazari, N.; Tilset, M. J. Am. Chem. Soc. 2014, 136 , 
7300-7316 
155 Zhao, T.-L.; Li, Y.; Li, S.-M.; Zhou, Y.-G.; Sun, F.-Y.; Gao, L.-X.; Hana, F.-S. Adv. Synth. Catal. 2011, 
353, 1543-1550 
156 S. Moulin, H. Dentel, A. Pagnoux-Ozherelyeva,S. Gaillard, A. Poater, L. Cavallo, J.-F. Lohier, J.-L. 
Renaud Chem. Eur. J. 2013, 19, 17881 – 17890. 
157 M. G. Coleman, A. N. Brown, B. A. Bolton, H. Guan, Adv. Synth. Catal. 2010, 352, 967-970. 
158 X. Lu,Y. Zhang, N. Turner, M. Zhang, T. Li Org. Biomol. Chem., 2014, 12, 4361–4371. 
159 W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923-2925. 
160 T. Ooi, M. Kameda, K. Maruoka J. Am. Chem. Soc. 2003, 17, 5104.  
161 L. Claisen, T. Ewan, Annalen, 1895, 284, 245. 
162 A. Hosomi, H. Hayashida, Y. Tominaga J. Org. Chem. 1989, 54, 3254-3256. 
163 Bruker, SMART, SAINT and SADABS, Bruker AXS Inc., Madison, Wisconsin, USA, 1997. 
164 G. M. Sheldrick, Acta Crystallogr. Sect. A 2008, 64, 112-122. 
165 M. N. Burnett, C. K. Johnson, ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal 
Structure Illustrations, Oak Ridge National Laboratory Report ORNL-6895, 1996. 
166 (a) S. L. Colletti, R. L. Halterman, Organometallics 1991, 10, 3438-3448; (b) S. L. Colletti, R. L. 
Halterman, Organometallics 1992, 11, 980-983. 
167 A. G. Schafer, J. M. Wieting, T. J. Fisher, A. E. Mattson, Angew. Chem. Int. Ed. 2013, 52, 11321 –
11324. 
168 R. Patchett, I. Magpantay, L. Saudan, C. Schotes, A. Mezzetti, F. Santoro, Angew. Chem. Int. Ed. 
2013, 52, 10352-10355. 
169 H. Yue, H. Huang, G. Bian, H. Zong, F. Li, L. Song, Tetrahedron: Asymmetry 2014, 25, 170-180. 
170 Y. Li, S. Yu, X. Wu, J. Xiao, W. Shen, Z. Dong, J. Gao, J. Am. Chem. Soc. 2014, 136, 4031-4039. 
171 Y.-S. Shih, R. Boobalan, C. Chen, G.-H. Lee, Tetrahedron: Asymmetry 2014, 25, 327-333. 
172 J. Li, Y. Tang, Q. Wang, X. Li, L. Cun, X. Zhang, J. Zhu, L. Li, J. Deng, J. Am. Chem. Soc. 2012, 134, 
18522-18525. 
173 R. Soni, J.-M. Collinson, G. C. Clarkson, M. Wills, Org. Lett. 2011, 13, 4304-4307. 
174 H. Mizoguchi, T. Uchida, T. Katsuki, Angew. Chem. 2014, 126, 3242-3246; Angew. Chem. Int. Ed. 
2014, 53, 3178-3182. 
175 A. Z. Gonzalez, J. G. Román, E. Gonzalez, J. Martinez, J. R. Medina, K. Matos, J. A. Soderquist, J. Am. 
Chem. Soc. 2008, 130, 9218-9219. 
176 K. Matsumura, N. Arai, K. Hori, T. Saito, N. Sayo, T. Ohkuma, J. Am. Chem. Soc. 2011, 133, 10696-
10699. 
177 R. C. Samanta, S. De Sarkar, R. Fröhlich, S. Grimme, A. Studer Chem. Sci., 2013, 4, 2177-2184. 
